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The success of cisplatin and its analogues for the treatment of different cancers has had a 
profound effect on establishing the application of metal complexes in medicine. Lately, 
increasing drug resistance and the emergence of unwanted side effects to currently available 
therapies have bred a need for novel pharmacological agents. Thus, the design and study of 
organometallic complexes as potential chemotherapeutics may potentially identify new drug 
candidates. Apart from platinum based compounds, platinum-like metals such as 
ruthenium(II), rhodium(III) and iridium(III), have been identified as biologically relevant 
metals.  The purpose of this study is to synthesize three classes of polynuclear complexes 
containing metals from the Platinum Group Metal (PGM) series and evaluate each class for 
pharmacological activity in vitro. Each complex class is based on a different ligand type.  
  
New mono- and polynuclear organometallic Platinum Group Metal (PGM) complexes based 
on three ligand classes have been synthesised and characterised using several analytical and 






P NMR, infrared and UV-vis spectroscopy. 
The first complex series is based on the thiourea containing ligand, 3,4-
dichloroacetophenonethiosemicarbazone, which has demonstrated in vitro pharmacological 
activity. This ligand was reacted with K2[PtCl4] to afford a tetranuclear cycloplatinated 
thiosemicarbazone complex (2.2). Reaction of 2.2 with different mono- and diphosphanes 
yielded two mono- and three dinuclear Pt(II) thiosemicarbazone ligands (2.3-2.7). In all of 
the complexes (2.2-2.7), the thiosemicarbazone ligands act as a dinegative tridentate [C,N,S] 
donor to each metal centre. Single crystal X-ray analyses of three of the complexes in this 
series, including the tetraplatinum derivative, confirmed the structural integrity of these 
complexes. Reactivity studies of the mononuclear platinum(II) complexes revealed that one 
complex is able to undergo oxidative addition reactions with different aryl iodide substrates. 
In vitro pharmacological studies of a selection of these complexes as antiparasitic agents have 
been carried out against the P. falciparum strains, D10 (cisplatin sensitive) and Dd2 (cisplatin 
resistant)) and Trichomonas vaginalis T1. Their cytotoxic effects on the A2780 (cisplatin 
sensitive) and A2780cisR (cisplatin resistant) human ovarian carcinoma cell line has also 
















antiparasitics and antitumor agents. No correlation between the number of platinum-
thiosemicarbazone moieties and pharmacological activity could be discerned. Instead, the 
type of ancillary ligand used to prepare each complex may influence the lipophilic nature of 
each complex thus explaining the trend observed.  
The second and third complex series are based on di- and tri-pyridyl aromatic ethers and 
esters respectively. The di- and tri-pyridyl aromatic ether ligands (4.1 and 4.2) were prepared 
using the Williamson ether synthetic method. The di- and tri-pyridyl ester ligands (5.1 and 
5.2) were isolated upon alkylation of the appropriate carboxylic acid derivative. 
Functionalization of these ligands (4.1, 4.2, 5.1 and 5.2) with either dichloro(p-cymene)-
ruthenium(II), dichloro(pentamethylcyclopentadienyl)rhodium(III) or dichloro(pentamethyl-
cyclopenta-dienyl)iridium(III) moieties yielded the corresponding di- or trinuclear 
organometallic complexes (4.3-4.8 and 5.3-5.8). All of the ligands act as monodentate donors 
to each metal centre and this coordination mode of the polyaromatic ether and ester ligands 
were confirmed upon elucidation of the molecular structures for three of the dinuclear 
complexes (4.5, 5.4 and 5.5). 
The di- and trinuclear platinum group metal complexes synthesized were evaluated for 
inhibitory effects on the P. falciparum strain NF54 (chloroquine sensitive), the T. vaginalis 
strain T1 and the tumor cell lines cisplatin-sensitive A2780 and cisplatin-resistant A2780cisR 
human ovarian cancer. All of the complexes were found to have moderate to high 
antiplasmodial activities and the compounds with the best activities were evaluated for their 
ability to inhibit formation of synthetic hemozoin in a cell free medium. The in vitro 
antitumor evaluations of these complexes revealed that the pyridyl ether complex series (4.2-
4.8) have no significant cytotoxic effect. In contrast, the pyridyl ester containing PGM 
complexes demonstrated moderate activities against these two tumor cell lines and was also 
found to be less toxic to healthy cells.  
Four Pd(II) analogues (7.1-7.4) of the cycloplatinated complexes (2.2-2.8) were prepared in 
order to assess the potential of palladium thiosemicarbazone complexes as catalyst precursors 
for the Suzuki-Miyaura cross couplings of a variety of aryl halides and aryl boronic acids. 
One mononuclear (7.2), two dinuclear (7.3 and 7.4) and one tetranuclear complex were 
tested. The dinuclear cyclopalladated thiosemicarbazone complex 7.4, which contains the 















efficiently catalyze the coupling of various aryl halides and aryl boronic acids, irrespective of 
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1.1. Introduction 
There are several focus areas in the design and application of medicinal compounds, with the 
greatest emphasis being placed on control of side effects, targeting of the drug to the specific 
organs, cells or tissues where it is needed, optimizing bioavailability of the drug, enhancing 
permeability and retention of the drug and overcoming intrinsic or acquired resistance to 
existing therapies.
1,2
  In this regard, the use of metal complexes as therapeutic and diagnostic 
agents is an area of important research.  
Certain metals play crucial roles in biological processes so it is only logical that the study of 
metal complexes, particularly transition metal complexes, would be an area of great potential 
in the treatment of diseases and other illnesses. Metal containing compounds offer several 
properties which may be beneficial to the design and synthesis of better therapeutic agents 
compared to purely organic compounds.
3
 Depending on the metal, these complexes can 
possess a wide range of coordination numbers, geometries, thermodynamic and kinetic 
properties as well as accessible redox states; all of which can be exploited in the pursuit for 
better drug therapies.
3
   
The use of synthetic organometallic complexes as therapeutic agents dates back to the early 
twentieth century.
4
 Paul Ehrlich, now known as the founding father of bioorganometallic 
chemistry, realized the potential of organoarsenic compounds as antiparasitics.
4
 The first 
patented organometallic drug, which also happens to be multinuclear, was Salvarsan® 
(Structure 1.1, Figure 1.1) and was used for the treatment of syphilis along with it second 
generation analogue, Neosalvarsan® (1.2).
4
 Not long after the discovery of these 
organoarsenicals, came the implementation of organomercury compounds in syphilis 
treatment. In time, the use of these organometallic complexes in drug therapies began to 
decrease as their highly toxic side effects became evident.
4
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Years later, the discovery of cisplatin and its analogues as antitumoral agents had a profound 
influence on establishing the field of metal complexes in medicine 
5
 and the amount of 
research already accomplished within this area is substantial.
3,6-8
 However, despite the 
considerable quantity of work completed there are still many avenues of research waiting to 
be explored particularly in the application of multinuclear organometallic complexes as 
chemotherapeutic agents.   
Cancer and parasitic diseases such as malaria are a serious threat, with the number of 
diagnosed cases increasing exponentially every year. For these illnesses, resistance to 
currently available drug therapies has led to a pressing need for new drug designs. The study 
of multinuclear Platinum Group Metal (PGM) complexes as potential chemotherapeutics 
against cancer and parasitic diseases has emerged as an area of great potential. By combining 
the biological properties of certain functional groups present in purely organic ligands to the 
various biological, thermodynamic, kinetic and redox properties of each metal in the platinum 
group series has yielded several possibilities for the treatment of these diseases. This review 
highlights the application of multinuclear PGM complexes against cancer and parasitic 
diseases. Against cancer, they have found application as both cytotoxic agents and pro-drugs 
for targeted photoactivated therapies.       
 
1.2. Multinuclear Platinum Group Metal Complexes: Cancer Chemotherapeutics. 
1.2.1. Cytotoxic Agents. 
 
Cancer is a class of disease that is known to affect millions of South Africans and is a leading 
cause of death worldwide. In 2008, it accounted for 7.8 million deaths worldwide.
9
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diseases wherein abnormal cells rapidly divide and invade other tissues.
10
  There are 
several types of cancers and they can be divided into subcategories
10
:  
 Sarcoma: Cancers that originate in connective or supportive tissues such as bone, 
cartilage and muscle. 
 Carcinoma: Cancers that originate in the skin and tissues that cover internal organs. 
 Lymphoma and myeloma: Cancers that originate in the cells of the immune system. 
 Leukemia: Cancers that originate in bone marrow and other blood forming tissues. 
 Central nervous system cancers: Cancers that originate in the brain and spinal cord 
tissue. 
The most common form of cancer treatment is chemotherapy which employs different drugs 
as cytotoxic agents all of which target DNA and/or cellular replication and expression.
11
  
Figure 1.2 depicts the biological targets of some currently used clinical cytotoxic agents. 








While most of the drugs clinically used today have some success, drug resistance is fast 
becoming a major obstacle particularly in recurring cases. There are two proposed causes of 
this resistance; genetic characteristics may render tumor cells inherently resistant or they may 
acquire resistance following exposure.
11
 In addition to intrinsic and acquired drug resistance, 
the processes targeted by these compounds also occur in healthy cells and thus they are also 
vulnerable to attack by these drugs leading to unwanted side effects. In particular, bone 
marrow cells and intestinal lining cells are susceptible.
11
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improved chemotherapies against cancer, the preferential targeting of cancer cells 
over healthy normal cells is essential.    
The investigation of metal complexes as chemotherapeutic agents has long been of interest 
and the most well-known complexes clinically used today are cisplatin and its analogues 
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The well-established cytotoxic activity of cisplatin against cancer is believed to be through 
exchange of the labile chlorido ligands with water or hydroxido ligands yielding partially 
hydrolyzed species which can then bind to biological macromolecules.
13,14
 In some cases, 
these hydrolysed/aqua species are able to bind to two adjacent guanine bases in the DNA 
chain causing distortions in the DNA structure which cannot be easily repaired by the cell’s 
existing enzymatic mechanisms thus triggering apoptotic cell death (Figure 1.4).
15,16
  
However, in order for cisplatin to exert its antiproliferative activity it needs to diffuse into the 
cell nucleus unchanged where it can then undergo hydrolysis or aquation.
13,15,16
 It has been 
found that up to 98 % of the intravenously administered dose of cisplatin is deactivated 
before it can reach its target.
2
 There are several proposed deactivation mechanisms (Figure 
1.4); the complex undergoes aquation in the extracellular membranes leading to formation of 
adducts with proteins such as serum albumin
2
 and further deactivation can transpire through 
binding of cisplatin to intracellular sulfur donors such as glutathione in the cytoplasm.
15,17
 
Apart from the deactivation of cisplatin prior to reaching its target, the complex is known to 
have high systemic toxicity and there is a tendency of patients developing tumor resistance to 
the drug.
18,19
 These problems can be partially overcome when cisplatin is used in combination 
therapy
20
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For these reasons research moved toward the design of platinum complexes with structural 
similarities to cisplatin. This first wave of research yielded only two complexes that reached 
broad clinical use, carboplatin and oxaliplatin.
21,22
 The replacement of the chlorido ligands 
with a carboxylato ligand and use of the inert chelating nitrogen donor ligand led to an 
increase in water solubility and favourably altered ligand exchange reaction rates.
23,24
 These 
findings have prompted studies into the use of other types of ligand systems that can achieve 
a similar stabilization of platinum. For example, the use of polydentate ligands or the 
coordination of one or more platinum metal ions to polyaromatic or heteraromatic ligands 
which are less likely to undergo dissociation before reaching the cell nucleus. These premises 
have thus led to an ever increasing amount of research into the anticancer activities of 
multinuclear platinum complexes. 
 
1.2.1.1. Multinuclear Platinum Complexes as Cytotoxic Agents 
One of the earliest reports on the development of polynuclear platinum complexes capable of 
DNA interactions was published by Farrel and co-workers in the late 1980’s.
25
 Consequent 
intensive studies of the cis or trans geometries of the metal, the flexibility of the polyamine 
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antitumor candidate.
26-31
 The polyamine-bridged triplatinum complex BBR3464 
(1.6, Figure 1.5) demonstrated high tumor cytotoxicity compared to cisplatin.
32
 It was able to 
form long range intra- or interstrand DNA crosslinks to a much higher degree than cisplatin.
31
 
The antitumor efficacy of BBR3464 was 2-3 orders of magnitude higher than cisplatin 
against cisplatin-resistant cell lines in vitro.
27,32
 It successfully completed phase I clinical 
trials against non-small cell lung, pancreatic, melanoma and ovarian cancers.
33
 However, it 
failed phase II trials due to a lack of major response in small cell lung cancer and in patients 
with gastric and gastro-esophageal adenocarcinoma.
34-36
 Nevertheless, the marginal success 
of BBR3464 demonstrated the validity of the concept of polynuclearity in the development of 
potential metallo-chemotherapeutics and ever-increasing reports are appearing in the 
literature of polynuclear complexes containing not only platinum but also other PGM metals.     
Two dinuclear platinum complexes (1.7 and 1.8, Figure 1.5) containing an aromatic diamine 
spacer have shown appreciable activity against the COC1 human varian cancer cell line.
37
  
Complexes 1.7 and 1.8 exhibited IC50 values of 1.08 and 4.97 µM respectively, lower than 
that of cisplatin (IC50 = 7.02 µM) in this cell line. Studies into the mode of cell death using 
flow cytometric assays found that these complexes induced apoptotic cell death. Cell cycle 
perturbation studies of 1.7and 1.8 showed that they arrest the cell cycle in the G2 (resting 
phase) and M (mitosis) phases. Cisplatin exhibits S phase (DNA synthesis) arrest on cell 
cycle progression suggesting that these diplatinum complexes have a different interaction 










































Figure 1.5. Structure of BBR3464
32
 and the dinuclear complexes 1.6 and 1.7 that exhibit activities better than 
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A trinuclear platinum complex (1.9) containing a central phenyl core was screened for in 
vitro cytotoxic activity against human non-small cell lung cancer (A-549) and the murine 
leukemia (P-388) cell lines.
38
 At a concentration of 10
-7
 M, complex 1.9 displayed percent 
cell inhibitions against P-388 and A-549 cell lines of 27.2 and 33.9 % respectively. These 
values compare favourably with cisplatin which showed inhibition rates of 3.4 % (P-388) and 
0.6 % (A-549) at the same concentration. DNA binding studies of complex 1.9 using UV, 
fluorescence and circular dichroism (CD) spectroscopy and an agarose gel mobility shift 




















The effect of the triplatinate complexes 1.10 – 1.12 (Figure 1.7) on cancer cell viability as 
well as cytotoxic effect in four cancer cell lines was investigated in comparison to cisplatin.
39
 
All of the complexes reduced cell viability in a dose-dependent manner with the maximum 
reduction in cell viability being reached at 50 µM. Table 1.1. lists the IC50 values for the 
complexes 1.10 – 1.12 as well cisplatin against the human HT29 colon-rectal carcinoma, 






































1.10: X = NCPh, Y = Cl-













































HT29 HepG2 MG63 MDA-MB-231 
cisplatin 58 65 60 66 
1.10 9 26 10 28 
1.11 21 28 8 23 
1.12 29 53 54 36 
 
All of the complexes showed better cytotoxicity than cisplatin against all four cell lines. 
Complex 1.10 was a better cytotoxic agent than 1.11 and 1.12 against the cell lines HT29 and 
HepG2 displaying IC50 values of 9 and 26 µM respectively. An IC50 value of 8 µM was 
displayed by complex 1.11 in the MG63 cell line. Complexes 1.10 and 1.12 exhibited similar 
activities in the MDA-MB-231 cell line. The polypyridyl ligands used to prepare these 
complexes were tested for activity and found to exhibit no inhibitory effects. Overall, it was 
found that these trinuclear platinum complexes prepared from heterocyclic ligands showed 
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The diplatinum containing metallacycle 1.13 was able to decrease the cell viability 
of both estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) 
breast cancer cell lines in a dose-dependent manner in vitro.
40
 Complex 1.13 showed a 
significantly higher potency against both cell lines compared to cisplatin and when the 
antiproliferative effects of 1.13 on DNA synthesis was ascertained it was found that it was 
more than five times more active than cisplatin (16 μM for 1.13 vs 86 μM for cisplatin) in the 
MDA-MB-231 line and 4.5 times more active than cisplatin (21 μM for 1.13 vs 98 μM for 
cisplatin) in the MCF-7 line. 
 
 
Four tetranuclear Pt(II) metallasquares (1.14 -1.17, Figure 1.8) were found to selectively bind 
to htelo G-quadruplexes over promoter G-quadruplexes (bcl2) and duplex DNA in cell free 
assays.
41
 In vitro assessments of the cyctotoxic effect of 1.14-1.17 on HeLa (human cervical 
cancer), HepG2 (Human hepatocellular liver carcinoma), MCF-7 (human breast 
adenocarcinoma), A549 (cisplatin-sensitive human lung adenocarcinoma) and A549/cis-R 
(cisplatin-resistant human lung adenocarcinoma) epithelial cell lines revealed these 
compounds to decrease cell viability in a dose-dependent manner.
41
 The cytotoxic activities 
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displayed activities against all cell lines that were significantly higher than 
cisplatin. Against the cisplatin-sensitive A549 and cisplatin-resistant A549/cisR cell lines, 
complexes 1.14-1.17 displayed similar activity profiles suggesting that these tetranuclear 
complexes may be able to overcome cisplatin resistance and possibly have a mechanism of 
action that is distinct from cisplatin.
41
   
1.2.1.2. Polynuclear Complexes containing other Platinum Group Metals as 
Cytotoxic Agents 
The relevance of ruthenium complexes in biology was first realized by Francis Dwyer and 
co-workers in the 1950’s.
42
 They investigated simple ruthenium coordination complexes 
containing 2,2-bipyridine and 1,10-phenanthroline ligands and discovered that these 
complexes exhibited tumor growth inhibition in a mouse xeno graph model as well as 
showing bacteriostatic and bacteriocidal activities.
43-45
 Their research was largely forgotten 
until Rosenberg and co-workers discovered the promising activity of cisplatin.
12,13
  
As mentioned earlier, the systemic toxicity, intrinsic and acquired drug resistance found in 
patients as well as the rapid deactivation of cisplatin before reaching its target has bred a need 
for alternative drug therapies. Apart from designing platinum complexes with different ligand 
systems, ruthenium and the other platinum group metals soon gained attention as potential 
chemotherapeutics.    Ruthenium is capable of accessing a range of oxidation states (Ru(II), 
Ru(III) and Ru(IV)) under physiological conditions and its compounds have also been shown 
to be less toxic than those of platinum.
24,46-49
 This reduced toxicity is believed to be a 
consequence of ruthenium being able to mimic iron in the binding to biological molecules 
like albumin and transferrin.
24
 Cancer cells rapidly divide and so exhibit a greater demand for 
iron causing transferrin receptors to be over-expressed thus leading to ruthenium based drugs 
to be more effectively delivered to cancer cells.
48,49
  
Rh(III) and Ir(III) are also gaining attention as potential anti-tumor metals. An account of the 
anti-tumor properties of RhCl3∙3H2O actually predates the discovery of cisplatin
50
 but the 
cytotoxic abilities of Rh(III) and Ir(III) were not seriously considered until recently.
51,52
 This 
lack of interest has been attributed to the kinetic inertness of these metal ions.
51-54
 However, it 
has been proposed that this lack of reactivity can be overcome using one of two rational 
approaches, (i) the use of one or more ligands that provide a strong trans effect to improve 
the rate of substitution and (ii) complexation of these metals to ligands that display 
independent cytotoxic activities and can thus interact with specific biological targets.
52
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One of the earliest reports of a potential ruthenium complex with anticancer activity 
was proposed by Clarke and co-workers (1.18, Figure 1.9) and thought to achieve its 
cytotoxic function by binding to DNA.
55,56
 The trinuclear complex ruthenium red (1.19) is 
also one of the earlier examples studied and believed to selectively bind to Ca(II)-
transporting proteins thus arresting Ca(II) transport into cells.
55
 One of the biggest hurdles to 
the biological studies of these complexes was their poor water solubility. This led to the next 
set of ruthenium complexes under investigation to be the highly water soluble Ru(II) 
chlorido-DMSO complexes such as 1.20, first discovered by Sava et al.
57-59
 This early work 
eventually led to the discovery of complex 1.21, also known as NAMI-A, which acts as an 
anti-metastatic agent by either inhibiting metastasis formation
60
 or reducing metastases size.
61
 
It has recently completed phase I clinical trials
62-65
 and is currently undergoing phase II 







































































In parallel with the discovery of NAMI-A, Keppler and co-workers found the promising 
activity of KP-1019 (1.22). In contrast to NAMI-A, KP1019 is an antineoplastic agent that 
induces apoptosis via the intrinsic mitochondrial pathway. It exhibits high selectivity and low 
toxicity through accumulation in transferrin-receptor over-expressing tumor cells and 
reduction to a Ru(II) species in the tumor environment.
66
 KP1019 has also completed phase I 
clinical trials
65-67
 and it shows better cellular uptake compared to NAMI-A as well as  
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The discovery of these two inorganic ruthenium complexes (1.21 and 1.22) has 
given rise to the investigation of organoruthenium complexes for cancer activities and most 
of the examples found in literature are largely made up of Ru(II) arene complexes which 
were first developed by two distinct research groups, Dyson and co-workers
24,73,74
 and Sadler 
and co-workers.
17,71
 The basis for the design and study of these arene-ruthenium(II) 
complexes was the suggestion that the previously studied Ru(III) complexes such as 1.21 and 
1.22 were precursors from which the active Ru(II) species was generated in vivo. Thus, it 
makes sense for research to move toward the preparation of Ru(II) complexes.
17,71
 The 
ruthenium-arene PTA complex 1.23 (Figure 1.10) and the extended arene-Ru(II) complex 
1.24 were among the first complexes of these type to be studied. They both showed great 
potential as cancer chemotherapeutics but were eventually found to have low selectivity for 

























1.23: RAPTA-C 1.24: RM175 1.25  




Nevertheless, subsequent studies of analogous complexes have shed light on the structure-
activity relationships of these compounds. It has been found that by changing the nature of 
the metal, the arene ligand or by introducing a chelating ligand, the activity of piano-stool 
complexes could be fine-tuned.
80-85
 For example, complex 1.25 which contains an iodo 
leaving group, the phenyl-pyridin-2-yl-diazene chelating group and an extended biphenyl 
arene system has been found to be highly water soluble. It has been proposed that this 
complex is able to enter the cytoplasm intact, where it proceeds to act as a catalyst of 
glutathione oxidation leading to increased oxidative stress and eventual apoptotic cell death.
79
   
Further to these studies, the application of complexes containing multiple metal-arene 
moieties either as cluster compounds or supported on different mono- or polydentate ligands 
is now emerging as an area of great potential. Therrien and co-workers reported on the in 
vitro activity of tri- and tetranuclear ruthenium arene cluster compounds (1.26 – 1.30, Figure 
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ovarian carcinoma cell lines.
86
 While the tetranuclear complexes (1.28 - 1.30) did not 
exhibit any activity at the highest concentration tested (100 µM), the trinuclear complexes 
exhibited activities in the low micromolar range (Table 1.2.).
86
 It was suggested that the 
marked difference in activities between the tri- and tetraruthenium complexes was a 
consequence of complexes 1.26 and 1.27 containing a hydrophobic pocket and a µ-oxo ligand 
and could thus form supramolecular interactions with hydrophobic arene units and hydroxyl 
groups present inside proteins.
86
 The inhibitory activities of 1.26 and 1.27were not as low as 
that of cisplatin in either cell line but it was noted that the compounds were much more active 




The influence of several structural features in the di- or trimetallic ruthenium and osmium 
complexes 1.31 – 1.38 (Figure 1.12) on in vitro antitumor activity was investigated by 
Mendoza-Ferri et al.
87
 They wished to compare the effect of the type of metal centre, the 
leaving halide ligand, nature of arene group and the number of metal centers on activity. The 
complexes were screened for activity against two cancer cell lines and their water solubility 















































1.29 1.30  
Figure 1.11. Structure of tri- and tetraruthenium arene clusters (1.26 – 1.30) screened against A2780 and 




















Table 1.2. Inhibition of cell viability (IC50) of complexes 1.26 – 1.30 on A2780 and A2780cisR ovarian 




A2780  A2780cisR 
1.26 9.8 ± 0.2 14.6 ± 0.7 
1.27 9.1 ± 0.9 28.9 ± 2.8 
1.28 >100 >100 
1.29 >100 >100 
1.30 >100 >100 
RAPTA-C (1.23) >100 >100 
cisplatin 1.5 ± 0.3 8.7 ± 1.6 
 
The water solubility was used as a measure for lipophilicity and it was found that for the 
dimetallic complexes 1.31 – 1.35 increasing the length of the spacer increases the lipophilic 
nature of the complex and a corresponding increase in activity is observed. Changing the 
metal centre also influenced activity, the osmium complexes 1.31 and 1.33 were 3 – 6 times 















1.31: M = Os, n = 6, arene = p-cymene, X = Cl
1.32: M= Ru, n = 6, arene = p-cymene, X = Cl
1.33: M = Os, n = 8, arene = p-cymene, X = Cl
1.34: M = Ru, n = 8, arene = p-cymene, X = Cl
1.35: M = Ru, n = 6, arene = p-cymene, X = Br
1.36: M = Ru, n = 6, arene = p-cymene, X = I
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Table 1.3. Solubility and Cytotoxic Values for Complexes 1.31 – 1.38 against SW480 and A2780 
  
IC50 (µM) 
Compound Solubility (mM) SW480 A2780 
1.31 1.6 88 + 4 n/d
a
 
1.32 3.9 26 +8 30 + 6 
1.33 0.2 15 + 5 29 + 13 
1.34 2.2 2.5 + 0.2 5.7 + 0.5 
1.35 0.6 54 + 4 52 + 15 
1.36 0.1 33 + 4 36 + 2 
1.37 0.6 25.7 + 0.3 43 + 1 




The trinuclear complex 1.38 was more water soluble than the dinuclear complexes 1.31 – 
1.36 but its activity against the A2780 tumor cell line was much lower than the other 
complexes. It also exhibited an IC50 value (59 µM) higher than most of the dimetallic 
complexes in the SW480 cell line. Only minor effects on the activity occur when the arene 
group is changed from p-cymene to biphenyl or when the leaving halide group is changed 
from chlorido to bromido or iodo. 
Water soluble triosmium carbonyl clusters (1.39 - 1.42, Figure 1.13) containing a 
cyclometallated benzoheterocycle have been investigated as telomerase inhibitors. 
Telomerase is crucial in cancer progression as it is a ribonucleoprotein that sustains the length 
of DNA by adding hexameric units to the end of the 3’ single strand terminus.
88,89
 The 
complexes containing sulfonated phosphine ligands were found to be the best inhibitors of 
telomerase function when tested on enzymes in a cell free medium. However, they were 
found to have decreased activity when tested for telomerase inhibition in the MCF-7 breast 
































































Tetraruthenium molecular rectangles (1.43-1.55) have been investigated for their anti-
proliferative activities.
90-92
 Complexes 1.43 and 1.44 (Figure 1.14) were found to be robust 
coordination assemblies that did not undergo ligand exchange reactions with N-donor or S-
donor biorelevant ligands.
92
 Studies of the DNA binding abilities revealed these compounds 
to have non-covalent interactions with DNA which did induce significant conformational 
changes in DNA. In vitro, both complexes displayed IC50 values in the low micromolar range 
against the human ovarian carcinoma cell lines, cisplatin-sensitive A2780 [IC50 = 19 μM 




The metalla-rectangles 1.45-1.47 (Figure 1.15) were screened for activity against SK-hep-1 
(liver cancer), HeLa (ovarian cancer), HCT-15 (colon cancer), A-549 (lung cancer) and 
MDA-MB-231 (breast cancer) cell lines.
91
 Complexes 1.45 and 1.46 did not display any 
significant inhibitory effects while 1.47 showed activities that were higher than cisplatin 
against the SK-hep-1 and HCT-15 cell lines and were similar to cisplatin against the HeLa, 
















































Complexes 1.48-1.55 demonstrated large differences in activities compared to each other 
when screened for inhibitory effects in vitro against SK-hep-l and HCT-15. Complexes 1.50 
and 1.53 displayed the highest cytotoxic activities against both cell lines; in the low 
micromolar range (6 -10 μM) while, 1.48 and 1.49 were not active. Complexes 1.51 and 1.55 
were moderately active with IC50 values between 16-39 μM. Complexes 1.52 and 1.53 




















1.2.2. Multinuclear PGM Complexes as Phototoxic Agents. 
Apart from the use of metal complexes simply as cytotoxic agents, they are being studied for 
their potential as photochemotherapeutics for Photodynamic Therapy (PDT) and 
Photoactivated Therapy (PACT). The redox active nature of metals such as rhodium, iridium 
and ruthenium make them attractive for targeted therapies like PDT and PACT. In both types 
of therapies, the potentially photoactive drug should ideally show preferential uptake by 
tumor cells but this is often not the case thus, alternatively, they should show little or no 
effect on either healthy or tumor cells in the absence of light.
93
 
Two  mixed metal trinuclear complexes, containing Rh(III) and either Ru(II) or Os(II) metal 
ions (1.56 and 1.57, Figure 1.16) have been studied for their effect to inihibt cell growth in 
mammalian cells upon photoexcitation.
94
 Previous studies of complexes 1.56 and 1.57 
showed that they were able to cleave plasmid DNA upon exposure to light of > 460 nm for 
20 min.
95
 Thus, these complexes were tested on African green monkey (Chlorocebus 
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1.46: I + VII; 1.46: I + VIII
1.47: III + VII; 1.48: I + V
1.49: II + V; 1.50: III + V
1.51: IV + V; 1.52: I + VI
1.53: II + VI; 1.54: III + VI
1.55: IV + VI  






































1.56: M = Ru








The cells were dosed with increasing concentrations of each complex starting at 3 µM. The 
treated cells were exposed to focused light of > 460 nm for 4 min before being incubated 
again for 48 hours. It was found that upon light exposure, complexes 1.56 and 1.57 were able 
to inhibit cell replication with the greatest cell death being observed for concentrations 
greater than 12 µM. Cells that were dosed with either 1.56 or 1.57 and not exposed to light 
showed normal growth confirming that these complexes only act upon photoexcitation. In the 
case of complex 1.56, its believed that its phototoxic effect arises from the MLCT excitation 
of ruthenium(II) resulting in charge transfer from Ru(II) to Rh(III) via the bridging π-ligands. 
The Rh(II) metal center acts as an electron acceptor which consequently cleaves DNA.
96
  
The phototoxic effect of three tetranuclear ruthenium functionalised porphyrin conjugates 
was studied in the MDA-MB-231 breast cancer cell line (1.58 – 1.60).
93
 The cell cultures 
were exposed for 24 hours to concentrations of each conjugate ranging from 0.1 – 10 µM 
before being irradiated at 590-700 nm with a fluence rate of 25 mW/cm
2
 and light doses from 




 A set of control cell cultures were also used, one containing only the cancer 
cells and culture medium was also irradiated and showed cell proliferation inhibition. The 
other control cell culture consisted of the cells dosed with the complexes and kept in the dark 













































































Figure 1.17. Metalloporphyrin conjugates 1.58 – 1.60.
93
  
In the dark, all three complexes exhibit cytotoxic effect with 1.60 showing the best IC50 value 
of 2.09 µM. Upon irradiation, all three complexes exhibited an increase in its cell 
proliferation activity and the effect shows a positive increase with increasing light doses. At 
moderate light doses (5 J/cm
2
), complex 1.58 is rendered 12 times (IC50 = 0.29 µM) more 
active compared to its dark cytotoxicity (IC50 = 3.34 µM). All three complexes were deemed 
good potential photosensitizers for PDT with complex 1.59 being the most potent inhibitor.  
Table 1.4. IC50 values of Complexes 1.58 – 1.60 in MDA-MB-231 cell line 








1.58 3.34 + 1.87 1.73 + 1.10 0.29 + 0.02 0.13 + 0.04 
1.59 24.62 + 6.38 10.64 + 1.61 3.93 + 1.24 1.71 + 0.64 
1.60 2.09 + 0.78 0.56 + 0.12 0.24 + 0.10 0.10 + 0.04 
 
Schmitt and co-workers have screened a series of tetranuclear iridium, rhodium and 
ruthenium porphyrin complexes (Figure 1.18) for activity as dual photosensitizers and 




































































































1.63: R = H
1.64: R = Me
1.65: R = 1-Me-4-isopropyl
1.66: R = 1,2,3,4,5,6-hexamethyl
1.67: R = 1,4-di(OOCEt)
1.68: M = Rh
1.69: M = Ir 1.70  




The dark cytotoxicities, absence of laser exposure, were determined for all complexes. After 
exposure for 24 hours, complexes 1.65, 1.66 and 1.70 exhibited moderate cytoxicity (≈ 50 
µM) against the melanoma cells while 1.63, 1.64 and 1.67 exhibited cytotoxicities greater 
than 100 µM. The rhodium complex (1.68) showed no activity.
97
 The complexes 1.64 and 
1.65 were rescreened against the cell line along with complexes 1.61 and 1.62, this time the 
melanoma cells were exposed to the compounds for 72 hours. The cytotoxic values were 
much lower than observed for the previous screening; 1.64, 1.65 and 1.62 exhibited values of 




Fluorescence studies of these complexes in the melanoma cells showed that complex 1.68 
was not taken up by the cells and would explain why the complex did not exhibit activity. 
The ruthenium complexes were found to accumulate in the cytoplasm and organelles. The 
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concentration of 10 µM, the ruthenium complexes 1.64 – 1.67 leads to 60-80 % 
phototoxicity for just 5 J/cm
2
 light exposition. The same level of phototoxicity was only 
reached for complex 1.70 with 30 J/cm
2
 exposition. As expected, complex 1.68 did not 
exhibit phototoxicity.   
The phototoxicity of two octanuclear porphyrin-ruthenium metalla-cubes (Figure 1.19, 1.71 
and 1.72) in the cervix (HeLa) and pulmonary (A549) cancer cell lines.
99
 In the dark, these 
complexes exhibited cytotoxicities greater than 70 µM. When cell cultures treated with 1 µM 
of each complex were exposed to irradiation at 652 nm with a fluence of 20 mW/cm
2
 and 
light doses from 2-20 J/cm
2
, they were found to exhibit good phototoxicity. The complexes 









































































1.3. Application of Platinum Group Metal Complexes Against Malaria  
Parasitic diseases have proven to be a major health problem particularly in developing 
countries. Presently, there are only a few effective drugs available for their treatment. The 
frequent manifestation of resistance to these current therapies have posed a serious 
impediment to their use making the discovery of new drugs leads an urgent and challenging 
task.
100
 In the past, big pharmaceutical companies were reluctant to invest in the research and 
development of parasitic disease chemotherapies as these illnesses mostly plague poorer, less 
developed countries where only low financial returns could be realized.
100,101
 However, in the 
last ten years, intervention by several international non-profit organizations has breathed new 
















Chapter 1. Multinuclear PGM Complexes as Pharmacological Agents 23 
The application of metal containing compounds for the treatment of parasitic 
diseases is a crucial area of research as they can show distinct selectivity toward parasite 
biomolecules over host biomolecules. Several strategies govern the study of metallo-
antiparasitics; incorporation of a metal into established antiparasitics could enhance its 
pharmacological action or favourably alter its pharmacokinetic parameters.
100
 Additionally, 
new metallo-antiparasitic agents could be developed which are able to deliver potent metal 
containing fragments capable of selectively interacting with parasite targets.
100
  
 Malaria is amongst the deadliest and most widespread parasitic diseases found today. A 
recent World Health Organisation (WHO) report estimated that 216 million cases of malaria 
infection were reported in 2010 with 655 000 resulting deaths mainly among African 
children.
102
 In fact, most of these malarial infections and deaths occurred in sub-Saharan 
Africa.  
There are four parasite species which cause malaria in humans: 
 Plasmodium falciparum 
 Plasmodium vivax 
 Plasmodium malariae 
 Plasmodium ovale 
All four species are transmitted to humans through the bite of an infected female Anopheles 
mosquito and P. falciparum is responsible for the greatest number of malarial deaths.
102
 The 
life cycle of the malaria parasite consists of two categories, the sexual stages in the insect 
vector and the asexual stages in the human host (Figure 1.20).
101,103
   
The bite of the female Anopheles mosquito injects parasite sporozoites into the human’s 
bloodstream. They rapidly invade liver cells (hepatocytes) where they evolve into the asexual 
form of the parasite known as schizonts containing a vast number of small round 
merosoites.
101
 These schizonts undergo asexual replication known as exoerythrocytic 
schizogony into erythrocytes and this ultimately results in the liver cells swelling and 
bursting thereby releasing merozoites into the bloodstream where they infect red blood cells 
in the host. Within the infected red blood cells they begin the trophozoite stage wherein they 
experience a period of active metabolism for the synthesis of proteins. This metabolism 
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Within the red blood cells, some of the merozoites develop into micro-
gametocytes, the sexual form of the parasite, and circulate in the blood stream until a female 
Anopheles mosquito bites the person and ingests the infected blood. The micro-gametocytes 
quickly grow into macro-gametocytes producing oocysts which eventually rupture and 
release infectious sporozoites that migrate to the mosquito’s salivary glands where they can 




    
 




P. falciparum infections were largely treated with chemotherapies using chloroquine (1.73, 
Figure 1.21) but employment of chloroquine for malaria treatment has been greatly reduced 
due to the emergence of resistance in most parts of the world. These days, it is only effective 
to treat P. falciparum in Egypt and a few countries in the Middle East and Central 
America.
106
  Currently, the standard first line therapy for uncomplicated P. falciparum 
malaria infections is artemisinin-based combined therapy (ACT).
106,107
 Artemisinin has 
demonstrated great effectiveness for the treatment of  P. falciparum infections. It is fast 
acting and able to eliminate malaria parasites at a rapid rate.
108
 ACT is a combination of 
artemisinin or an artemisinin derivative and a second drug with a separate parasite target in 
order to enhance efficiency and decrease the risk of resistance development. The five ACT 
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Chloroquine and other related aminoquinolines have been shown to selectively build up 
within the parasite and are believed to target the formation of hemozoin. The digestion of the 
infected host’s hemoglobin to provide essential amino acids for its growth and nutrition for 
the parasite is a vital step.
109
 A side product of this hemoglobin digestion is free heme which 
is toxic to the parasite. The parasite removes this threat by conversion of the free heme into a 
crystalline solid known as hemazoin which is nontoxic to the parasite. Aminoquionlines can 
efficiently obstruct the formation of hemazoin through π-π stacking of the hydrophobic 
quinoline residues with heme thus causing a build-up of toxic heme and eventual death of the 
parasite.
110,111






























1.78: R= H - Dihydroartemisinin
1.79: R= CH3 - Artemether




































1.84: Pyrimethamine  
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In the case of artemisinin and its derivatives, the actual mode of inhibition has yet to be 
clearly defined but it is accepted that these drugs selectively target parasites because of their 
enhanced uptake by parasitized erythrocytes.
112
 Despite the effectiveness of ACT treatments, 
the emergence of resistance to these drugs is a very real possibility and is under intense 
monitoring.
107
 Resistance of P. falciparum to artemisinins was observed at the Cambodia-
Thailand border.
113
 Suspected resistance has also been reported in Cambodia, Vietnam, 
Myanmar and Thailand.
114
 The artesunate/mefloquine and dihydroartemisinin/piperaquine 
combination therapies have both presented resistance.
115-117
 Measures are being taken to limit 
the spread of artemisinin-resistant strains,
114
 however it is still of great import to find 
alternative drug candidates as most of the currently developed drugs are mainly artemisinin 
derivatives and may eventually become susceptible to parasite resistance as well. 
 
One of the earliest attempts to produce metal complexes with antimalarial activity was 
published in 1987.
118
 An extensive series of complexes were prepared using amodiaquine 
(1.75) and primaquine and a variety of metals including Cr(III), Fe(III), Pd(II) and Rh(III). 
However the results were disappointing, most of the complexes showed no enhancement in 
activity compared to the uncomplexed drugs. Study of metal conjugates of chloroquine has 
shown much more promise. 
 
Sánchez-Delgado et al reported that a [Ru(II)-chloroquine]2 dimer and mononuclear Rh(I) 
complex (Figure 1.22) proved active against P. falciparum strains in vitro.
119
 The dinuclear 
ruthenium complex (1.85) is 4.5 times more active than chloroquine diphosphate against two 
chloroquine resistant P. falciparum strains, FcB1 and FcB2. The rhodium complex (1.86) 
exhibited activities similar to chloroquine diphosphate. In vivo studies of the complexes in the 
rodent malaria parasite P. berghei showed that at the same concentration of chloroquine 
diphosphate required to kill 50 % of parasitemia, 1.85 reduced parasitemia by 94 % and 1.86 













































Consequent to the initial chloroquine metal conjugate work pioneered by Sánchez-Delgado et 
al, came the discovery of the chloroquine analogue, Ferroquine (1.87).
121
 The metallocene 
containing complex has shown impressive antiplasmodial activity and is even active in 
chloroquine resistant strains.
120-123
 It has completed Phase I clinical trials and is expected to 
complete Phase II clinical trials against uncomplicated malaria soon. Ruthenium-arene 


























































 28 Synthesis and Study of Multinuclear PGM complexes as in vitro Pharmacological Agents 
They were evaluated for in vitro activity against three chloroquine resistant (W2, 
Dd2 and K1) and four chloroquine sensitive (FcB1, 3D7, PFB and F32) P. falciparum strains. 
Complexes 1.88 – 1.91 were found to be moderate inhibitors of the chloroquine sensitive P. 
falciparum strains with activities lower than chloroquine diphosphate. Against the 
chloroquine-resistant strains these complexes displayed consistently better activities 
compared to chloroquine diphosphate. The most potent inhibitor was found to be complex 
1.90 which was 5 times more potent than CQDP against the Dd2 and K1 strains. The results 
obtained in this study clearly illustrate the concept of enhanced activity of metal-chloroquine 
conjugates against resistant malarial strains. 
 
Iridium-chloroquine analogues (1.92 – 1.94) have also been studied for in vitro 
antiplasmodial activity on cultures of P. Berghei (Figure 1.24).
125
 These complexes were able 
to inhibit parasite growth at nanomolar concentrations. They displayed IC50 values of 72 nM 
(1.92), 59 nM (1.93) and 126 nM (1.94). The dinuclear derivative (1.93) was more active 































1.94: (CH3)2CO  




Arene ruthenium complexes containing bis-chelating chloroquine analogues (1.95-1.97, 
Figure 1.25) have also shown promising activities against a chloroquine sensitive (D10) and a 
chloroquine resistant (Dd2) P. falciparum strain.
126
 Against the D10 parasitic strain, all three 
complexes displayed activities in the low micromolar range. Complex 1.97 exhibited the best 
IC50 value (0.07 µM) which was only slightly higher than chloroquine (IC50 = 0.025 µM). 


















































There are fewer examples of antiplasmodial PGM metal complexes that are non-quinolone 
based. A series of cationic platinum complexes containing substituted bipyridyl and 
phenanthroline ligands were tested for antiplasmodial activity against the D10 (chloroquine 
sensitive) and K1 (chloroquine resistant) strains.
127
 They inhibited parasite growth at 
concentrations in the nanomolar range. Several examples of mononuclear ruthenium and 
palladium thiosemicarbazone complexes (Figure 1.26) were reported to show antiplasmodial 
activity in the micromolar range against NF54 (chloroquine sensitive),
128
 Dd2 (chloroquine 
resistant),
128
 W2 (chloroquine resistant)
129
 and D10 (chloroquine sensitive)
129















1.98: Ar = phenyl, 5-chlorophenyl, naphthyl or ferrocenyl
         R = H or 1-ipropyl-3-methyl  
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While there are several reports on the use of mononuclear PGM complexes as 
antiparasitics agents, there are few examples of multinuclear derivatives. The encouraging 
data published for mononuclear derivatives emphasize the potential of multinuclear 
analogues as antiparasitics agents.  
 
Mono and multinuclear cyclopalladated complexes containing tridentate thiosemicarbazone 
ligands (1.00 – 1.109, Figure 1.26) showed promising activities against two P. falciparum 
strains, the 3D7 (chloroquine sensitive) and K1 (chloroquine resistant) strains.
130
 Two 
tetranuclear (1.100 and 1.101), two mononuclear (1.102 and 1.103) and six dinuclear (1.102-
1.109) complexes were screened in this study. Complexes 1.106 – 1.107 did not show any 
appreciable inhibitory effect on either strain; this was attributed to their poor solubility in 
DMSO and water. The rest of the complexes displayed activities in the mid to low 
micromolar range with best activities observed against the 3D7 strain. Complexes 1.102 – 
1.104 showed the best antiplasmodial activities (IC50 = 2.43, 3.03 and 2.94 µM respectively). 
While they were not as potent as chloroquine in either strain, complexes 1.101 – 1.109 were 
more vastly more active than their free ligands emphasizing that chelation to a metal can 










1.102: R = CH3 


















1.104: R = CH3 









1.100: R = CH3 

















1.106: R = CH3 

















1.108: R = CH3 
1.109: R = CH2CH3  
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1.4. Conclusions 
Cancer and parasitic diseases such as malaria pose a serious threat, with the number of 
diagnosed cases increasing exponentially every year. Intrinsic and acquired drug resistance 
and systemic toxicity to currently used chemotherapies has led to an urgent need for new 
drug leads. Multinuclear PGM complexes have emerged as valid candidates to circumvent 
the problems currently faced by purely organic molecules. In cancer, not only can these types 
of complexes be employed as cytotoxic agents, they can also be used as photoactivated 
chemotherapeutics for localized tumor inhibition. 
Whilst there are scant reports on the use multinuclear PGM complexes as antiparasitals, the 
promising results obtained for mononuclear complexes serves as motivation for the 
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1.5. Aims and Objectives 
1.5.1. Aim 
The overall aim of this research project was to synthesize new platinum group mono- or 
multinuclear organometallic complexes and evaluate their activity as (i) biological agents 
against malaria and cancer or (ii) as catalyst precursors for cross coupling reactions.  
1.5.2. Specific Objectives  
1.5.2.1. Synthesis 
The synthetic objectives of this project were to prepare new mono- and polynuclear 
complexes containing platinum, palladium, ruthenium, rhodium or iridium and fully 
characterize these compounds using several analytical and spectrometric techniques. The type 
of complex prepared is divided into three sub-categories. These sub-categories are based on 
the synthesis of three different types of ligand systems, each of which was used to prepare 
new complexes with different platinum group metals. 
i. The preparation of mono- and polynuclear cycloplatinated thiosemicarbazone 
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ii. The synthesis of di- and trinuclear ruthenium(II), rhodium(III) and iridium(III) 
pyridyl ether complexes with the general structure II and III containing benzyl 

















Figure 1.29. General structures of di- and trinuclear complexes containing pyridyl ether scaffolds 
 
iii. The preparation of di- and trinuclear ruthenium(II), rhodium(III) and iridium(III) 
pyridyl ester complexes with general structures IV and V from ligands containing 





















Figure 1.30. General structures of di- and trinuclear complexes containing pyridyl ester scaffolds 
 
1.5.2.2. Pharmacological Studies 
A selection of the PGM complexes synthesized were evaluated in vitro for activity as 
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polynuclear cyclopalladated complexes of the thiosemicarbazone, 3,4-
dichloroacetophenone thiosemicarbazone were able to moderately inhibit P. falciparum 
parasite growth in vitro.
130
 The purpose for preparation of cycloplatinated derivatives is to 
assess whether replacing palladium with the biologically active metal, platinum, will lead to 
an increase in antiparasitic activity. 
The biological activity of mono- and polynuclear 4-pyridyl ruthenium arene complexes has 
been established.
132
 The rationale behind synthesizing pyridyl ether and ester ligands is to 
potentially increase the lipophilic nature of the scaffolds to which the metal-moieties will be 
conjugated thus increasing pharmacological activity and to determine if the number of metal 
moieties (2 vs 3 moieties) has an effect on pharmacological activity. Further to this, the effect 
of changing the metal moieties from [dichloro(p-cymene)ruthenium] to 
[dichloro(pentamethylcyclopentadienyl)rhodium] or [dichloro(pentamethylcyclopenta-
dienyl)iridium] moieties on antiparasitic and anticancer activities will be evaluated. 
1.5.2.3. Preliminary Screening of Cyclopalladated Thiosemicarbazone Complexes as 
Catalyst Precursors    
Four cyclopalladated thiosemicarbazone complexes that are analogous to the 
cycloplatinated complexes have been prepared (I, Figure 1.28). These complexes were 
evaluated for their ability to catalyze the Suzuki-Miyaura cross coupling reaction of a variety 
of aryl halides and aryl boronic acids. This is a preliminary investigation to determine if there 
is potential in these types of tridentate Pd(II) complexes as catalyst precursors for cross 
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2.1. Introduction 
Thiosemicarbazones are a class of Schiff base compounds that contain a thiourea moiety. 







 As chemotherapeutics their mode of action is believed to be through 
the inhibition of ribonucleotide reductase thus arresting DNA synthesis.
15
 As antiplasmodial 
agents, thiosemicarbazones may affect processes, some associated with hemoglobin (Hb) 
digestion in the food vacuole of the parasite, through several possible inhibitory mechanisms 
of action.
5,16-21
 The ability of thiosemicarbazones to form stable complexes with a variety of 
metals is also believed to be of great importance to their biological activities. The lipophilic 
nature of the complex might be enhanced compared to the free ligand and certain side effects 
may decrease or be altogether avoided since the ligand could dissociate and the metal ion can 
then interact with its intended target.
22-24
  
Research into the synthesis and application of thiosemicarbazone metal complexes as 
biological agents is thus an area of great promise. The discovery of cisplatin and its analogues 
as antitumoral agents had a profound influence on establishing the field of metal complexes 
in medicine
25
 and the amount of research already accomplished within this area is 
substantial.
26-31
 Despite the considerable quantity of work completed, there are still many 
little-researched avenues such as the preparation of mono- and polynuclear complexes from 
biologically active hybrid ligands. Hybrid ligands are defined as bis- or polydentate 
molecules which contain at least two different functionalities containing donor atoms capable 
of binding to a metal.
32
 Thiosemicarbazones are prime hybrid candidates as they fulfill this 
basic criterion.  
Several bonding modes have been observed for thiosemicarbazones.
33-39
 For 
arylthiosemicarbazones the most common type of bonding modes observed are the tridentate 
[D,N,S] (I, Figure 2.1; where D = ortho carbon or heteroatom on the ortho carbon) or 
bidentate [N,S] (II). Depending on the metal, sulfur can coordinate either as a neutral (thione) 
or anionic (thiol) donor.
40
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The coordination chemistry of thiosemicarbazones is a well established area with reviews on 
the subject being published as far back as 1974.
41
 There have been extensive reports on the 

















 Thiosemicarbazone complexes 
containing metals from the Platinum Group Metal (PGM) series have also been 
reported.
40,54,55
 PGM thiosemicarbazone complexes are gaining attention not just because of 
the structurally diverse complexes that can be prepared but due to the potential applications 
of these compounds in biology as well as catalysis.
54-69
 Coupling the known bioactivities of 
thiosemicarbazones to the potentially beneficial biological properties of PGM metals such as 
palladium and platinum may result in a cooperative effect whereby the thiosemicarbazone 
ligand helps the metal reach its intended target (DNA) and the ligand can then dissociate and 
inhibit its cellular target. 
 
Mononuclear thiosemicarbazone Pt(II) complexes have been widely studied for their in vitro 
pharmacological activity.
70-76
 From these studies, certain trends in bioactivities have been 
discerned. Many thiosemicarbazones have demonstrated broad spectrum bioactivities
3,77-79
 
and consequent complexation with platinum brings about an enhancement in these 
bioactivities.
70
 In the case of aryl-thiosemicarbazones, it has been observed that ortho-
platination of the ring leads to high antitumor activity.
80,81
 Variation of the substituents on the 
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In contrast, the extension of these evaluations of Pt(II) thiosemicarbazones as 
pharmacological agents to polynuclear derivatives remains relatively unexplored. Di- (III) 
and tetranuclear (IV) platinum thiosemicarbazone complexes (Figure 2.2) have shown 
antileukemic activity in vitro that is comparable to cisplatin.
80,83,84
 In the tetranuclear 
complex, the thiosemicarbazone ligand chelates platinum in a tridentate fashion and this 
cyclometalated derivative showed better activity than the dinuclear derivative. Dinuclear 
Pt(II) complexes containing bis(thiosemicarbazones) (V) derived from 3,5-diacetyl-1,2,4-
triazol demonstrated in vitro activities in the low micromolar range against the cisplatin 
sensitive (A2780) and cisplatin resistant (A2780cisR) human ovarian carcinoma cell lines.
85
 
These examples attest to the viability of polynuclear Pt(II) thiosemicarbazone complexes as 
pharmacological agents.  
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In this chapter, the synthesis, characterisation and reactivity of a series of cycloplatinated 
thiosemicarbazone complexes is discussed. The thiosemicarbazone ligand employed is 3,4-
dichloroacetophenonethiosemicarbazone (2.1) which has been extensively studied for activity 
as an antiparasitic agent.
1,86,87
 The DNA damaging effects of platinum is well known
88,89
 and 
incorporation of this metal into the thiosemicarbazone moiety may enhance the bioactivities 
of 2.1. Structure-activity studies of mononuclear Pt(II) thiosemicarbazone complexes have 
shown that tridentate [C,N,S] cycloplatinated thiosemicarbazones demonstrate better 
activities compared to bidentate [N,S] Pt(II) derivatives
70
 and on this premise cycloplatinated 
complexes of 2.1 were synthesized. Further to this, di- and tetranuclear Pt(II) 
thiosemicarbazone complexes have been reported to have the ability to form DNA 
interhelical cross-links unlike cisplatin, indicating that these complexes have a different 
biochemical mechanism of action to cisplatin.
70
 This may result in these polynuclear 
cycloplatinated complexes not being susceptible to the same deactivation and resistance 
mechanisms as cisplatin. The antiproliferative and antiparasitic studies of these complexes 
will be presented in Chapter 3. 
 
2.2. Results and Discussion 
2.2.1. Synthesis of 3,4-dichloroacetophenonethiosemicarbazone (2.1) 
 
The ligand 2.1 was synthesized by Schiff base reaction of thiosemicarbazide with 3,4-
dichloroacetophenone in the presence of acetic acid (Scheme 2.1.). This ligand has been 
reported and characterization of 2.1 with proton and carbon NMR and infrared spectroscopy 
agrees with the literature.
1
 A broad singlet observed at 10.23 ppm in the 
1
H NMR spectrum is 
assigned to the hydrazinic proton of the thiourea moiety and the terminal amine protons are 
observed as two singlets at 8.29 and 8.13 ppm due to restricted rotation of the C-NH2 bond as 
a consequence of delocalization of the nitrogen’s lone pair of electrons.
40,90-92
 The aromatic 
protons Ha and Hb are observed as doublets at 7.86 and 7.59 ppm respectively due to mutual 
coupling to each other. A strong intensity absorption band at 1594 cm
-1
 in the infrared 
spectrum is characteristic of the C=N bond vibraton and confirms formation of the Schiff 
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2.2.2. Synthesis and Characterization of Cycloplatinated Complexes 
 
The tetranuclear complex 2.2 was prepared by stirring a suspension of the ligand 2.1 and 
K2[PtCl4] in an ethanol-water mixture at 50 °C for five days (Scheme 2.2.) yielding a 
tetranuclear complex that is formed by a Pt4S4 core. The mono- and di-platinum complexes 
(2.3 - 2.7) were synthesized by cleavage of the bridging Pt-S bonds of 2.2 with either a mono- 
or diphosphane in acetone at room temperature. All of the complexes were isolated as orange 
















































P    P = bis(diphenylphoshino)ferrocene (2.5), 70 % yield
 
             trans-bis(diphenylphosphino)ethylene (2.6), 67 % yield
             
             1,3-bis(diphenylphosphino)propane (2.7), 63 % yield
2.3: L = PPh3, 50 % yield
2.4: L = 1,3,5 -triaza-7-phospha-adamantane 
             (PTA), 74 % yield
(ii)
(ii)
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On examination of the 
1
H NMR spectral data for complex 2.2 (Figure 2.3), the 
absence of the proton resonances for the thioamide and ortho-protons (observed at 10.23 and 
7.85 ppm respectively for 2.1) presents evidence of the coordination of the ortho-carbon to 
platinum and the formation of a second imine bond thus suggesting that sulfur bonds to the 
metal in the thiolato form. In the free ligand 2.1, the amine protons resonate as two distinct 
singlets at 8.29 and 8.13 ppm. Coordination to platinum effectively ‘locks’ the ligand into 
one conformation, most likely the trans conformation as this gives rise to a highly conjugated 
stable system, and the NH2 protons are observed as a broad singlet upfield at 7.32 ppm. The 
remaining aromatic protons also experience this shielding effect and shift upfield. This shift 










C NMR spectrum reveals the resonance of the carbon bonded to sulfur shifts from 
179.1 ppm for the free ligand (2.1) to 166.6 ppm for 2.2 agreeing with coordination of sulfur 
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further evidence of coordination to platinum. The imine carbon (Cg) also shifts 
downfield, from 145.2 ppm in 2.1 to 165.0 in 2.2, as a result of coordination of the imine 
nitrogen to the metal.  The infrared spectrum for 2.2 shows only two strong absorption bands 
in the N-H region at 3321 and 3149 cm
-1
 agreeing with only two N-H bonds now present in 
the complex. Absorption bands at 1598 and 1561 cm
-1
 correspond to two C=N bonds, the 
high frequency band is assigned to the newly formed imine and the lower energy band to the 
metal coordinated (via nitrogen) imine. 
 
Compared to the tetranuclear complex 2.2, a slight upfield shift is observed for protons Hb 
and He for complexes 2.3 and 2.5 - 2.7. This shielding of the aromatic protons is not observed 
for complex 2.4, where the resonances for the aromatic and amine protons overlap to form a 
multiplet between 7.19 and 7.21 ppm. For complexes 2.3 and 2.5 - 2.7, satellites are observed 
for the proton resonance of Hb. Figure 2.4. shows the proton NMR spectra for complex 2.3 
where these satellites are clearly visible. A coupling constant of 20-25 Hz is observed and 
this corresponds to a 
3
J coupling of 
195






A downfield shift of the azomethyl protons by approximately 0.25 ppm is observed for 2.3-
2.7 compared to 2.2. This is consistent with deshielding of these protons upon coordination of 
the imine nitrogen to the metal. For complex 2.4, two sets of resonances are observed for the 
PTA ancillary ligand. A singlet at 4.20 ppm is assigned to the CH2 protons adjacent to 
 
Figure 2.4. Expansion of the 
1
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phosphorus. The CH2 protons of the N-CH2-N moiety usually exhibit two doublets 
due to geminal coupling between Hequatorial and Haxial.
96,97
 In complex 2.4, these protons are 




P NMR spectra for complexes 2.3-2.7, only one phosphorus resonance is observed 
with platinum satellites confirming coordination of the phosphane to platinum. A 
1
J coupling 
constant of between 1680 and 1888 Hz is consistent with similar cycloplatinated 
complexes.
93
 In complex 2.6, where the bridging ligand is trans-
bis(diphenylphosphino)ethylene, a triplet with platinum satellites is observed (Figure 2.5.). 










C NMR spectra for complexes 2.3 – 2.7, the C-S carbon resonates at approximately 
177.0 ppm, similar to that of the tetranuclear complex (2.2). The ortho-carbon is observed at 
between 154.0 and 155.0 ppm. The chloro-substituted carbons of the coordinated 
thiosemicarbazone ligand appear to be equivalent and are observed at ca. 131.0 ppm. For 
complex 2.4, two distinct resonances are seen at 135.3 and 133.15. The methyl carbon for all 
of the complexes resonates at approximately 13.0 ppm. 
 
The IR spectra shows the expected two absorption bands in the imine region between 1627 
and 1563 cm
-1
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strong absorption bands in the N-H region, between 3300 and 3500 cm
-1
, is 
consistent with only two N-H bonds present in the complexes.  
 
Complexes 2.2 - 2.7 were all analysed using electro spray ionisation mass spectrometry (ESI-
MS) run in the positive mode. Each complex exhibited a m/z peak corresponding to the [M + 
H] adduct. 
 
2.2.3. X-ray Structure Analysis  
Single crystals of complexes 2.2 – 2.4 suitable for single-crystal X-ray diffraction were 
obtained by exposing dimethyl sulfoxide solutions of each complex to air. Table 2.1. 
summarizes the data collection and processing parameters for each complex and Table 2.2. 
lists selected bond angles and lengths.   Complex 2.2 (Figure 2.6.) crystallizes with 3 solvent 
molecules of DMSO with a monoclinic system. Each platinum center is bridged by the sulfur 
of the adjacent Pt-thiosemicarbazone unit to form an 8-membered Pt4S4 core around which 
the four thiosemicarbazone ligands reside. Each metal center is coordinated to the iminic 
nitrogen, ortho-carbon and sulfur of one thiosemicarbazone ligand and the fourth 
coordination site is occupied by the sulfur of the adjacent thiosemicarbazone ligand. A 







Figure 2.6. a) Molecular structure of 2.2 with ellipsoidal model of 25% probability level and another half 
molecule was generated via symmetry code of 1-x, y, 0.5-z. Solvent molecules and hydrogen atoms have been 
omitted for clarity. b) View of complex 2.2 down the 010 plane showing ring formed by the Pt4S4 core. Atom 
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The bond lengths observed between platinum and each coordinated atom agree with 
those reported for similar tetranuclear platinum thiosemicarbazone complexes.
98
 A 
lengthening of the C-S bond for S(1A)-C(9A) and the S(1B)-C(9B) is observed with values 
for the bond distances in close agreement with the bond length expected for a  C-S single 
bond (1.82 Å) rather than a normal C=S double bond (1.56 Å),
99
 corroborating that sulfur 
coordinates to palladium in the thiolato form.
100
  The bond angles, N(1A)-Pt(1A)-S(1B)#2, 
N(1B)-Pt(1B)-S(1A) ,  C(1A)-Pt(1A)-S(1A) and  C(1B)-Pt(1B)-S(1B) are all less than 180° 
confirming the slight deviation from the expected square-planar geometry around platinum.   
 
Table 2.1. Data Collection and Processing Parameters for 2.2∙3DMSO , 2.3∙2DMSO and 2.4  
 
2.2∙3DMSO 2.3∙2DMSO 2.4 
Formula C42H46Cl8N12O3Pt4S7 C31H34Cl2N3O2PPtS3 C15H19Cl2N6PPtS 
Formula weight 2055.29 873.75 612.38 
Crystal system, Space group Monoclinic,C2/c Orthorhombic,  Pca21 Monoclinic,  P21/c 
a (Å) 14.7265(6) 15.9511(4) 19.176(4) 
b (Å) 30.6788(14) 9.2259(2) 6.0493(12) 
c (Å) 14.2547(6) 23.0990(6) 17.977(4) 
β (deg ) 111.9020(10) 90 114.13(3) 
V/Å
3
 5975.3(4) 3399.32(14) 1903.2(7) 
Z 4 4 4 
Dc (g cm
-3
) 2.285 1.707 2.137 
µ (mm
-1
) 9.987 4.550 7.860 
θ range for data collection 
(deg.) 
1.63 to 28.33 3.49 to 28.28 3.36 to 28.28 
Limiting indices 
-19 < h < 18 
-40 < k < 40 
-19 < l < 19 
-21 < h < 21 
-12 < k < 12 
-30 < l < 30 
-25 < h < 23 
-8 < k < 0 
0 < l < 23 
no. of reflns measd 67775 136324 4703 
no. of reflns used (Rint) 7432 (0.0358) 8405 (0.0498) 4703 (0.0000) 
no. of params 342 414 237 
final R [I > 2σ(I)] 
   
R1 0.0204 0.0214 0.0182 
wR2 0.0454 0.0382 0.0389 
R (all data) 
   
R1 0.0269 0.0280 0.0216 
wR2 0.0485 0.0403 0.0402 
goodness of fit on F
2
 1.068 1.145 1.126 
 
The mononuclear complexes 2.3 and 2.4 (Figures 2.7a and 2.7b) crystallize with 
orthorhombic and monoclinic systems respectively. The molecular structure of each complex 
confirms that the platinum-sulfur bridging bonds in complex 2.2 are cleaved and the 
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distorted square-planar coordination sphere around the metal and this is confirmed 
by the slight deviation of the bond angles observed around platinum for complexes 2.3 and 
2.4.  
Table 2.2. Selected bond lengths (Å) and angles (deg.) for 2.2-2.4 
 
2.2∙3DMSO 2.3∙2DMSO 2.4 
 
A B 
Pt1-C1 2.004(3) 1.999(4) 2.039(3) 2.027(3) 
Pt1-N1 1.996(3) 1.995(3) 2.038(2) 2.035(2) 
Pt1-S1 2.3169(8) 2.3513(8 2.2359(7) 2.3322(11) 
Pt1-P1 - - 2.2359(7) 2.2101(7) 
N1-C7 1.307(4) 1.302(5) 1.298(3) 1.301(3) 
N2-C9 1.293(5) 1.300(5) 1.316(4) 1.313(3) 
C1-Pt1-S1 164.12(11) 100.70(3) 163.57(8) 163.74(7) 
C1-Pt1-P1 - - 97.00(8) 98.56(8) 
N1-Pt1-C1 80.61(13) 81.42(15) 80.78(10) 80.73(9) 
N1-Pt1-S1 83.97(9) 84.08(9) 82.80(7) 83.07(6) 
N1-Pt1-P1 - - 177.17(7) 168.56(6) 





The bond distances observed between the metal and the coordinated carbon, nitrogen and 
sulfur atoms in 2.3 and 2.4 are similar to the tetranuclear complex 2.2 indicating that the 
electron density distribution between platinum and the thiosemicarbazone ligand does not 
change after cleavage. These bond distances are also in close agreement with similar 








Figure 2.7. a)  Structure of complex 2.3∙2DMSO with ellipsoidal model of 30% probability level; b) Structure 
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2.2.4. Reactivity Studies of Mononuclear Cycloplatinated Thiosemicarbazone 
Complexes 
 
The ability of the mononuclear Pt(II) complexes 2.3 and 2.4 to undergo oxidative addition 
reactions was evaluated using different mono-, di- and tri-halomethylbenzenes. These 
reactions were first carried out using complex 2.3 (Scheme 2.3.). The reaction was allowed to 
stir at room temperature for 18 hours. No change in the proton and phosphorus NMR was 















Platinum is able to easily access its +4 oxidation state and there is literature evidence of Pt(II) 
complexes undergoing oxidative addition reactions.
103,104
 Thus, there are two possible reasons 
why complex 2.3 was not reactive; the metal center is not easily accessible due to the steric 
bulk of the triphenylphosphine ligand or the carbon-bromide bond was too strong to add 
across these types of tridentate cycloplatinated complexes.  
 
Further reactivity studies were carried out using 2.4 which has less steric bulk around the 
metal compared to 2.3, as evidenced by their molecular structures (section 2.2.2), and 
iodomethylbenzenes (Scheme 2.4.). Complex 2.4 was suspended in DCM and the appropriate 
mono-, bis- or tris-(iodomethyl)benzene was added and the reaction allowed to proceed at 
room temperature for 18 hours. Pale orange solids were isolated and the products of these 




P{1H} NMR and IR spectroscopies and mass 
spectrometry. For the reaction of 2.4 with iodomethylbenzene to give 2.8, COSY, HSQC and 
























































































Comparison of the proton NMR spectrum of 2.8 to that of 2.4 reveals that the NH2 protons of 
the thiosemicarbazone ligand shift downfield from 7.09 to 7.20 ppm (Figure 2.7.). The 
proton Hb shifts upfield from 7.19 ppm in the precursor complex (2.4) to 7.11 ppm in 2.8 and 
this slight shielding of this proton could be due to greater electron density around the metal 
center. The aromatic protons of the methyl benzene group occur as a multiplet at 7.55 ppm.  
 
The alkyl region of the spectrum was harder to assign. Several signals are observed in this 
region, a doublet of doublets between 5.40 and 5.10 ppm, a doublet with platinum satellites 
and a multiplet between 4.21 and 4.72 ppm. Integration of this region suggests that the PTA 
protons as well as the methyl protons of the benzyl group occur in this region. Definite 
assignment of a PTA proton to a specific resonance is not possible as there may be through 
space coupling of the methylbenzene group and PTA. Thus, 2D NMR experiments were 





technique which can be used to ascertain which protons undergo through-bond spin-spin 
coupling to other protons in the molecule. The COSY 2D NMR for 2.8 reveals that the 
doublet of doublets observed between 5.00 and 5.50 ppm couple to each other as well as one 



















H NMR spectra for 2.4 (a) and 2.8 (b). 
 
 
Figure 2.8. {1H-1H}COSY 2D NMR spectrum for complex 2.8 
 




H) 2D technique 
that can be used to determine which protons experience through-space coupling to other 
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assists in showing which protons couple to other nuclei such as 
13
C and thus 
allowing us to correlate which protons are on the same carbon. HSQC and NOESY NMR 
experiments for complex 2.8 were thus used to determine which proton resonances are on the 







C} HSQC 2D NMR spectrum for complex 2.8 
  
The HSQC 2D NMR spectrum shows that the doublet of doublets observed are for protons 
attached to the same carbon and is most likely the protons Hβ and the doublet with platinum 
satellites seen upfield also occur on the same carbon and can be assigned to Hα protons; a 




 The other multiplet 
observed in the alkyl region is also due to protons on the same carbon and is thus the alkyl 
protons of the benzyl ligand. The splitting of these proton signals is most likely due to 
through space coupling to the PTA proton resonances. This is confirmed by the NOESY 
NMR spectrum. The PTA resonances show through space coupling to the aromatic protons of 

























H} NOESY NMR spectrum for complex 2.8 
 
The phosphorus NMR shows a shift of the PTA phosphorus resonance from -61.25 ppm in 
complex 2.4 to -39.79 ppm for complex 2.8. Greater shielding of the phosphorus nucleus in 
2.8 compared to 2.4 would be expected if there was greater electron density around the metal 
due to oxidative addition of benzyl iodide. The IR spectrum for 2.8 shows a shift of the C=N 
vibration of the uncoordinated imine from 1625.8 (for complex 2.4) to 1601.9 cm
-1
, agreeing 
with greater electron density around the metal leading to shortening of the Pt-S bond and thus 
elongation of the N=C bond.  
 
The proton NMR for complexes 2.9 and 2.10 were found to be similar to that 2.8. The same 
splitting pattern of the PTA and methyl protons is observed. As determined through 2D 
Proton NMR experiments for complex 2.8, these broad signals are due to through-space 
interactions of the PTA and central benzene ring protons because of steric effects. 
Additionally, there may be interactions between the TSC-Pt-PTA moieties for complex 2.10. 
The phosphorus NMR for 2.9 shows a singlet at -39.90 ppm suggesting that the complex 
formed is similar to that of 2.8. For complex 2.10, three phosphorus resonances are observed; 
singlets at -42.61 and -47.15 ppm and a doublet at -44.04 ppm, all with platinum satellites. 
This pattern could be due to two possibilities; the orientation of the TSC-Pt-PTA moieties 
may be different at each position relative to each other and there may also be through-space 
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Complex 2.8 was also analysed using low resolution Electrospray Ionisation Mass 
Spectrometry (ESI-MS). A base peak corresponding to the complex with loss of the iodo 
ligand was observed (Figure 2.11). This data confirms that oxidative addition of the 
iodobenzyl bond does occur across the platinum center. 
 
(a) Complex 2.8: [M-I]
+
 = 704 
 
 




Six new cycloplatinated thiosemicarbazone complexes (2.2-2.7) have been prepared using the 
ligand 3,4-dichloroacetophenonethiosemicarbazone (2.1) in moderate to good yields. The 
complexes have been characterized using NMR and IR spectroscopies and mass 
spectrometry. The molecular structures of 2.2-2.4 were determined using single crystal X-ray 
diffraction and show that the ligand coordinates to platinum in the expected tridentate manner 
via the ortho-carbon, imine nitrogen and thiolato sulfur. Reactivity studies of the 
mononuclear complex 2.4 with mono-, bis- and tris-(iodomethyl)benzene revealed that this 
complex was able to undergo oxidative addition reactions.  
 
A selection of these complexes have been evaluated for antiparasitic and antiproliferative 
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2.4. Experimental  
2.4.1. General Methods  
Thiosemicarbazide, 3,4-dichloro-acetophenone, triphenylphosphane, 1,3,5-triaza-7-phospha-
adamantane, bis(diphenylphosphinoferrocene) and trans-bis(diphenylphosphino)-ethylene 
were purchased from Sigma-Aldrich and used without further purification. Potassium 
tetrachloroplatinate was kindly donated by AngloAmerican Platinum Limited. Ligand 2.1, 
3,4-dichloroacetophenonethiosemicarbazone, was prepared using a previously reported 
literature method.
1
 All solvents used were analytical grade and dried over molecular sieves. 
Nuclear Magnetic Resonance (NMR) Spectra were recorded on a Varian Unity XR400 MHz 
(
1
H at 399.95 MHz, 
13
C at 100.58 MHz, 
31





C at 75.46 MHz, 
31
P at 121.47 MHz) or Bruker Biospin GmbH (
1
H at 400.22 
MHz, 
13
C at 100.65 MHz, 
31
P at 162.00 MHz) spectrometer at ambient temperature. 








H} NMR shifts are reported using tetramethylsilane (TMS) 




H} NMR spectra were measured relative to H3PO4 as the 
external standard. NMR spectra were recorded in deuterated dimethylsulfoxide (DMSO-D6) 
unless otherwise stated. Infrared (IR) absorptions were measured on Perkin-Elmer Spectrum 
100 FT-IR Spectrometer as KBr pellets. Microanalyses for C, H, and N were carried out 
using a Thermo Flash 1112 Series CHNS-O Analyser and melting points were determined 
using a Büchi Melting Point Apparatus B-540. Mass Spectrometry determinations were 
carried out on all new compounds using either electron impact (EI) on a JEOL GC Matell 
instrument or electrospray ionisation (ESI) on a Waters API Quattro Micro instrument in 
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A solution of the 3,4-dichloroacetophenone (1.00 g, 5.30 mmol) in ethanol (10 cm
3
) was 
added dropwise to a stirred suspension of thiosemicarbazide (0.55 g, 5.99 mmol)  in ethanol 
(20 cm
3
). Acetic acid (1cm
3
) was then added and the reaction mixture was stirred at reflux for 
18 hours. Upon cooling to room temperature, the product (2.1) precipitated out of solution 
and was collected by filtration, washed with ethanol and diethyl ether and dried under 
vacuum. The product (2.1) was isolated as a fluffy white solid (0.485 g, 35%). M.p.: 191-192 
ºC
 
(lit. mp.: 196 – 198 ºC). 
1
H NMR (300.08 MHz, DMSO-d6): δ (ppm) = 10.23 (br s, 1H, 
NH), 8.29 (s, 1H, NH2), 8.26 (s, 1H, He), 8.13 (s, 1H, NH2), 7.86 (d, 
3
J(HaHb)  = 8.52 Hz, 1H, 
Ha), 7.59 (d,
 3
J(HbHa)  = 8.52 Hz, 1H, Hb), 2.27 (s, 3H, Hh). 
13
C NMR (75.46 MHz, DMSO-
d6): δ (ppm) = 179.1 (Ci), 145.2 (Cg), 138.2 (Cf), 131.5 (Cc), 131.2 (Ce), 130.0 (Cd), 128.0 
(Ca), 126.5 (Cb), 13.6 (Ch). IR (KBr, cm
-1
) υ = 3421 (s, N-H), 3181 (m, N-H), 3141 (m, N-H), 
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K2[PtCl4] (0.862 g, 2.08 mmol) was dissolved in deionized water (10 cm
3
) and ethanol (150 
cm
3
) added. The ligand 2.1 (0.520 g, 2.08 mmol) was then added to the resulting milky 
orange suspension. The reaction mixture was heated to 50 °C for 5 days before being cooled 
to room temperature. The orange-yellow product (2.2) was isolated by vacuum filtration, 
washed with ethanol (3 x 10 cm
3
) and dried. Yield: 0.880 g, 23 %. Mp: 226-228 °C, 
decomposition without melting). 
1
H NMR (300 MHz, DMSO-d6): δ (ppm) = 7.47 (s, 4H, He), 
7.25 (br s, 8H, NH2), 6.74 (s, 4H, Hb), 2.08 (s, 12H, Hh).  
13
C NMR (300 MHz, DMSO-d6): δ 
(ppm) = 166.6 (Ci), 165.0 (Cg), 153.8 (Ca), 149.2 (Cf), 130.88 (Cc, Cd), 126.4 (Ce), 124.5 (Cb), 
13.2 (Ch). IR (KBr, cm
-1
) υ =  3321(w, N-H), 3149 (w, N-H), 1598 (s, C=N), 1561(m, C=N), 
1561 (s, C=Caromatics). Elemental Analysis for  C36H28Cl8N12Pt4S4: found C 25.42; H, 2.36; N, 
8.34  %; calculated for C36H28Cl8N12Pt4S4·C4H18O: C, 25.35; H, 2.44; N, 8.87. ESI-MS: m/z  
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2.4.4. General Method for Synthesis of Mono- and Bis-phosphane Pt(II) 
Thiosemicarbazone Complexes 
The tetrameric complex, 2.2, (1 mol. equiv.) was suspended in acetone (15 cm
3
). For 
complexes 2.3 and 2.4, the monophosphane (4 mol. equiv.) was added and for complexes 2.5-
2.7, the bis(diphenylphoshane) (2 mol equiv.) was added and the reaction was stirred at room 
temperature for 3 hours. The product was collected as an orange solid by filtration, washed 
with acetone (2 x 5 cm
3
) and dried under vacuum.  
 



















Triphenylphosphane (0.145 g, 0.552 mmol) was reacted with complex 2.2 (0.255 g, 0.140 
mmol). The product (2.3) was isolated as an orange amorphous solid (0.198 g, 50 %).  Mp: 
299-301 ºC, decomposition without melting. 
1
H NMR (300.08 MHz, DMSO-d6): δ (ppm) = 
7.46-7.59 (m, 15H, PPh3), 7.16 (s, He), 7.02 (s, NH2), 6.19 (s, 2H, Hb, 
3
J(Pt-H): 25.5 Hz), 
2.35 (s, 3H, Hh). 
13
C NMR (100.65 MHz, DMSO-d6): δ (ppm) = 177.5 (Ci), 167.1 (Cg), 155.2 
(Ca), 152.7 (Cf), 134.4-134.3 (PPh3), 131.8 (Cc and Cd), 129.05 (PPh3), 130.3 (Ce), 125.5 (Cb), 
13.6 (Ch). 
31
P NMR (162.00 MHz, DMSO-d6): δ (ppm) = 25.70 (PPh3, 
1
J(Pt-P): 1888 Hz). IR 
(KBr, cm
-1
) υ = 3472 (m, N-H), 3340 (s, N-H), 1598 (s, C=N), 1579 (m, C=N), 1497 (s, C=C 
aromatics). Elemental Analysis for C27H22Cl2N3PPtS: found C, 45.47; H, 3.15; N, 5.63 %; 
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1,3,5-Triaza-7-phosphaadamantane (0.0383 g, 0.244 mmol) was reacted with complex 2.2 
(0.102 g, 0.0558 mmol). The product (2.4) was isolated as an orange amorphous solid (0.102 
g, 74 %.).  Mp: 303-304 ºC, decomposition without melting. 
1
H NMR (400.22 MHz, DMSO-
d6): δ (ppm) = 7.19-7.20 (m, 4H, He, NH2, Hb), 4.51 (q, 6H, 
1
J(Hβ(axial)Hβ(equatorial)): 13.10 and 
13.48 Hz, Hβ), 4.20 (s, 6H, Hα), 2.28 (s, 3H, Hh). 
13
C NMR (100.65 MHz, DMSO-d6): δ 
(ppm) = 177.7 (Ci), 166.7 (Cg), 154.8 (Ca), 152.6 (Cf), 135.3 (Cc), 133,15 (Cd), 127.9 (Ce), 
125.7 (Cb), 72.43 (Cα), 51.0 (Cβ), 13.6 (Ch). 
31
P NMR (162.00 MHz, DMSO-d6): δ (ppm) = -
65.70 (PPh3, 
1
J(Pt-P): 1680 Hz). IR (KBr, cm
-1
) υ = 3413 (s, N-H), 3257 (s, N-H), 1621 (s, 
C=N), 1563 (m, C=N), 1501 (s, C=C aromatics). Elemental Analysis for C15H19Cl2N6PPtS: 
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Bis(diphenylphosphinoferrocene)  (0.0657 g, 0.118 mmol) was reacted with complex 2.2 
(0.106 g, 0.0580 mmol). The product (2.5) was isolated as an orange amorphous solid (0.120 
g, 70 %).  Mp: 225-227 ºC. 
1
H NMR (400.22 MHz, DMSO-d6): δ (ppm) = 7.42-7.54 (m, 
20H, PPh2), 7.17 (s, 2H, He), 7.15 (s, 4H, NH2), 6.13(s, 2H, Hb, 
3
J(Pt-H): 20.0 Hz), 5.04 (br s, 
4H, Hα), 4.23 (br s, 4H, Hβ), 2.36 (s, 6H, Hh). 
13
C NMR (75.46 MHz, DMSO-d6): δ (ppm) = 
177.1 (Ci), 166.5 (Cg), 154.1 (Ca), 152.0 (Cf), 132.9 (PPh2), 131.0 (Cc and Cd), 128.0 (PPh2) 
126.7 (Ce), 124.8 (Cb), 73.5 – 74.9 (Cα and Cβ), 13.1 (Ch). 
31
P NMR (162.00 MHz, DMSO-
d6): δ (ppm) = 11.62 (PPh2, 
1
J(Pt-P): 1881.8 Hz). IR (KBr, cm
-1
) υ = 3475 (s, N-H), 3383 (s, 
N-H), 1595 (s, C=N), 1573 (m, C=N), 1499 (s, C=C aromatics). Elemental Analysis for 
C52H42Cl4FeN6P2Pt2S2: found C, 42.36; H, 2.71; N, 5.53 %; calculated C, 42.64; H, 2.89; N, 
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Trans-bis(diphenylphosphino)ethylene (0.0468 g, 0.118 mmol) was reacted with complex 2.2 
(0.102 g, 0.0557 mmol). The product (2.6) was isolated as an orange amorphous solid 
(0.0976g, 67 %). Mp: 312-314 ºC. 
1
H NMR (400.22 MHz, DMSO-d6): δ (ppm) = 7.31-7.52 
(m, 22H, Hα, PPh2), 7.13(s, 2H, He), 7.12 (s, 4H, NH2), 6.30 (s, 2H, Hb, 
3
J(Pt-H): 24.1 Hz), 
2.33 (s, 6H, Hh). 
13
C NMR (100.65 MHz, DMSO-d6): δ (ppm) = 177.3 (Ci), 167.4 (Cg), 154.6 
(Ca), 152.4 (Cf), 135.0 (Cα), 134.0 (PPh2), 132.11 (Cc and Cd), 129.3 (PPh2) 127.5 (Ce), 125.7 
(Cb), 13.7 (Ch). 
31





J(Pt-P): 1870.0 Hz). IR (KBr, cm
-1
) υ = 3456 (s, N-H), 3324 (s, N-H), 1627 (s, C=N), 
1606 (m, C=N), 1492 (s, C=C aromatics). Elemental Analysis for C44H36Cl4N6P2Pt2S2: found 
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1,3-bis(diphenylphosphino)propane (0.0493 g, 0.120 mmol) was reacted with complex 2.2 
(0.107 g, 0.0589 mmol). The product (2.7) was isolated as an orange amorphous solid 
(0.0988g, 63 %). Mp: 307-310 ºC, decomposition without melting. 
1
H NMR (400.22 MHz, 
DMSO-d6): δ (ppm) = 7.90-7.60 (m, 8H, PPh2) 7.60-7.30 (m, 12H, PPh2), 7.12 (s, 2H, He), 
7.05 (s, 4H, NH2), 6.16 (s, 2H, Hb, 
3
J(Pt-H): 22.95 Hz), 2.81 (m, 4H, Hα), 2.32 (s, 6H, Hh), 
1.76 (br s, 2H, Hβ). 
13
C NMR (100.65 MHz, DMSO-d6): δ (ppm) = 177.2 (Ci), 166.1 (Cg), 
154.3 (Ca), (Cf), 132.6 (PPh2), (Cc and Cd), 128.3 (PPh2) (Ce), (Cb), 29.3 (Cα), 20.66 (Cβ), 
(Ch). 
31
P NMR (162.00 MHz, DMSO-d6): δ (ppm) = 16.55 (PPh2, 
1
J(Pt-P): 1845.9 Hz). 
Elemental Analysis for C45H40Cl4N6P2Pt2S2: found C  41.02, H 3.41, N 6.24 %; calculated  C, 
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2.4.5. Reactivity Studies: Oxidative Addition Reaction 
 




















Complex 2.4 (0.1006 g, 0.1643 mmol) was suspended in DCM (10 cm
3
) and the appropriate 
iodomethylbenzene (0.0361 g, 0.1656 mmol) was added. The reaction mixture was refluxed 
for 18 hours, cooled to room temperature and the product (2.8) was isolated as a pale orange 





H NMR (400.22 MHz, DMSO-d6): δ (ppm) = 7.55 (s, 5H, Ar-H), 7.20-7.23 (m, 3H, He and 
NH2), 7.11 (s, 1H, Hb), 4.00 – 5.50 ppm (m, 14H, PTA-H and Ar-CH2), 2.31 (s, 3H, Hh). 
31
P 
NMR (162.00 MHz, DMSO-d6): δ (ppm) = -39.80 (PPh2, 
1
J(Pt-P): 1778 Hz). IR (KBr, cm
-1
) 




2.4.6. X-ray Structure Analysis  
 
Crystals suitable for single-crystal X-ray diffraction of complexes 2.2∙3DMSO, 2.3∙2DMSO 
and 2.4 were grown from the DMSO-d6 NMR samples by exposure of the solutions to air.  X-
ray single crystal intensity data were collected on a Nonius Kappa-CCD diffractometer using 
graphite monochromated MoK radiation ( = 0.71073 Å). Temperature was controlled by 
an Oxford Cryostream cooling system (Oxford Cryostat). The strategy for the data collections 
was evaluated using the Bruker Nonius "Collect” program. Data were scaled and reduced 
using DENZO-SMN software.
106
 Absorptions corrections were performed using SADABS.
107
 
The structure was solved by direct methods and refined employing full-matrix least-squares 
with the program SHELXL-97
108
  refining on F
2
.Packing diagrams were produced using the 
program PovRay and graphic interface X-seed.
109
 For complex 2.2∙3DMSO, all non-
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refined anisotropically. All hydrogen atoms were positioned geometrically with 
distance of N-H being 0.88 Å and C-H distances ranging from 0.95 Å to 0.98 Å and refined 
as riding on their parent atoms, with Uiso (H) = 1.2 - 1.5 Ueq (C or N). In the asymmetric unit, 
one DMSO molecule is on general positions. Another one is on twofold rotation axis and it is 
disordered and shows high thermal motions, therefore the carbon and oxygen atoms were 
refined isotropically and the hydrogen atoms were not placed. The complex 2.2 main 
molecule is located at special positions on twofold rotation axis. The structure was refined 
successfully to R factor of 0.0204. For complex 2.3∙2DMSO, all non-hydrogen atoms were 
refined anisotropically. All the hydrogen atoms, except those on the N3 atom, were placed in 
idealised positions in a riding model with Uiso set at 1.2 or 1.5 times those of their parent 
atoms and fixed C-H bond lengths ranging from 0.95 Å to 0.98 Å. The hydrogen atoms H3A 
and H3B on N3 were located in the difference electron density maps and refined with simple 
bond lengths constraints. One DMSO molecule was disordered over two positions with site 
occupancy of 0.5 each. For complex 2.4, All non-hydrogen atoms were refined 
anisotropically. All the hydrogen atoms were placed in idealised positions in a riding model 
with Uiso set at 1.2 or 1.5 times those of their parent atoms and restrained with fixed bond 































Chapter 2. Synthesis of Cycloplatinated Thiosemicarbazone Complexes 69 
 
2.5. References 
1. X. Du, C. Guo, E. Hansel, P. S. Doyle, C. R. Caffery, T. P. Holler, J. H. McKerrow 
and F. E. Cohen, J. Med. Chem., 2002, 45, 2695. 
2. R. B. De Oliveira, E. M. De Souza-Fagundes, R. P. P. Soares, A. A. Andrade, A. U. 
Krettli and C. L. Zani, Eur. J. Med. Chem., 2008, 43, 1983. 
3. K. J. Duffy, A. N. Shaw, E. Delorme, S. B. Dillon, C. Erickson-Miller, L. Giampa, Y. 
Huang, R. M. Keenan, P. Lamb, N. Liu, S. G. Miller, A. T. Price, J. Rosen, H. Smith, 
K. J. Wiggall, L. Zhang and J. I. Luengo, J. Med. Chem., 2002, 45, 3573. 
4. M. Abid, S. M. Agarwal and A. Azam, Eur. J. Med. Chem., 2008, 43, 2035. 
5. A. Walcourt, M. Loyevsky, D. B. Lovejoy, V. R. Gordeuk and D. R. Richardson, Int. 
J. Biochem. Cell Biol., 2004, 36, 401. 
6. N. Fujii, J.P. Mallari, E.J. Hansell, Z. Mackey, P.  Doyle, Y.M.  Zhou, J. Gut, P.J. 
Rosenthal, J.H. Mckerrow and R.K. Guy, Bioorg. Med. Chem. Lett., 2005, 15, 121. 
7. C. Costello, T. Karpanen, P. A. Lambert, P. Mistry, K. J. Parker, D. L. Rathbone, J. 
Ren, L. Wheeldon and T. Worthington, Bioorg. Med. Chem. Lett., 2008, 18, 1708. 
8. S. A. Khan and M. Yusuf, Eur. J. Med. Chem., 2009, 44, 2597. 
9. S. A. Khan, P. Kumar, R. Joshi, P. F. Iqbal and K. Saleem, Eur. J. Med. Chem., 2008, 
43, 2029. 
10. I. Dilovic, M. Rubcic, V. Vrdoljak, S.K. Pavelic, M. Kralj, I. Piantanida and M. 
Cindric, Bioorg. Med. Chem, 2008, 16, 5189. 
11. M.-C. Liu, T.S. Lin and A.C. Sartorelli, J. Med. Chem., 1992, 35, 3672. 
12. H. G. Petering, H. H. Buskirk and G. E. Underwood, Cancer Res., 1964, 24, 367. 
13. J. M. Kolesar, W. R. Schelman, P. G. Geiger, K. D. Holen, A. M. Traynor, D. B. 
Alberti, J. P. Thomas, C. R. Chitambar, G. Wilding and W. E. Antholine, J. Inorg. 
Biochem., 2008, 102, 693. 
14. D. Kovala-Demertzi, M.A. Demertzis, E. Filou, A.A Pantazaki, P.N. Yadav, J.R. 
Miller, Y. Zheng and D.A. Kyriakidis,, Biometals, 2003, 16, 411. 
15. K. C. Agrawal, B. A. Booth, E. C. Moore and A. C. Sartorelli, J. Med. Chem., 1972, 
15 (11), 1154. 
16. J. H. McKerrow, E. Sun, P. J. Rosenthal and J. Bouvier, Annu. Rev. Microbiol., 1993, 
47, 821. 













 70 Synthesis and Study of Multinuclear PGM complexes as in vitro Pharmacological Agents 
18. S. E. Francis, D. J. Sullivan Jr and D. E. Goldberg, Annu. Rev. Microbiol., 
1997, 51, 97. 
19. D. Sweeney, M. L. Raymera and T. D. Lockwood, Biochem. Pharm., 2003, 66, 663. 
20. A. Chipeleme, J. Gut, P. J. Rosenthal and K. Chibale, Biorganic and Medicinal 
Chemistry, 2007, 15, 273. 
21. V. L. Lew, T. Tiffert and H. Ginsburg, Blood, 2003, 101, 4189. 
22. M. N. Hughes; The Inorganic Chemistry of Biological Processes; John Wiley: 
Chichester, 1981. 
23. H. Beraldo and D. Gambino, Mini-reviews in Medicinal Chemistry, 2004, 4, 31. 
24. N. Farrel, Coord. Chem. Rev., 2002, 232, 1. 
25. B. Lippert; Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug; 
VCHA & Wiley-VCH: Zurich, 1999. 
26. C. G. Hartinger, A. D. Phillips and A. A. Nazarov, Curr. Top. Med. Chem., 2011, 11, 
2688. 
27. A. Garoufis, S. K. Hadjikakou and N. Hadjiliadis, Coord. Chem. Rev., , 2009, 253, 
1384. 
28. A. Garoufis, S. K. Hadjikakou and N. Hadjiliadis, In Metallotherapeutic Drugs and 
Metal-based Diagnostic Agents: The Use of Metals in Medicine; Eds. M. Gielen and 
E.R.T Tiekink, Ed.; Chichester: John Wiley & Sons Ltd, 2005. 
29. Z. Guo and P.J. Sadler, Angew. Chem. Int. Ed., 1999, 38, 1512. 
30. P. C. A. Bruijnincx and P. J. Sadler, Curr. Opin. Chem. Biol., 2008, 12, 197. 
31. M. A. Jakupec, M. Galanski, V. B. Arion, C. G. Hartinger and B. K. Keppler, Dalton 
Trans., 2008, 183. 
32. W. -H. Zhang, S. W. Chien and T. S. A. Hor, Coord. Chem. Rev., 2011, 255, 1991. 
33. T. S. Lobana, R. Rekha, R. J. Butcher, A. Castineiras, E. Bermejo and P. V. 
Bharatam, Inorg. Chem., 2006, 45, 1535. 
34. T. S. Lobana, S. Khanna and R. J. Butcher, Z. Anorg. Allg. Chem., 2007, 633, 1820. 
35. T. S. Lobana, S. Khanna, R. J. Butcher, A. D. Hunter and M. Zeller, Inorg. Chem., 
2007, 46, 5826. 
36. E. M. Jouad, A. Riou, M. Allain, M. A. Khan and G. M. Bouet,, Polyhedron, 2001, 
20, 67. 
37. S. Lhuachan, S. Siripaisarnpipat and N. Chaichit, Eur. J. Inorg. Chem., 2003, 263. 
38. E. Bermejo, R. Carballo, A. Castineiras, R. Domınguez, C. M. Mossmer, J. Strahle 














Chapter 2. Synthesis of Cycloplatinated Thiosemicarbazone Complexes 71 
39. Z. Lu, C. White, A. L. Rheingold and R. H. Crabtree, Inorg. Chem., 1993, 
32, 3991. 
40. T. S. Lobana, R. Sharma, G. Bawa and S. Khanna, Coord. Chem. Rev., 2009, 253, 
977. 
41. M. A. Ali and S. E. Livingstone, Coord. Chem. Rev., 1974, 13, 115. 
42. M. Cindric, M. Rubcic, I. Dilovic, G. Giester and B. Kamenar, Croat. Chem. Acta, 
2007, 80 (3-4), 583. 
43. N. A. Mangalam and M. R. P. Kurup, Spectrochim. Acta, Part A, 2009, 71, 2040. 
44. P. Ren, T. Liu, J. Qin and C. Chen, Spectrochim. Acta, Part A, 2003, 59, 1095. 
45. R. M. El-Shazly, G.A.A Al-Hazmi, S.E. Ghazy, M.S. El-Shahawi and A.A. El-Asmy, 
J. Coord. Chem., 2006, 59, 845. 
46. J. S. Casas, M. V. Castano, M. C. Cifuentes, J. C. Garcia-Monteagudo, A. Sanchez, J. 
Sordo and U. Abram, J. Inorg. Biochem., 2004, 98, 1009. 
47. V. M. Leovac, L. S. Jovanovic, V. S. Jevtovic, G. Pelosi and F.Bisceglie, Polyhedron, 
2007, 26, 2971. 
48. Z. Afrasiabi, E. Sinn, W. Lin, Y. Ma, C. Campana and S. Padhye,, J. Inorg. Biochem., 
2005, 99, 1526. 
49. S. Laly and G. Parameswaran, Asian J. Chem., 1993, 5 (3), 712. 
50. B. Garcia, J. Garcia-Tojal, R. Ruiz, R. Gil-Garcia, S. Ibeas, B. Donnadieu and J. M. 
Leal, J. Inorg. Biochem., 2008, 102, 1892. 
51. M. B. Ferrari, S. Capacchi, G. Pelosi, G. Reffo, P. Tarasconi, R. Albertini, S. Pinelli 
and P. Lunghi, Inorg. Chim. Acta, 1999, 286, 134. 
52. J. P. Scovill, D. L. Klayman and C. F. Franchino, J. Med. Chem., 1982, 25 (10), 1261. 
53. J. Patole, S. Padhye, M. S. Moodbidri and N. Shirsat, Eur. J. Med. Chem., 2005,, 40, 
1052. 
54. D. Pandiarajan and R. Ramesh, Inorg. Chem. Commun., 2011, 14, 686. 
55. B. Demoro, C. Sarniguet, R. Sánchez-Delgado, M. Rossi, D. Liebowitz, F. Caruso, C. 
Olea-Azar, V. Moreno, A. Medeiros, M. A. Comini, L. Otero and D. Gambino, 
Dalton Trans., 2012, 41, 1534. 
56. D.  Kovala-Demertzi, P. N. Yadav, M. A. Demertzi, J. P. Jasiski, F. J. Andreadaki and 
I. D. Kostas, Tet. Lett., 2004, 45, 2923. 
57. I. D. Kostas, F. J. Andreadaki, D. Kovala-Demertzi, C. Prentjas and M. A. Demertzis, 













 72 Synthesis and Study of Multinuclear PGM complexes as in vitro Pharmacological Agents 
58. K. S. O. Ferraz, L. Ferandes, D. Carrilho, M .C. X. Pinto, M. D. F. Leite, E. 
M. Souza–Fagundes, N. L. Speziali, I. C. Mendes and H. Beraldo, Bioorg. Med. 
Chem., 2009, 17, 7138. 
59. M. Vieites, P. Smircich, M. Pagano, L. Otero, L.L. Fischer, H. Terenzi, M.J. Prieto, 
V. Moreno, B. Garat and D. Gambino, J. Inorg. Biochem., 2011, 105, 1704. 
60. P. Kalaivani, R. Prabhakaran, F. Dallemer, P. Poornima, E. Vaishnavi, E. 
Ramachandran, V. V. Padma, R. Renganathan and K. Natarajan, Metallomics, 2012, 
4, 101. 
61. F. Beckford, D. Dourth, M. Shaloski Jr., J. Didion, J. Thessing, J. Woods, V. Crowell, 
N. Gerasimchuk, A. Gonzalez-Sarrías and N.P. Seeram, J. Inorg. Biochem., 2011, 
105, 1019. 
62. F.A. Beckford, G. Leblanc, J. Thessing, M. Shaloski Jr, B.J. Frost, L. Li and N.P. 
Seeram, Inorg. Chem. Commun., 2009, 12, 1094. 
63. G. Raja, N. Sathya and C. Jayabalakrishnan, J. Coord. Chem., 2011, 64 (5), 817. 
64. S. Grguric-Sipka, C.R. Kowol, S.-M. Valiahdi, R. Eichinger, M.A. Jakupec, A. 
Roller, S. Shova, V.B. Arion, B.K. Keppler, Eur. J. Inorg. Chem., 2007, (18), 2870. 
65. P. Chellan, N. Shunmoogam-Gounden, D. T. Hendricks, J. Gut, P. J. Rosenthal, C. 
Lategan, P. J. Smith, K. Chibale and G. S. Smith, J. Eur. Med. Chem., 2010, 3520. 
66. P. Chellan, S. Nasser, L. Vivas, K. Chibale and G. S. Smith, J. Organomet. Chem., 
2010, 695, 2225. 
67. G. Xie, P. Chellan, J. Mao, K. Chibale, and G. S. Smith, Adv. Synth. Catal., 2010, 352 
(10), 1641. 
68. T. Stringer, B. Therrien, D.T. Hendricks, H. Guzgay and G. S. Smith, Inorg. Chem. 
Comm., 2011, 14 (6), 956. 
69. P. Pelagatti, A. Venturini, A. Leporat, M. Carcelli, M. Costa, A. Bacchi, G. Pelizzi 
and C. Pelizzi, J. Chem. Soc., Dalton Trans., 1998, 2715. 
70. A. G. Quiroga and C. N. Ranninger, Coordination Chemistry Reviews, 2004, 248, 
119. 
71. J. S. Casas, E. E. Castellano, J. Ellena, M. S. García-Tasende, M. L. Pérez-Parallé, A. 
Sánchez, Á. Sánchez-González, J. Sordo and Á. Touceda, J. Inorg. Biochem., 2008, 
102, 33. 
72. G. A. Al-Hazmi, N. M. El-Metwally, O. A. El-Gammal and A. A. El-Asmy, 














Chapter 2. Synthesis of Cycloplatinated Thiosemicarbazone Complexes 73 
73. D. Kovala-Demertzi, P. N. Yadav, M. A. Demertzis and M. Coluccia, J. 
Inorg. Biochem., 2000 78, 347. 
74. A. I. Matesanz, J. Perles and P. Souza, Dalton Trans., 2012, 41, 12538. 
75. D. Santos, B. Parajón-Costa, M. Rossi, F. Caruso, D. Benítez, J. Varela, H. Cerecetto, 
M. González, N. Gómez, M. E. Caputto, A. G. Moglioni, G. Y. Moltrasio, L. M. 
Finkielsztein and D. Gambino, J. Inorg. Biochem., 2012, 117, 270. 
76. S. Halder, P. Paul, S. -M. Peng, G. -H. Lee, A. Mukherjee, S. Dutta, U. Sanyal and S. 
Bhattacharya, Polyhedron, 2012, 45, 177. 
77. J. P. Scovill, D. L. Klayman and D. G. Franchino, J. Med. Chem., 1982, 25, 1261. 
78. J. S. Lewis, J. M. Connet, J. R. Garbow, T. L. Buettner, Y. Fujibayashi, J. W. 
Fleshman and M. J. Welch, Cancer Res., 2002, 62, 445. 
79. R. I. Maurer, P. J. Blower, J. R. Dilworth, C. A. Reynolds, Y. Zheng and G. E. 
Mullen, J. Med. Chem., 2002, 45, 1420. 
80. C. Navarro-Ranninger, I. López-Solera, J. M. Pérez, J. H. Rodriguez-Ramos, J. L. 
García-Ruano, P. R. Raithby, J. R. Masaguer and C. Alonso, J. Med. Chem., 1993, 36, 
3795. 
81. C. Navarro-Ranninger, I. López-Solera, V. González, J. M. Pérez, A. Alvarez-Valdés, 
A. Martín, P. R. Raithby, J. R. Masaguer and C. Alonso, Inorg. Chem., 1996, 35, 
5181. 
82. J. Reedijk, J. Chem. Soc., Chem. Commun., 1996, 801. 
83. A. G. Quiroga, J. M. Pérez, C. Alonso and C. Navarro-Ranninger App. Organomet. 
Chem., 1998, 12, 809. 
84. A. G. Quiroga, J. M. Perez, I. Lopez-Solera, J. R. Masaguer,  A. Luque, P. Roman, A. 
Edwards, C. Alonso and C. Navarro-Ranninger, J. Med. Chem., 1998, 41, 1399. 
85. A. I. Matesanz, C. Herńandez, A. Rodríguez, and P. Souza, Dalton Trans., 2011, 40, 
5738. 
86. J. A. Castillo-Garit, M. C. Vega, M. Rolón, Y. Marrero-Ponce, A. Gómez-Barrio, J. 
A. Escario, A. A. Bello, A. Montero, F. Torrens, F. Pérez-Giménez, V. J. Arán and C. 
Abad, Eur. J. Med. Chem., 2011 46, 3324  
87. R. V. C. Guido, G. H. G. Trossini, M. S. Castilho, G. Oliva, E. I. Ferreira and A. D. 
Andricopulo, J. Enzym. Inhib. Med. Chem., 2008, 23 (6), 964. 
88. S. Komeda, Metallomics, 2011, 3, 650. 













 74 Synthesis and Study of Multinuclear PGM complexes as in vitro Pharmacological Agents 
90. T. S. Lobana, G. Bawa, R. J. Butcher, B. -J. Liaw and C.W. Liu, 
Polyhedron, 2006, 25, 2897. 
91. T. S. Lobana, A. Sánchez, J. S. Casas, A. Castiñeiras, J. Sordo, M. S. García-Tasende 
and E. M. Vázquez-López, J. Chem. Soc. Dalton Trans., 1997, 4289. 
92. T. S. Lobana, S. Khanna, R. J. Butcher, A. D. Hunter and M. Zeller, Polyhedron, 
2006, 25, 2755. 
93. D. Vazquez-Garcıa, A. Fernandez, J. J. Fernandez, M. Lopez-Torres, A. Suarez, J. M. 
Ortigueira, J. M. Vila and H. Adams, J. Organomet. Chem., 2000, 595, 199. 
94. T. G. Appleton and J. R. Hall, Inorg. Chem., 1971, 10 (8), 1717. 
95. G. Natile, L. Maresca and L. Cattalini, J. Chem. Soc, Chem. Commun., 1976, 24. 
96. P. Smolenski and A. J. L. Pombeiro, Dalton Trans., 2008, 87. 
97. P. Smolenski, C. Dinoi, M. Fatima, C. G. da Silva and A. J. L. Pombeiro, J. 
Organomet. Chem., 2008, 693, 2338. 
98. A. G. Quiroga, J. M. Perez, I. Lopez-Solera, J. R. Masaguer, A. Luque, P. Roman, A. 
Edwards, C. Alonso, C. Navarro-Ranninger, J. Med. Chem., 1998, 41, 1399. 
99. L. E. Shutton; Tables of Interatomic Distances and Configurations in Molecules and 
Ions (Supplement);; The Chemical Society: London, 1965. 
100. Z. Afrasiabi, E. Sinn, W. Lin, Y. Ma, C. Campana and S. Padhye, J. Inorg. Biochem., 
2005, 99, 1526. 
101. T. S. Lobana, G. Bawa, G. Hundal and M. Zeller, Z. Anorg. Allg. Chem., 2008, 634, 
931. 
102. D. Vazquez-Garcıa, A. Fernandez, J. J. Fernandez, M. Lopez-Torres, A. Suarez, J. M. 
Ortigueira, J. M. Vila and H. Adams, J. Organomet. Chem., 2000, 595, 199. 
103. S. Achar, J. J. Vittal and R. J. Puddephatt, Organometallics, 1996, 15, 43. 
104. S. Achar and R. J. Puddephatt, J. Chem. Soc., Chem. Commun., 1994, 1985-1986,  
105. G. Natile, L. Maresca and L. Cattalini, J. Chem. Soc., Chem. Commun., 1976, 24. 
106. Z. Otwinowski and W. Minor; Methods in Enzymology, Macromolecular 
Crystallography; Academic Press  New York, 1997. 
107. G. M. Sheldrick, SADABS; University of Göttingen, Germany, 1997. 
108. G. M. Sheldrick, SHELXL-97 and SHELXS-97, Program for Crystal Structure 
Refinement; University of Göttingen, Germany, 1997. 















Chapter 3. In vitro Pharmacological Evaluation of Pt(II) Thiosemicarbazone Complexes 75 
 
3.1. Introduction 
The study of platinum-based cancer therapeutics is a well-established area of research. The 
most well-known clinically used drugs today are cisplatin and its analogues (Figure 3.1).
1,2
 
As discussed in Chapter 1, while these drugs have proven effective for the treatment of 
several cancers, there are several drawbacks to their use. In the case of cisplatin, patients tend 
to develop tumor resistance overtime and systemic side effects such as ototoxicity, 
neurotoxicity and nephrotoxicity are common. Additionally, a large portion of the 
intravenously administered dose of cisplatin is deactivated before it can reach its target.
3
 
These serious shortcomings have bred a need for the design of platinum complexes that are 
more robust; compounds that can maintain their structural integrity during transport and then 
deliver the bioactive species to its intended target.  
Complexes containing ligands that can chelate to platinum in a bi- or tridentate manner may 
be less susceptible to decomposition and thus more likely to reach their cancer targets intact. 
Thiosemicarbazones are well-known for their ability to chelate to a variety of metals in a 
polydentate fashion.
4
 These compounds have also exhibited biological activity in vitro as 
antiparasitics,
5-10
 and antitumoral agents.
11-15
 Their antiproliferative activities are believed to 
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Examples of platinum thiosemicarbazone complexes as in vitro antitumoral agents have been 
reported. The tetraplatinum complex I and mononuclear complex II (Figure 3.2.) have both 
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been screened against several antitumoral cell lines.
16,17
 In most cases, they 
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A series of di- and trinuclear platinum thiosemicarbazone complexes (III - XI, Figure 3.3.) 
where each thiosemicarbazone moieity coordinates to the metal as a tridentate donor have 












































R= H, t-Bu, 3-OMe or 5-Cl
VII - XI:
R= H, t-Bu, 3-OMe or 5-Cl  
Figure 3.3. Di- (III-VI) and trinuclear (VII-XI) thiosemicarbazone Pt(II) complexes screened for antitumor 
activity against WHCO1 cell line.
18
 
   
In the study of thiosemicarbazones as biological agents, these compounds have also emerged 
as promising candidates for the treatment of parasitic diseases.
5-10
 Their in vitro antiparasitic 
activities have been studied extensively and their modes of action are believed to arise from 
several possible inhibitory mechanisms. Thiosemicarbazones may affect processes associated 
with hemoglobin (Hb) digestion in the food vacuole of the parasite. Their ability to chelate 
endogenous metals such as Fe(III) can inhibit parasite growth by withholding it from metal 
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pathway.
9,19
 Alternatively, the resulting chelate complexes could inhibit cysteine 
proteases, effectively enhancing the natural inhibitory effect of endogenous metals on the 
protease catalytic site.
20
 Another possible mechanism of cysteine protease inhibition could be 
through covalent modification of the cysteine thiol groups within the parasite via the 
electrophilic centers (the thione carbon and/or imine carbon) of the thiosemicarbazone 
moiety. All of the above inhibitory mechanisms would compromise the parasite’s ability to 
degrade host hemoglobin required for parasite protein synthesis.
21-24
  
The study of thiosemicarbazone complexes containing metals from the Platinum Group series 
as antiparasitic agents is still a relatively new area of research. An extensive series of 
mononuclear [O,N,S] tridentate Pd(II) and Pt(II) thiosemicarbazone complexes (3.12-3.23, 
Figure 3.3.) have been reported to exhibit moderate activity as antiparasitics against P. 
falciparum strains and T. vaginalis. Against the Trichomonas vaginalis parasite strain T1, the 
palladium and platinum complexes containing the 4-picoline ancillary ligand showed high % 









R = H, L = PPh3 (XII), PTA (XIII), 4-picoline (XIV)
R = 3-OMe, L = PPh3, (XV) PTA (XVI), 4-picoline (XVII) 
R = 3-tBu, L = PPh3 (XVIII), PTA (XIX), 4-picoline (XX)
R = 5-Cl, L = PPh3 (XXI), PTA (XXII), 4-picoline (XXIII)  




We have recently reported on the synthesis and antiplasmodial activity of cyclopalladated 
mono-, di- and tetranuclear thiosemicarbazone complexes (Complexes 1.96-1.105, Figure 
3.4.).
26
 These compounds exhibited moderate to low antiparasitic activity in vitro. 
Based on the moderate activities displayed by these Pd(II) complexes, we wanted to evaluate 
how changing the metal to platinum would affect the bioactivies of the cyclometalated 
compounds. In this chapter, the in vitro evaluation of the mono-, di- and tetranuclear 
cycloplatinated thiosemicarbazone complexes 2.2-2.6 as antitumoral and antiparasitic agents 
will be discussed. An NMR study of the stability of these complexes in the presence of 
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potential mechanism of action with respect to inhibition of β-hematin formation 










1.102: R = CH3 


















1.104: R = CH3 









1.100: R = CH3 

















1.106: R = CH3 

















1.108: R = CH3 
1.109: R = CH2CH3  




3.2. In vitro Screening of Thiosemicarbazone Complexes 
3.2.1. In Vitro Antitumour Activity  
The in vitro antiproliferative effect of compounds 2.1- 2.6 (Figure 3.5) was evaluated against 
the cisplatin sensitive (A2780) and cisplatin resistant (A2780cisR) ovarian cancer cell lines. 
Table 3.1 lists the IC50 data ascertained for 2.1-2.6. Ligand 2.1 exhibited the highest activity 
out of all the compounds tested against both cell lines [IC50 = 11.3 μM (A2780) and 13.8 μM 
(A2780cisR)]. Cyclometalation of ligand 2.1 led to a decrease in in vitro activity against both 
cell lines which is in contrast to previous reports where cycloplatination had a beneficial 
effect on activity.
17,27-30
 However, most of these published accounts of an increase in activity 
were determined in other tumor cell lines. In order to confirm that the cycloplatinated 
complexes 2.2-2.6 are less active than 2.1 as antitumor agents in general, all of the 




































































































Figure 3.5. Compounds 2.1 – 2.6 that have been screened for in vitro pharmacological activity. 
 
Complexes 2.2-2.5 are moderately cytotoxic against both cell lines with complex 2.4 showing 
the lowest IC50 values [IC50 = 21.20 μM (A2780) and 32.00 μM (A2780cisR)]. Complexes 
2.2, 2.4 and 2.5 are less active against the cisplatin resistant (A2780cisR) cell line, while 
complex 2.3 is more active in this cell line (IC50 = 99 μM) compared to A2780 (IC50 = 129 
μM). While none of the compounds tested showed activities comparable to cisplatin against 
the A2780 cell line, ligand 2.1 shows a markedly better activity than cisplatin against the 
A2780cisR line. Despite having lower IC50 values compared to cisplatin, the calculated 
resistance indices for 2.1-2.6 are much lower than that of cisplatin suggesting that these types 
of complexes are markedly less susceptible to the same resistance mechanisms that inhibit 
cisplatin’s activity against the A2780cisR cell line.
31
 
Metalation of the thiosemicarbazone ligand seems to have an adverse effect on cytotoxicity 
and no direct correlation between the number of platinum-thiosemicarbazone moieties and 
pharmacological activity can be discerned. Against the A2780 cell line, the tetranuclear 
complex 2.2 (IC50 = 51.5 μM) is more active than complex 2.6 (IC50 = >200 μM) but is less 
active than the dppf containing complex 2.5 (IC50 = 36.5 μM). Instead, the type of ancillary 
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role in enhancing activity. The lipophilic nature of the phosphane in each complex 
could rationalize the trend in antiproliferative activity observed for 2.3-2.6. Table 3.2 shows 
the calculated logP (ClogP) values of each phosphane used to prepare complexes 2.3-2.6. 
These values were calculated using the ChemDraw Ultra 2010 version 12.0.2.1076 program.  
Table 3.1. IC50
a
 determinations for 2.1-2.6 against A2780 and A2780cisR cancer cell lines 
Compound IC50 in A2780 (µM) IC50 in A2780cisR (µM) RI 
2.1 11.3 ± 2.7 13.8 ± 2.6 1.22 
2.2 51.5 ± 1.0 67.0 ± 10 1.11 
2.3 129 ± 31 99.0 ± 4.7 0.76 
2.4 21.2 ± 1.2 32.0 ± 7 1.51 
2.5 36.5 ± 3.6 >200 -- 
2.6 > 200 175 ± 1.7 -- 
Cisplatin
b 1.5 25.0 16.67 
a
 IC50: lowest compound concentration that inhibits 50 % of cell growth.  
b 
IC50 values for cisplatin were determined using the same experimental assay and protocol as for 1-6 but were 
not determined at the same time as compounds 1-6. 
 
A logP value can be used as general guide to a compound’s ability to enter a cell by passive 
diffusion.
32
 High logP values indicate an affinity for lipids and suggest a compound is able to 
enter the lipid bilayer that surrounds cells.
32
 However, a balance between lipophilicity and 
hydrophilicity is essential; if a compound is too lipophilic (high ClogP) then poor absorption 
or permeation from the lipid bila er into the cytoplasm may be likely. The 
bis(diphenylphosphino)ethylene spacer displays the highest ClogP value (7.17) and most 
likely increases the lipophilic nature of complex 2.6 to such a degree that it cannot enter the 
cell and thus displays no significant activity against either cell line. Complex 2.3 and 2.5 have 
values of 5.68 and 5.01 respectively and complex 2.5 shows a much lower IC50 (36.5 μM) 
compared to 2.3 (129 μM) against the A2780 cell line. The improved activity of 2.5 
compared to 2.3 may also be due to the presence of the ferrocenyl moiety. Incorporation of 
ferrocene into a molecule has been shown to increase antiproliferative activity.
33
  
Table 3.2. Calculated ClogP values of each phosphane and the IC50 data of the corresponding complex 
Phosphane ClogP of 
Phosphane
a 
Complex IC50 of Complex  
A2780 (µM) 
IC50 in A2780cisR 
(µM) 
PPh3 5.68 2.3 129 ± 31 99.0 ± 4.7 
PTA -1.43 2.4 21.2 ± 1.2 32.0 ± 7 
dppf 5.01 2.5 36.5 ± 3.6 >200 
dppe 7.17 2.6 > 200 175 ± 1.7 
a
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Complex 2.4 demonstrated the best IC50 out of all compounds tested against both 
cell lines and its ancillary ligand, PTA, has the lowest ClogP value (-1.43) indicating that this 
phosphane has a high hydrophilic nature. While PTA is not very lipophilic, its hydrophilic 
nature adds the right counter balance to the lipophilic nature of the Pt-TSC moiety (ClogP = 
2.77) and may account for why this mononuclear complex has the best activity. This positive 
increase in activity has also been observed for other thiosemicarbazone complexes where 
replacement of the triphenylphosphane ligand with PTA led to higher activity.
18,34
 The 
solubility of complex 2.4 in aqueous media could also be much higher compared to the other 
complexes as evidenced by Grguric-Sipka and co-workers who reported that changing the 




Ultimately, in vitro assessment of compounds 2.1-2.6 revealed that the free ligand 2.1 was the 
best inhibitor of cell growth. However, the lower IC50 values observed for the complexes may 
likely be due to the phosphane ligands used for the preparation of 2.3-2.6. Structural 
modification of the phosphanes, such as adding water soluble groups, to give added 
hydrophilicity to the cycloplatinated complex could very likely improve the pharmacological 
effect of these complexes as was observed for complex 2.4. Replacement of the phosphane 
with another type of ancillary ligand such as a monodentate nitrogen ligand such as 4-




 3.2.2. In Vitro Antiparasitic Activity  
3.2.2.1. In vitro P. falciparum Activity 
The antiparasitic activity of complexes 2.1 – 2.6 in vitro against two Plasmodium falciparum 
strains, D10 (chloroquine sensitive) and Dd2 (chloroquine resistant) and the Trichomonas 
vaginalis parasite strain T1 was determined. Table 3.3 shows the antiplasmodial data 
ascertained for compounds 2.1 – 2.6. Ligand 2.1 did not exhibit significant activity against 
the D10 strain (IC50 = 95.8 μM). However, its cycloplatinated derivatives 2.2-2.4 do show 
much higher activity, suggesting the incorporation of platinum does influence the 
antiplasmodial activity of the thiosemicarbazone ligand. The tetranuclear complex 2.2 (IC50 = 
32.29 μM) is 3 times more active than ligand 2.1. Complexes 2.3 (IC50 = 19.93 μM) and 2.4 
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in antiplasmodial activity upon metalation has been observed for other 
thiosemicarbazone metal complexes. The cyclopalladated derivatives of 2.1 (complexes 1.96, 
1.98, 1.100, 1.102 and 1.104, Figure 3.4, section 3.1) also displayed improved inhibition 
compared to 2.1 in the 3D7 (CQ sensitive) and K1 (CQ and pyrimethamine resistant) P. 
falciparum strains.
26
 Gold(III) and gold(I) coordination complexes of 2.1 and other similar 
thiosemicarbazones have also demonstrated improved antiplasmodial activities over the free 
ligands.
37,38
 Mononuclear arene-ruthenium complexes containing bidentate [N,S] aryl-
thiosemicarbazone ligands were found to have enhanced inhibitory effects on the NF54 (CQ-
sensitive) and Dd2 (CQ-resistant) P. falciparum strains
39
 and the same trend was observed of 




Table 3.3. Antiplasmodial Data obtained for complexes 2.1-2.6 
Complex D10: IC50
a









2.2 32.29 ± 2.28 Not tested -- 
2.3 19.93 ± 3.74 14.47 ± 1.98 0.72 
2.4 21.42 ± 1.22 24.90 ± 3.24 1.16 
2.5 Not active
d 
Not tested -- 
2.6 Not active
d 
Not tested -- 
Chloroquine 
diphosphate 
0.012 ± 0.001 0.146 ± 2.08 12.17 
a 
The minimum compound concentration required for 50 % inhibition in vitro. 
b
 resistance index: determined as [IC50 Dd2]/[IC50 D10]. 
c 
IC50 value for 2.1 were determined in a previous experiment using the same assay. 
d 




Complexes 2.2-2.4 show only moderate activity compared to chloroquine diphosphate while 
2.5 and 2.6 show no activity at the highest compound concentration tested. The inactivity of 
complexes 2.5 and 2.6 can be attributed to the presence of the diphosphane ligands which, as 
described for the antitumor studies (section 3.2.1.), could adversely affect the lipophilic 
nature of the Pt-TSC moieties. Complex 2.2 was not as active as the mononuclear complexes 
2.3 and 2.4 and this may very likely be due to decreased hydrophilicity of the tetranuclear 
complex (Table 3.4). Lipophilicity and hydrophilicity have been put forth as important 
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As discussed in section 3.2.1, the calculated logP value is a parameter that is used to 
estimate the lipophilic nature of a compound and can be used to explain the differences in in 
vitro activities observed. Complex 2.2 is highly lipophilic (ClogP = 14.96) and thus not very 
hydrophilic suggesting that 2.2 may not be able to accumulate within the acidic food vacuole 
efficiently and thus only displays moderate inhibitory effect. Complexes 2.3 and 2.4 have 
lower ClogP values of 9.46 and 6.32 respectively and show better antiplasmodial activities 
compared to 2.2. They are still quiet lipophilic and this could account for their lower activity 
compared to chloroquine. 
Table 3.4. Calculated logP values for 2.2-2.4 and their antiplasmodial data for the D10 strain 
Complex D10: IC50 (µM) ClogP 
2.2 32.29 ± 2.28 14.96 
2.3 19.93 ± 3.74 9.459 
2.4 21.42 ± 1.22 6.318 
Chloroquine 0.012 ± 0.001 5.06 
 
Complex 2.3 [IC50 = 19.98 μM (D10) and 14.47 μM (Dd2)], which contains the 
triphenylphosphane ancillary ligand, was more active compared to 2.4 [IC50 = 21.42 μM 
(D10) and 24.90 μM (Dd2)] against both P. falciparum strains. This is in contrast to the 
antitumor studies of 2.3 and 2.4, however a strict comparison of the data ascertained against 
parasite strains and tumor cell lines is not possible as these are very different illnesses that 
operate under different mechanisms and thus compounds 2.1-2.6 most likely have completely 
different inhibitory targets against P. falciparum and tumor cell lines. It can be said that 
complex 2.3 appears to display selectivity toward P. falciparum over the tumor cell lines 
A2780 and A2780cisR. Further in vitro screening of 2.3 against other P. falciparum strains 
and tumor cell lines need to be investigated to confirm this. Complex 2.3 was more active 
against the Dd2 strain compared to the D10 strain but complex 2.4 showed the opposite trend. 
Nevertheless, complexes 2.3 and 2.4 displayed resistance indices of 0.72 and 1.16 
respectively that are much lower than chloroquine diphosphate. In fact RI values of less than 
or close to 1 is seen as favourable for potential antiplasmodial drug candidates.
41
 This 
suggests that mononuclear cycloplatinated thiosemicarbazones may very likely not be 
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3.2.2.2. In vitro T. vaginalis Activity 
Compounds 2.1 – 2.6 were investigated for further antiparasitic effects against the 
Trichomonas vaginalis strain T1. Trichomonas vaginalis is a flagellated facultative anaerobic 
protozoan, which causes the sexually transmitted infection trichomoniasis in humans and is 
reported to infect more than 170 million people worldwide, mainly in industrialized 
countries.
45
 Infection can have serious implications like premature birth and increased risk of 
acquiring HIV, cervical cancer and aggressive prostate cancer.
45-48
  Metronidazole is the 
current FDA-approved treatment
49
 but approximately 5% of all cases reported display 
resistance to this compound and this percentage is increasing.
50
 There is therefore a need to 
find alternative forms of treatment due to this increase in resistance. 
The effect of compounds 2.1-2.6 on parasite viability was determined at a single dose 
concentration if 100 μM on the T. vaginalis strain T1. In contrast to the inhibitory studies for 
P. falciparum, complex 2.4 is the only compound that showed a significant percentage 
inhibition (92.5 %) of the T. vaginalis parasite (Table 3.5). Metronidazole, the current FDA 
approved treatment, exhibited a 100 % inhibition at this concentration (100 µM), comparable 
to 2.4. The tetranuclear complex 2.2 showed a moderate percent inhibition of 68.7% while 
ligand 2.1 and the complexes 2.3, 2.5 and 2.6 displayed only mild effects on parasite viability 
(42.3, 24.5 and 42.3 % respectively). Since 2.4 was deemed to be the most potent inhibitor 
out of all compounds tested, its IC50 value was determined. Although this compound is not as 
potent as metronidazole, complex 2.4 represents a potential new chemotype.  
Table 3.5. Percent inhibition data of compounds 2.1-2.6 against T. vaginalis 
COMPOUND % INHIBITION (100µM) IC50 T1 Strain (µM) 
1 51.3 Not determined 
2 68.7 Not determined 
3 42.3 Not determined 
4 92.5 21.1 
5 24.5 Not determined 
6 42.3 Not determined 
Metronidazole
a 100 0.79 
a 
Current FDA approved treatment for T. Vaginalis infections 
 
Cysteine proteases are integral to the parasitic life cycle. They are involved in several parasite 
functions including host invasion, nutrition and protein processing.
51
 Thiosemicarbazones are 
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the parasite and a recent study of the interactions of Pt(II) complexes and cysteine 




Furthermore, it was found that the presence of an aromatic ring enhanced the inhibitory 
activity of these complexes compared to clinical drugs, cisplatin and carboplatin. However, 
the type and rate of active site cysteine binding was unique for each cysteine protease. 
Different cysteine proteases have structurally different folds and this can sterically influence 
how the complex binds to the cysteine protease targets within each parasite.
52
 This could 
account for the contrasting activities observed for complexes 2.3 and 3.4 against the P. 
falciparum and T. vaginalis parasite strains.  Moreover, it has been shown that the PTA 
ligand forms specific interactions within the active site of a cysteine protease when bound to 
a different metal center.
53
  
3.2.3. β-Hematin Inhibition Assay.  
In the life cycle of the Plasmodium falciparum parasite, degradation of the infected host’s 
hemoglobin to provide essential amino acids for its growth and nutrition is a vital step.
54
 A 
side product of this hemoglobin digestion is free heme which is toxic to the parasite. The 
parasite removes this threat by conversion of the free heme into a crystalline solid known as 
hemozoin which is nontoxic to the parasite.  Thus, this process is one potential target in the 
design of possible antiplasmodial therapeutics. Clinically used drugs, amodiaquine and 
chloroquine are believed to inhibit the formation of hemozoin.
55
   
The ability of a potential drug to inhibit formation of hemozoin can be measured using a β-
hematin (synthetic hemozoin) inhibition assay. Complex 2.3 exhibits the best antiplasmodial 
activity against the two malarial strains tested [IC50 = 19.98 μM (D10) and 14.47 μM (Dd2)] 
and was thus chosen, along with ligand 2.1 [IC50: 95.8 μM (D10)], for β-hematin inhibition 
studies. Compounds 2.1 and 2.3 were tested using a modified NP-40 detergent mediated 
hematin formation screen.
56
 Evidence suggests that neutral lipid particles within the digestive 
food vacuole act as the site of nucleation and crystal growth of hemozoin.
57
 NP-40 is a low 
cost, lipophilic detergent that can mediate the formation of synthetic hemozoin (β-hematin). 
The NP-40 mediated assay attempts to mimic the conditions of the acidic food vacuole in the 
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Figure 3.6 shows the dose-response curves obtained for the compounds 2.1 and 2.3 
along with amodiaquine and chloroquine. Neither ligand 2.1 nor complex 2.3 were found to 
hinder β-hematin formation at the concentrations tested compared to amodiaquine and 
chloroquine. This result suggests that arylthiosemicarbazones and their cycloplatinated 

































Figure 3.6. Concentration Dose Response Curves for NP-40 detergent mediated β-Hematin Assays of 2.1, 2.3, 
amodiaquine and chloroquine. 
   
3.3. Stability Studies 
As mentioned earlier, one of the drawbacks of using cisplatin as a chemotherapeutic agent is 
the fact that very little of the administered dose reaches its intended target. It has been found 
that up to 98 % of the intravenously administered dose of cisplatin is deactivated before it can 
reach its target.
3
  This may occur either by cisplatin undergoing aquation in the extracellular 
membranes leading to formation of adducts with proteins such as serum albumin
3
 or through 
binding of cisplatin to intracellular sulfur donors such as glutathione in the cytoplasm.
58,59
 
Thus, it is important that potential platinum metallotherapeutics exhibit stability in the 
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Previous spectroscopic studies of the interaction of cisplatin and an excess of 







was also found to form adducts with cysteine.
60-62
 These findings suggest that cisplatin may 
be deactivated by sulfur containing residues in the extracellular membranes. Further to this, 
the interaction of cisplatin with amino acids such as histidine, arginine, aspartic acid and 
glutamic acid have also been investigated to determine if further deactivation of cisplatin 
occurs through interaction with nitrogen donors.
61-66
   
A preliminary NMR study of compounds 2.1 – 2.6 in the presence of one amino acid and four 
different short peptides was carried out in deuterated DMSO. Table 3.6 lists the amino acid 
and peptide sequences. Methionine was chosen based on previous studies of cisplatin with 
this amino acid.
60,61
 Short peptides were used as cisplatin is believed to interact with the 
amino acid side-chains on the surface of proteins within cells.
67,68
 A solution of each 
compound and the appropriate amino acid or peptide in DMSO-d6 was heated to 37 °C and 
the 
1
H NMR spectra recorded. For all of the experiments, compounds 2.1 – 2.6 remain stable 
in the presence of the different peptides and methionine up to 10 days.  
  








Figures 3.7 - 3.9 show the spectra obtained for the ligand 2.1 and complex 2.4 after 10 days 
in the presence of methionine and the peptide Ala-Gly-Lys-Gly-Ala. No changes in the 
























H NMR spectra for A: Ligand 2.1; Met; 2.1 + Met after 10 days at 37 °C and B: Complex 2.4; Met; 



























H NMR spectra of A: Ala-Gly-Lys-Gly-Ala; B: complex 2.4; C: 2.4 + peptide 
 
The lack of interaction observed between each complex and the corresponding molecule may 
imply that thiosemicarbazone ligand (2.1) and its cycloplatinated analogues (2.2-2.6) may 
remain intact in the blood and cytoplasm. This result suggests that cycloplatinated 
thiosemicarbazones may be able to reach their antitumoral target intact. However, it is 
important to note that these NMR studies were carried out in DMSO-d6 and are only a 
preliminary screen. Since the compounds have shown stability in the presence of certain 
simple peptides, the next step is stability studies of compounds 2.1-2.6 with different 
biomolecules in biological media at physiological pH (7.3) and temperature in order to 
ascertain if these compounds do indeed remain intact under physiological conditions. 
3.4. Summary 
The thiosemicarbazone complex 2.1 and its mono-, di- and tetraplatinum complexes 2.2-2.6 
were screened for antiparasitic activity against Plasmodium falciparum and Trichomonas 
vaginalis strains and for antitumor activity against cisplatin-sensitive and cisplatin-resistant 
human ovarian carcinoma cell lines. They were found to exhibit moderate to low parasite 
growth inhibition and antiproliferative activities. The in vitro activities obtained for 2.1-2.8 
against the A2780 and A2780cisR cell lines revealed that cyclometalation of ligand 2.1 led to 
a decrease in in vitro activity. This is in contrast to previous reports where cycloplatination 
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The lipophilic nature of the phosphane in each complex may influence the 
antiproliferative activities of 2.3-2.6. Complex 2.4 demonstrated the best IC50 out of all 
compounds tested against both cell lines and its ancillary ligand, PTA, has a high hydrophilic 
nature providing the right counter balance to the high lipophilicity of the platinum-
thiosemicarbazone moiety. Complex 2.5 had a better activity than complex 2.3 and can be 
attributed to the presence of the ferrocenyl group which is known to enhance biological 
activity. Overall, the moderate activities observed could be improved through structural 
modification of the phosphanes to increase the hydrophilicity of the cycloplatinated 
complexes or by replacement of the phosphane with another type of ancillary ligand such as a 
monodentate nitrogen ligand. 
Against the D10 and Dd2 P. falciparum strains, complexes 2.2-2.4 were much more active 
than their free ligand 2.1 and the inactivity of complexes 2.5 and 2.6 may be attributed to the 
presence of the diphosphane ligand. The highly lipophilic nature of complex 2.2 may result in 
the complex being unable to enter the acidic food vacuole of the parasite efficiently thus 
accounting for moderate antiplasmodial activity. Complex 2.3 displayed the best inhibitory 
activity against both strains yet was much less active against the A2780 and A2780cisR cell 
lines suggesting that complex 2.3 may be selective for P. falciparum over tumor cell lines. 
Further in vitro screening of 2.3 against other P. falciparum strains and tumor cell lines need 
to be investigated to confirm this. All of the compounds (2.1 – 2.6) with the exception of 2.4 
displayed moderate to low effects on parasite viability in the T. vaginalis strain T1. 
When ligand 2.1 and complex 2.3 were evaluated for their ability to inhibit β-hematin 
formation in vitro, it was found that these compounds do not target this process at the 
concentrations used in the assay. Thiosemicarbazones and their metal complexes may act 
upon cysteine protease functions within the parasite, and a study of their interaction with 
different cysteine protease enzymes must be carried out to validate this hypothesis. 
Preliminary stability studies of compounds 2.1 – 2.6 experiments with different short peptides 
and the amino acid methionine using 
1
H NMR imply that these compounds may be stable in 
the blood and plasma and they may reach their antitumoral target intact. Further studies of 
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3.5. Experimental 
3.5.1. P. falciparum in vitro assay.  
The test samples were tested in triplicate on one occasion against chloroquine-sensitive 
(CQS) D10 strain and chloroquine-resistant (CQR) Dd2 strain of Plasmodium falciparum. 
Continuous in vitro cultures of asexual erythrocyte stages of P. falciparum were maintained 
using a modified method.
69
 Quantitative assessment of antiplasmodial activity in vitro was 
determined via the parasite lactate dehydrogenase assay using a modified method.
70
 The test 
samples were prepared to a 20 mg/cm
3
 stock solution in 100% DMSO and sonicated to 
enhance solubility. Samples were tested as a suspension if not completely dissolved. Stock 
solutions were stored at -20ºC. Further dilutions were prepared on the day of the experiment. 
Chloroquine (CQ) was used as the reference drug in all experiments. A full dose-response 
was performed for all compounds to determine the concentration inhibiting 50% of parasite 
growth (IC50–value). Test samples were tested at a starting concentration of 100 μg/cm
3
, 
which was then serially diluted 2-fold in complete medium to give 10 concentrations; with 
the lowest concentration being 0.2 μg/cm
3
. The same dilution technique was used for all 
samples. CQ was tested at a starting concentration of 100 ng/cm
3
 against the CQR strain and 
1000 ng/cm
3
 against the CQS strain. The highest concentration of solvent to which the 
parasites were exposed to had no measurable effect on the parasite viability (data not shown). 
The IC50-values were obtained using a non-linear dose-response curve fitting analysis via 
Graph Pad Prism v.4.0 software. 
3.5.2. T. vaginalis in vitro assay.  
Cultures of T. vaginalis T1 strain were grown in 5 cm
3
 completed TYM Diamond’s media in 
a 37ºC incubator for 24h. One hundred millimolar stocks of the compounds were made by 
dissolving in DMSO, were screened against T1 stain of T. vaginalis. Samples were tested as a 
suspension if not completely dissolved. Cells untreated and inoculated with 5µL DMSO are 
used as controls.  Five microliters of 100mM stocks of compound library were inoculated for 
a final concentration of 100µM.  Results were calculated based on counts utilizing a 
hemocytometer after 24h. For IC50 values, increasing concentrations of the compound (0-
100µM) were tested for inhibitory activity and concentrations that inhibited at approximately 
50% were then obtained by linear regression analysis.  These predicted IC50 values were then 
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3.5.3. A2780 and A2780R cancer in vitro assay.  
The human A2780 and A2780cisR ovarian carcinoma cells were obtained from the European 
Collection of Cell Cultures (Salisbury,UK). Cells were grown routinely in RPMI-1640 
medium with 10% foetal calf serum (FCS) and antibiotics at 37 ◦C and 5% CO2. Cytotoxicity 
was determined using the MTT assay (MTT = 3(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide). Cells were seeded in 96-well plates as monolayers with 100 cm
3
 of cell 
solution (approximately 20,000 cells) per well and pre-incubated for 24 h in medium 
supplemented with 10% FCS. Compounds were prepared as DMSO solution then dissolved 
in the culture medium and serially diluted to the appropriate concentration, to give a final 
DMSO concentration of 1%. 100 cm
3
 of drug solution was added to each well and the plates 
were incubated for another 72 h. Subsequently, MTT (5 mg/cm
3
 solution) was added to the 
cells and the plates were incubated for a further 2 h. The culture medium was aspirated, and 
the purple formazan crystals formed by the mitochondrial dehydrogenase activity of vital 
cells were dissolved in DMSO. The optical density, directly proportional to the number of 
surviving cells, was quantified at 540 nm using a multiwell plate reader and the fraction of 
surviving cells was calculated from the absorbance of untreated control cells. Evaluation is 
based on means from three independent experiments, each comprising three microcultures 
per concentration level. 
3.5.4. Detergent mediated assay for β-hematin inhibitors.  
The β-hematin formation assay method described by Carter et al.
55
 was modified for manual 
liquid delivery. Stock solutions of the test compounds were prepared at 10 mM, 2 mM and 
0.4 mM by dissolving each sample in DMSO with sonication. Test compounds were 
delivered to a 96 well plate in triplicate from 0-500 μM (final concentration) with a total 
DMSO volume of 10 μL in each well. Deionized H2O (70 μL) and NP-40 (20 μL; 30.55 μM) 
were then added. A 25 mM haematin stock solution was prepared by sonicating hemin in 
DMSO, for complete dissolution, and then suspending 177.76 μL of this in a 2M acetate 
buffer (pH 4.8). The homogenous suspension (100 μL) was then added to the wells to give 
final buffer and hematin concentrations of 1 M and 100 μM respectively.  The plate was 
covered and incubated at 37°C for 5-6 hours in a water bath. Analysis of the assay was 
carried out using the pyridine-ferrichrome method developed by Ncokazi and Egan.
71
  A 
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(pH 7.4) was prepared and 32 μL added to each well to give a final pyridine 
concentration of ± 5% (v/v). Acetone (60 μL) was then added to assist with hematin 
dispersion. The UV-vis absorbance of the plate wells was read on a SpectaMax plate reader. 
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4.1. Introduction 
The use of metals such as rhodium, iridium and ruthenium for the preparation of polynuclear 
complexes is attractive since these metals are stable in several oxidation states giving rise to 
interesting metal complex architectures as well as physical and/or electronic properties.
1-9
 Di- 
and polyaromatic or heteroaromatic ethers have been utilized for the preparation of 
homometallic complexes.
10-14
 Poly aryl ethers are known to exhibit high thermal stability and 
have been studied as polymeric or dendritic supports in catalysis and biology.
14-17
  
From a pharmacological standpoint, polyaryl ethers are believed to have potential as a drug 
delivery system. Conjugation of a bio-active moiety to a polyether scaffold may stabilize 
these compounds sufficiently to allow them to reach their biological target where they can be 
released.
16
 While larger dendrimeric polyaryl ethers have been proposed as potential drug 
delivery agents, smaller di- or tri-aryl ethers could still have biologically relevant properties.  
The study of diaryl ether containing molecules as pharmacological agents has become 
particularly pertinent since structure-activity relationship analyses of several biologically 
important natural products have shown that these compounds contain diaryl ether 
functionalities.
18
 Some of these small molecule diaryl ethers have been proposed to act as 
tyrosine kinase inhibitors and have had some success for the treatment of metastatic non-
small cell lung cancer and pancreatic cancer.
19
 The aryl-ether containing compound, cis-
tamoxifen (I, Figure 4.1.), is currently used clinically to treat early and advanced ER+ 
(estrogen receptor positive) breast cancer.
20
 Furthermore, the organometallic analogue, 
ferrocifen (II), showed enhanced growth inhibition activity in vitro compared to cis-
tamoxifen.
21-23
 More recently, pentamethylcyclopentadienyl rhodium derivatives have also 
been found to exhibit biological effect in vitro against the MCF7 and the MDA-MB-231 
breast cancer cell lines thus demonstrating the potential of aromatic ethers as antiproliferative 
agents.
20
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Figure 4.1. Aryl ether containing compounds with tumor growth inhibitory effects, cis-tamoxifen and 
ferrocifen and the diaryl ether compound Triclosan that is active in vitro against two strain of P. 
falciparum. 
 
Apart from the potential pharmacological benefits of aryl ethers against cancer, these 
compounds may also be active against tropical diseases such as malaria. In fact, the diaryl 
ether, Triclosan (III, Figure 4.1.) along with its derivatives has demonstrated in vitro activity 
against a chloroquine sensitive and a chloroquine resistant strain of P. falciparum.
24,25
 A 
library of 4-pyridone functionalized diaryl ethers have also been studied for in vitro and in 
vivo antiplasmodial activity against different strains of P. falciparum and all of the 
compounds were found to inhibit parasite growth in the low nanomolar range in vitro, 
exhibiting values that were either comparable or significantly lower than chloroquine.
26
  
Mono- and polynuclear ruthenium-arene and pentamethylcyclopentadienyl rhodium and 
iridium pyridyl complexes have demonstrated promising pharmacological activities 
particularly as antiproliferative agents making them viable candidates for further study.
27-29
 
Thus, the coupling of metallated pyridyl functionalities to a simple aryl ether scaffold may 
lead to an enhanced biological effect whereby the aryl ether framework would stabilize the 
metal moieties allowing them to be delivered intact to their pharmacological target.  
In this chapter, the synthesis and characterization of two new di- and tripyridyl aromatic ether 
compounds along with their Ru(II), Rh(III) and Ir(III) functionalized organometallic 
complexes is described.  
The choice to prepare a simple dipyridyl ether ligand system is based on structure analyses of 
previously reported compounds that revealed simple diaryl ether derivatives to have 
biological activity.
18,19
 For the preparation of the tripyridyl ether ligands, a tris-
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and some of their metal complexes have been reported to exhibit in vitro cytotoxic 
effects as both antiparasitic and antitumoral agents.
30-36
  
The design of these complexes aims to couple the biological properties of different 
functionalities to give an enhanced in vitro antiparasitic or antitumor effect; namely, the 
established in vitro pharmacological activities of half-sandwich Ru(II), Rh(III) and Ir(III) 
moieties and alkyl-pyridines as well as the lipophilic nature of aryl ethers. All of the 
compounds synthesized were evaluated in vitro as antitumor agents against two tumor cell 
lines of human ovarian cancer and as antiparasitic agents against the P. falciparum strains, 
NF54 (chloroquine sensitive) and Dd2 (chloroquine resistant), and the T. vaginalis strain G3 
and the results of these studies are presented in Chapter 6. 
4.2. Results and Discussion 
4.2.1. Synthesis and characterisation of di- and tripyridyl aromatic ether ligands  
 
The new di- and tripyridyl aromatic ether ligands, [3,5-Bis-(pyridin-4-ylmethoxy)-phenyl]-
methanol (4.1) and 2,4,6-Tris-[4-(pyridin-4-ylmethoxy)-phenyl]-[1,3,5]triazine (4.2), were 
prepared using two typical Williamson-ether synthesis protocols (Scheme 4.1.).
37
 For ligand 
4.1, the aromatic alcohol, 3,5-di(hydroxyl)benzylalcohol was reacted with 4-
bromomethylpyridine hydrobromide in THF with 18-crown-6 as the phase transfer catalyst 
for the weak base, K2CO3. After purification by organic-aqueous solution extraction, the 
product (4.1) was isolated as an amorphous solid in 40 % yield. 
 
This method (eqn 4.1.) proved unsuccessful for the preparation of the tripyridyl ligand (4.2) 
and instead tris(4-hydroxylphenyl)triazine was reacted with 4-bromomethylpyridine 
hydrobromide in DMF at 80 °C with K2CO3 as base yielding the ligand 4.2 as a yellow solid 
in 52 % yield.  
Examination of the proton NMR spectra for ligands 4.1 and 4.2 gives convincing evidence 
for the formation of the aromatic ether functionalities. A singlet occurring at 5.18 and 5.21 
ppm for 4.1 and 4.2 respectively is assigned to the alkyl ether protons Hd. This resonance 
shift is typical for aryl-alkyl ethers.
37,38
 For both ligands, the pyridyl protons, Ha and Hb, 
resonate between 8.55 - 8.75 ppm (Ha) and 7.40 – 7.43 ppm (Hb) as doublets as a result of  
through-bond coupling to each other. Coupling constants of between 6 – 9 Hz are observed 
and agree with a 
3

































4.1: brown solid, 40 %



































For 4.1, the benzyl protons Hi resonate at 4.58 ppm as a singlet and relatively upfield to this 
shift the hydroxyl proton resonates as a broad singlet at 4.22 ppm. Two singlets at 6.90 and 
6.59 ppm are respectively assigned to the protons Hg and Hf of the tri-substituted benzene 
ring. In the triazine functionalized ligand 4.2, the protons of the benzene rings are observed as 
doublets at 8.65 and 7.12 ppm. The more downfield resonance is assigned to Hg as these 
protons would experience a high de hielding effect due to their close proximity to the triazine 
ring.  




H} NMR spectroscopy reveals that the ortho and meta 
carbons of the pyridyl rings resonate at approximately 150.0 (Ca) and 121.5 (Cb) ppm. The 
alkyl ether carbons occur at 67.8 and 67.9 ppm for 4.1 and 4.2 respectively. In the case of 4.1, 
the benzyl carbon resonates at 63.4 ppm and the most deshielded carbon resonance of 158.1 
ppm is due to the ether functionalized aromatic carbons Ce. For 4.2, the carbons of the 
triazine ring resonate at 158.1 ppm. The unsubstituted carbons of the benzene rings of 4.2 are 
observed at 141.57 (Cf) and 128.3 (Cg) ppm. The alkyl-substituted carbon Cc of the pyridyl 
ring exhibits a resonance at 134.0 ppm. 
Further evidence confirming that etherification had occurred was garnered from the infrared 
analyses of 4.1 and 4.2. Both ligands show one strong absorption bands in the region of 1130-
1170 cm
-1 
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stretching frequency is assigned to a strong absorption band at 1597 cm
-1
; a similar 
frequency is observed for 4.2. The triazine C=N bond present in 4.2 vibrates at a higher 
frequency compared to the pyridyl imine and is assigned to an absorption band at 1607 cm
-1
.  
Electron-Impact (EI) mass spectrometry was used to analyse 4.1 and 4.2. Both compounds 
exhibit at base peak corresponding to its ionized parent ion, [M]
+
.  
4.2.2. Synthesis and Characterisation of PGM Complexes 
Ligands 4.1 and 4.2 were peripherally metalated using the precursors, dichloro(p-
cymene)ruthenium(II) dimer, dichloro(pentamethylcyclopentadienyl)rhodium(III) dimer and 



























































4.4: M = Rh, orange solid, 80 %











For complexes 4.3 – 4.6, the appropriate ligands were reacted with the corresponding dimers 
in DCM at room temperature. This method proved unsuccessful for the synthesis of 
complexes 4.7 and 4.8, most likely due to the fact that ligand 4.2 and the rhodium and iridium 
dimers are only partially soluble in DCM. These complexes (4.7 and 4.8) were therefore 
prepared by reaction of the corresponding dimer and 4.2 in refluxing methanol (Scheme 4.3.). 
Complexes 4.3- 4.8 were isolated as air-stable solids in moderate to high yields.  
Metallation of the pyridyl nitrogens in ligands 4.1 and 4.2 was confirmed using both NMR 








































































4.7: M = Rh, orange solid, 71 %























Comparison of the 
1
H NMR spectra of 4.3 – 4.8 with their corresponding free ligands (4.1 
and 4.2) reveals for all the complexes, a downfield shift of the doublet associated with the 
pyridyl protons ortho to nitrog n to around 9.00 ppm. Figures 4.2. and 4.3. show the proton 
NMR spectra for two dinuclear (4.3 and 4.5, Figure 4.2.) and two trinuclear (4.6 and 4.8, 
Figure 4.3.) complexes along with their corresponding free ligand. This deshielding of the Ha 
proton resonances is characteristic of metal coordination to nitrogen and arises from 
increased back-bonding between the metal and nitrogen causing reduced electron density in 
the ortho carbon-hydrogen bond. This effect has been reported for other mono- and 
multinuclear Ru(II), Rh(III) and Ir(III) complexes containing monodentate 4-pyridyl 
ligands.
27,29,39-44
 A minimal change in the resonances associated with the other protons of the 
now metallated pyridyl ether ligands were observed confirming that coordination of the metal 
occurs only at the pyridyl nitrogens and that there was no coordination to the nitrogen atoms 
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Figure 4.2. Proton NMR spectra for 4.1 (Acetone-d6), 4.3 and 4.5 (CDCl3) 
 
For the Ru(II) complexes 4.3 and 4.6, the proton resonances corresponding to the aromatic 
protons of the p-cymene ring are observed downfield compared to the alkyl ether protons at 
5.47 and 5.26 ppm; with the lower frequency resonance assigned to the protons ortho to the 
methyl substituent. For complex 4.3 these resonances are observed as distinct doublets with 
the expected 
3
J coupling of between 5.50 and 6.00 Hz. However, for complex 4.6 they are 
seen as broad singlets. This broadening of the proton signals is also observed for the other 
resonances associated with 4.6 (Figure 4.3.).  
The trinuclear complexes, 4.6 – 4.8, exhibit low solubility in the chlorinated solvents DCM 
and chloroform and are insoluble in other common organic solvents such as methanol, 
ethanol and acetone. Thus, the broadening of the proton NMR signals for 4.6 is attributed to 
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arene ring are observed at 1.30 and 1.56 ppm for complexes 4.3 and 4.6 respectively; 
the methyl protons resonate at ca. 2.10 ppm for both complexes. The rhodium and iridium 
functionalized complexes 4.4-4.5 and 4.7-4.8 display a singlet at approximately 1.55 ppm for 




H NMR Spectra for 4.2, 4.6 and 4.8 in CDCl3. 
 
 




H} NMR spectroscopy reveals a high frequency 
shift of the resonance assigned to Ca compared to the free ligand (4.1) to between 155.0 and 
153.0 ppm (Table 4.1.). As was observed in the proton NMR spectra for complexes 4.3-4.5, 
little to no effect is observed on the other carbon resonances assigned to the metal-
coordinated ligand. The resonances assigned to the alkyl ether carbons (Cd) occur at 
approximately the same shift of between 67.5 - 67.8 ppm. The benzyl carbon (Ci) also occurs 
at essentially the same resonance in the complexes (4.3 – 4.5) compared to the free ligand 
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The p-cymene moieties of complex 4.3 show a singlet at 82.9 and 82.0 ppm due to 
the resonances of the unsubstituted aromatic carbons of the ring. The isopropyl substituted 
aromatic carbon (Cm) and the methyl substituted carbon (Cp) resonates at 97.2 and 103.2 ppm 
respectively. These resonances agree with similar mononuclear 4-pyridyl complexes.
27
 For 
complexes 4.4 and 4.5, the carbons of the pentamethylcyclopentadienyl ring occur at 94.1 
and 85.8 ppm respectively. The carbon of the methyl substituents (Ck) are seen at 
approximately 8.5 ppm.   









H} NMR shift (ppm) 
Compound Ca Cc Cd Ce Ci 
4.1 149.7 159.5 67.8 146.3 63.4 
4.3 154.5 159.9 67.5 148.7 64.1 
4.4 153.1 159.2 67.8 148.7 64.5 
4.5 153.2 159.2 67.6 149.1 64.6 
 
Due to the low solubility of complexes 4.6 – 4.8 in most common deuterated solvents, 
ascertaining decent 
13
C NMR spectra proved difficult. Even NMR experiments run overnight 
at 30 °C in a mixture of DMSO-d6 and CDCl3 failed to give spectra with good resolution.  
Metallation of the pyridyl nitrogens was further confirmed for complexes 4.3 - 4.8 using IR 
spectroscopy. For all complexes, a high energy shift of the absorption band associated with 
the pyridyl C=N vibration was observed compared to the corresponding free ligand. For the 
dinuclear complexes a shift to approximately 1615 cm
-1
 compared to 4.1 (where it is 
observed at 1597 cm
-1
) was noted and for the trinuclear complexes the C=Npyridyl vibration is 
observed between 1613 and 1623 cm
-1
. The C=N vibration associated with the triazine 
functionality in complexes 4.6 – 4.8 shows no change compared to the free ligand (4.2) and is 
still observed at approximately 1606 cm
-1
, providing further evidence that no complexation to 
the triazine nitrogens had occurred . 
High resolution Electrospray Ionisaton Mass Spectrometry was used to determine the 
molecular ions for each complex (Table 4.2.). Complexes 4.3 and 4.4 exhibited a base peak 
corresponding to a triply charged complex; with 4.4 forming an acetonitrile adduct. The 
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Table 4.2. Mass Spectral Data for Complexes 4.3 – 4.8 
Complex Base peak m/z Assignment 
4.3 312.01 [M + 3H]
3+
 
4.4 351.01 [M + 3H + 3CH3CN]
3+
 
4.5 1083.2 [M - Cl]
+
 







4.7 810.2 [M + 2H + 2CH3OH]
2+
 






4.2.3. Electronic Spectral Analysis 
The electronic properties of compounds 4.1 – 4.8 were analyzed using UV-vis Spectroscopy. 
Figures 4.4. and 4.5. show the UV-vis spectra for the dipyridyl (4.1 and 4.3-4.5) and 
tripyridyl compounds (4.2 and 4.6-4.8) respectively. Table 4.3 lists the energy absorptions 
observed. All of the complexes were analysed at a concentration of 0.5 μM in DCM 
(dipyridyl compounds) or DMSO (tripyridyl compounds). Assignment of the absorption 
bands were made based on similar complexes reported in the literature.
42,45,46
   
 
Table 4.3. Spectral Data for compounds 4.1 – 4.8 ascertained using UV-vis Spectrometry 
Compound λmax (nm)
a 
4.1 358 (π-π*)   
4.3 343 (π-π*) 383-471 (MLCT, d–πligand)  
4.4 336 (π-π*) 369-469 (MLCT, dmetal –πligand)  
4.5 323 (π-π*) 415-465 (MLCT, dmetal –πligand)  
4.2 345 (π-π*) 409 (π–π*)  
4.6 343 (π-π*) 405 (MLCT, dmetal –πligand) 482 (LMCT, πligand–dmetal) 
4.7 345 (π-π*) 410 (MLCT, dmetal –πligand)  
4.8 368 (π-π*) 374 (MLCT, dmetal –πligand) 446 (LMCT, πligand–dmetal) 
a
 transitions are given in parentheses. 
All of the complexes exhibit a hyperchromic shift in the absorption bands compared to their 
corresponding free ligand. In the visible region, the absorption bands are fairly broad which is 
characterisitic of highly conjugated aromatic systems. Ligand 4.1 shows a broad soret band in 
the UV region at 345 nm and is attributed to the intraligand π-π* transitions of the aromatic 
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Figure 4.4. UV-vis Spectra for compounds 4.1 and 4.3-4.5. The compou ds were analysed at 




Figure 4.5. UV-vis Spectra for compounds 4.2 and 4.6-4.8; with expansion of the visible region inset. The 
compounds were analysed at ambient temperature using a 0.5 μM solution of each compound in DMSO in a 1 
cm glass cuvette. 
 
complexes (4.3-4.5). Compared to corresponding dinuclear complexes, the absorption spectra 
of 4.1 is much less intense. The complexes (4.3-4.5) are intensely coloured and the metal to 
ligand and ligand to metal charge transfer (MLCT and LMCT) bands  thus absorb strongly in 
the visible region while the free ligand is a pale beige colour and shows no absorption in the 
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The tripyridyl functionalized triazine ligand 4.2 is a bright yellow solid and shows a 
strongly absorbing soret band in the visible region at 409 nm due to the intraligand π-π* 
transitions. The MLCT bands for the complexes (4.6-4.8) absorb strongly in this region and 
most likely mask the intraligand absorptions in the visible region. Complexes 4.6 and 4.8 
show shoulders to their MLCT bands at 482 and 446 nm respectively and these absorptions 
are most likely due to ligand to metal charge transfers (LMCT). 
4.2.4. Single Crystal X-ray Diffraction Analysis  
Singles crystals of complex 4.5 suitable for single crystal X-ray analysis were grown from a 
mixture of methanol and hexane.  Complex 4.5 crystallized in monoclinic space group Pn 
with one molecule of methanol and three molecules of water in the asymmetric unit. The 
molecular structure of 4.5 validates the proposed structures of 4.3 - 4.8 put forth by the 
spectroscopic and spectrometric characterizations discussed earlier.  Figure 4.5 shows the 
complex structure of 4.5·C0.5H5O2 with the solvent molecules omitted and the crystal data is 
listed in Table 4.4. Tables 4.5 and 4.6 list selected bond lengths and angles for the molecular 
structure of 4.5. 
 
 
Figure 4.5. Molecular structure of 4.5 with hydrogen atoms and solvent molecules omitted. 
 
 
Each iridium metal center adopts a typical ‘piano-stool’ conformation with the two chlorido 
and the pyridyl ring as the three legs and a pseudo-tetrahedral coordination geometry. 
Comparison of the Ir-C bond lengths between the metal and each bonded carbon of the 
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symmetrically bound to iridium. The Ir-Cl, Ir-C and Ir-N bond lengths observed in 
4.5 are approximately 2.41 Å (Ir-Cl), 2.12 Å (Ir-C) and 2.10 Å (Ir-N). 
 







Formula weight 1162.04 
Crystal system Monoclinic 
Space group Pn 
a (Å) 8.9586(19) 
b (Å) 20.905(5) 
c (Å) 12.436(3) 











θ range for data collection (deg.) 2.47 to 25.80 
Limiting indices -10 < h < 10 
 -25 < k < 25 
 -15 < l < 15 
no. of reflns meads 12247 
no. of reflns used (Rint) 7998 (0.0000) 
no. of params 429 
R1 0.0343 
wR2 0.0871 
goodness of fit on F2 1.029 
 
These values agree with those observed for similar complexes in the literature
39,43,47,48
 as well 
as the expected length calculated from the covalent radii of iridium, chlorine (Ir-Cl: 2.40 Å), 
carbon (Ir-C: 2.09 Å) and nitrogen (Ir-N: 2.09 Å).
49
 In the coordinated pyridyl-ether ligand, 
the C-N bond lengths in the pyridyl ring are found to be between 1.25 – 1.40 Å and the alkyl 
C-O bond lengths of the ether functionalities between 1.41 and 1.43 Å, comparing favourably 
to the interatomic distances typical of pyridines and ethers (C=N: 1.34 Å and C-O: 1.43 Å).
50
  
 In 4.5, the bond angles observed for Cl-Ir-Cl and N-Ir-Cl are all close to 90 ° and the bond 
angles formed between the bonded carbons of the Cp* ligand, iridium and chloride ligand 
vary from 90 to 150 °. This trend has also been observed within the molecular structures of 
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Table 4.5. Selected bond lengths observed for complex 4.5·C0.5H5O2 
Bond Length (Å) 
Ir1-N1 2.095(12) Ir2-N2 2.067(11) 
Ir1-C1 2.122(14) Ir2-C30 2.090(18) 
Ir1-C2 2.120(17) Ir2-C31 2.171(17) 
Ir1-C3 2.146(14) Ir2-C32 2.238(19) 
Ir1-C4 2.158(11) Ir2-C33 2.141(19) 
Ir1-C5 2.120(17) Ir2-C34 2.11(3) 
Ir1-Cl1 2.408(4) Ir2-Cl3 2.418(7) 
Ir1-Cl2 2.405(4) Ir2-Cl4 2.419(5) 
N1-C11 1.303(19) N2-C27 1.25(2) 
N1-C15 1.343(18) N2-C28 1.43(2) 
O1-C16 1.408(18) O3-C24 1.429(19) 
O1-C17 1.381(16) O3-C19 1.399(18) 
 
Table 4.6. Selected bond lengths observed for complex 4.5· C0.5H5O2 
Bond Angles (°) 
C4-Ir1-Cl1 93.0(5) C33-Ir2-Cl3 110.9(5) 
C3-Ir1-Cl1 118.3(5) C32-Ir2-Cl3 91.9(6) 
C1-Ir1-Cl1 138.3(6) C30-Ir2-Cl3 145.5(5) 
C2-Ir1-Cl1 155.8(5) C31-Ir2-Cl3 107.8(5) 
C5-Ir1-Cl1 100.5(5) C34-Ir2-Cl3 149.9(6) 
N1-Ir1-Cl1 87.5(3) N2-Ir2-Cl3 86.1(4) 
C4-Ir1-Cl2 127.7(4) C33-Ir2-Cl4 100.8(5) 
C3-Ir1-Cl2 99.4(5) C32-Ir2-Cl4 133.4(5) 
C1-Ir1-Cl2 132.2(6) C30-Ir2-Cl4 128.1(5) 
C2-Ir1-Cl1 100.7(5) C31-Ir2-Cl4 161.2(5) 
C5-Ir1-Cl2 163.8(4) C34-Ir2-Cl4 97.6(7) 
N1-Ir1-Cl2 87.4(3) N2-Ir2-Cl4 87.5(4) 
Cl2-Ir1-Cl1 89.43(16) Cl3-Ir2-Cl4 86.4(3) 
 
4.3. Summary 
Two new pyridyl ether ligands have been synthesised and peripherally metallated with 
ruthenium, rhodium and iridium precursors to give the corresponding di- and trinuclear 
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characterised using a variety of analytical and spectroscopic techniques. The 
molecular structure of 4.5 confirms the monodentate coordination of the pyridyl ether ligands 
to each metal put forth by the spectroscopic and spectrometric characterisations of complexes 
4.3 - 4.8. 
 
A study of their in vitro antiparasitic and antitumor activity has been undertaken and the 
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4.4. Experimental 
4.4.1. Chemicals and General Methods  
1,2,3,4,5-Pentamethylcyclopentadiene, α-phellandrene, 4-bromomethylpyridine 
hydrobromide, 3,5-dihydroxybenzylalcohol and 4-cyanophenol were purchased from Sigma-
Aldrich and used without further purification. Ruthenium trichloride trihydrate, rhodium 
trichloride trihydrate and iridium trichloride trihydrate were kindly donated by 
AngloAmerican Platinum Limited. All solvents used were analytical grade and dried over 











 were synthesised using literature 
methods.  
4.4.2. Spectroscopic and Analytical Methods 
Nuclear Magnetic Resonance (NMR) Spectra were recorded on a Varian Unity XR400 MHz 
(
1
H at 399.95 MHz, 
13
C at 100.58 MHz), Varian Mercury XR300 (
1
H at 300.08 MHz, 
13
C at 
75.46 MHz) or Bruker Biospin GmbH (
1
H at 400.22 MHz, 
13
C at 100.65 MHz) spectrometer 




C{1H} NMR shifts are reported using 
tetramethylsilane (TMS) as the internal standard and 
31
P{1H} NMR spectra were measured 
relative to H3PO4 as the external standard. NMR spectra were recorded in either deuterated 
dimethylsulfoxide (DMSO-d6) or deuterated chloroform (CDCl3-d1) unless otherwise stated. 
Infrared (IR) absorptions were measured on Perkin-Elmer Spectrum 100 FT-IR Spectrometer 
as either KBr pellets or using a Universal Diamond Attenuated Total Reflection (ATR) 
accessory. Microanalyses for C, H, and N were carried out using a Thermo Flash 1112 Series 
CHNS-O Analyser and melting points were determined using a Büchi Melting Point 
Apparatus B-540. Mass Spectrometry determinations were carried out on all new compounds 
using either electron impact (EI) on a JEOL GC Matell instrument or electrospray ionisation 
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4.4.3. Synthesis of Pyridyl-ether Ligands 

















To a solution of 3,5-dihydroxybenzylalcohol (0.0659 g, 0.474 mmol) in acetone (30 cm
3
), 
potassium carbonate (0.3903 g, 2.82 mmol) and 18-crown-6 (0.0248 g, 0.0942 mmol) was 
added. The mixture was stirred at room temperature for 15 minutes before 4-
bromomethylpyridine hydrobromide (0.250 g, 0.989 mmol) was added and the reaction 
mixture heated to reflux for 48 hours. The reaction solvent was then evaporated under 
reduced pressure and the crude brown residue was extracted with DCM (50 cm
3
). The 
organic layer was washed with deionized water (4 x 20 cm
3
) and brine (1 x 20 cm
3
), dried 
over magnesium sulfate, filtered and the solvent evaporated under reduced pressure to afford 
the product (4.1) as a brown amorphous solid. Yield: 0.0618 g, 41 %. Mp: 194-196 °C, . 
1
H 
NMR (400 MHz, Acetone-d6): δ (ppm) = 8.58 (d, 
3
J(Ha-Hb): 6.39 Hz, 4H, Ha), 7.42 (d, 
3
J(Hb-
Ha): 5.59 Hz, 4H, Hb), 6.90 (s, 2H, Hg), 6.59 (s, 1H, Hf), 5.18 (s, 4H, Hd), 4.58 (s, 2H, Hi), 
4.22 (br s, 1H, Hj).  
13
C NMR (400 MHz, Acetone-d6): δ (ppm) = 159.5 (Ce), 149.7 (Ca), 
146.3 (Cc), 145.5 (Ch), 121.45 (Cb), 105.5 (Cg), 100.4 (Cf), 67.8 (Cd), 63.4 (Ci). IR (atr, cm
-1
) 
υ =  3184 (br w, O-H), 1597 (s, C=N), 1166 (s, -C-O-CH2-). Elemental Analysis for  
C19H18O3N2: found C, 67.89; H, 5.73; N, 8.03 %; calculated for C19H18O3N2·0.5CH4O: C, 
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2,4,6-Tris(4-hydroxyphenyl)triazine (0.100 g, 0.280 mmol) and potassium carbonate (0.232 
g, 1.68 mmol) was added to DMF (30 cm
3
) and stirred for 5 minutes at room temperature. 4-
Bromomethylpyridine hydrobromide (0.234 g, 0.924 mmol) was then added and the reaction 
mixture was heated to 80 °C for 18 hours with stirring. Upon cooling to room temperature, 
the reaction mixture was diluted with ethyl acetate (100 cm
3
) and washed with deionized 
water (3 x 50 cm
3
) and brine (1 x 50 cm
3
). The organic layer was then dried over magnesium 
sulfate, filtered and the solvent evaporated under reduced pressure to afford the product (4.2) 
as a bright yellow amorphous solid. Yield: 0.0924 g, 52 %. Mp: 253-254 °C, .
1
H NMR (400 
MHz, CDCl3-d1): δ (ppm) = 8.71 (d, 
3
J(Ha-Hb): 9.19Hz, 6H, Ha),  8.65 (d, 
3
J(Hg-Hf): 5.99 Hz, 
6H, Hg), 7.41 (d, 
3
J(Hb-Ha): 4.80 Hz, 6H, Hb), 7.12 (d, 
3
J(Hf-Hg): 8.80 Hz, 6H, Hf), 5.21 (s, 
6H, Hd).  
13
C NMR (400 MHz, Acetone-d6): δ (ppm) = 158.1 (Ci), 149.8 (Ca), 141.57 (Ce), 
134.0 (Cc), 128.3 (Cg), 123.3 (Ch), 121.5 (Cb), 115.12 (Cf), 67.9 (Cd). IR (atr, cm
-1
) υ =  
1607(w, C=Ntriazine), 1592 (w, C=Npyridyl), 1131 (s, -C-O-CH2-).  Elemental Analysis for 
C39H30O3N6: found C, 72.07; H, 5.10; N, 12.52 %; calculated for C39H30O3N6·0.5C4H8O2: C, 
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4.4.4. Synthesis of Dinuclear Ru(II), Rh(III) and Ir(III) Pyridyl-ether Complexes 
4.4.4.1. General Synthetic Method for Dinuclear Complexes 
The ligand [3,5-Bis-(pyridin-4-ylmethoxy)-phenyl]-methanol (4.1) (1 molar equivalent) was 
dissolved in DCM (15 cm
3
) and the appropropriate ruthenium, rhodium or iridium dimer (1.1 
molar equivalent) was added and the reaction solution was stirred for 16 hours at room 
temperature. The reaction solvent was then reduced under reduced pressure to approximately 
a third of its original volume. The product was then precipitated from solution by addition of 































[3,5-Bis-(pyridin-4-ylmethoxy)-phenyl]-methanol (4.1) (0.0400 g, 0.124 mmol) was reacted 
with dichloro(p-cymene)ruthenium(II) dimer (0.0833 g, 0.136 mmol). The product (4.3) was 
isolated as dark red amorphous solid. Yield: 0.0931 g, 80 %. Mp: 141 °C, decomposition 
without melting.
1
H NMR (400 MHz, CDCl3-d1): δ (ppm) = 8.93 (d, 
3
J(Ha-Hb): 5.11 Hz, 4H, 
Ha), 7.26 (d, 
3
J(Hb-Ha): 4.39 Hz,4H, Hb), 6.54 (s, 2H, Hg), 6.26 (s, 1H, Hf), 5.44 (d, 
3
J(Ho-
Hn): 5.99 Hz, 4H, Ho), 5.25(d, 
3
J(Hn-Ho): 5.59 Hz, 4H, Hn), 5.00 (s, 4H, Hd), 4.53 (s, 2H, Hi), 
4.46 (br s, 1H, Hj), 2.00-2.90 (m, 2H, Hl), 2.03 (s, 6H, Hq), 1.30 (d, 
3
J(Hk-Hl): 6.79 Hz, 12H, 
Hk).  
13
C NMR (400 MHz, CDCl3-d1): δ (ppm) = 159.9 (Ce), 154.5 (Ca), 148.7 (Cc), 144.8 
(Ch), 122.2 (Cb), 106.2 (Cg), 103.2 (Cp), 100.8 (Cf), 97.2 (Cm), 82.9 (Co), 82.0 (Cn), 67.5 (Cd), 
64.1 (Ci), 30.6 (Cl), 22.2 (Ck), 18.2 (Cq). IR (atr, cm
-1
) υ =  3435(br s, O-H), 1598 (s, C=N), 
1595 (s, C=Caromatics), 1160 (s, -C-O-CH2-). Elemental Analysis for  C39H46Cl4N2O3Ru2: 
found C 47.92; H, 5.40; N, 2.46 %; calculated for C39H46Cl4N2O3Ru2·0.5CH2Cl2: C, 47.93; 











































[3,5-Bis-(pyridin-4-ylmethoxy)-phenyl]-methanol (4.1) (0.0473 g, 0.147 mmol) was reacted 
with dichloro(pentamethylcyclopentadienyl)rhodium(III) dimer (0.1006 g, 0.163 mmol). The 
product (4.4) was isolated as a bright orange amorphous solid. Yield: 0.1104 g, 80 %. Mp: 
228 - 230 °C.
1
H NMR (400 MHz, CDCl3-d1): δ (ppm) = 8.91 (br s, 4H, Ha), 7.38 (d, 
3
J(Ha-
Hb): 6.39 Hz, 4H, Hb), 6.57 (s, 2H, Hg), 6.33 (s, 1H, Hf), 5.07 (s, 4H, Hd), 4.58 (s, 2H, Hi), 
2.61 (br s, 1H, Hj), 1.58 (s, 30H, Hk).  
13
C NMR (400 MHz, CDCl3-d1): δ (ppm) = 159.2 (Ce), 
153.1 (Ca), 148.7 (Cc), 144.8 (Ch), 122.9 (Cb), 106.6 (Cg), 101.3 (Cf), 94.1 (Cl), 67.8 (Cd), 
64.5 (Ci), 8.8 (Ck).  IR (atr, cm
-1
) υ =  3443(br w, O-H), 1615 (s, C=N), 1152 (s, -C-O-CH2-). 
Elemental Analysis for  C39H48Cl4N2O3Rh2: found C, 47.13; H, 5.42; N, 2.04 %; calculated 


















































[3,5-Bis-(pyridin-4-ylmethoxy)-phenyl]-methanol (4.1) (0.0372 g, 0.115 mmol) was reacted 
with dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (0.1013 g, 0.127 mmol). The 
product (4.5) was isolated as a bright yellow amorphous solid. Yield: 0.0865 g, 67 %. Mp: 
195 °C, decomposition without melting.
1
H NMR (400 MHz, CDCl3-d1): δ (ppm) = 8.89 (d, 
3
J(Ha-Hb): 5.60 Hz, 4H, Ha), 7.38 (d, 
3
J(Ha-Hb): 4.80 Hz, 4H, Hb), 6.59 (s, 2H, Hg), 6.36 (s, 
1H, Hf), 5.12 (s, 4H, Hd), 4.59 (s, 2H, Hi), 2.39 (br s, 1H, Hj), 1.54 (s, 30H, Hk).  
13
C NMR 
(400 MHz, CDCl3-d1): δ (ppm) = 159.2 (Ce), 153.2 (Ca), 149.1 (Cc), 144.6 (Ch), 123.0 (Cb), 
106.7 (Cg), 101.3 (Cf), 85.8 (Cl), 67.6 (Cd), 64.6 (Ci), 8.5 (Ck).  IR (atr, cm
-1
) υ =  3458 (br w, 
O-H), 1615 (s, C=N), 1152 (s, -C-O-CH2-). Elemental Analysis for  C39H48Cl4N2O3Ir2: found 
C 39.14; H, 4.49; N, 1.80 %; calculated for C39H48Cl4N2O3Ir2∙C6H12Cl3O: C, 39.65; H, 4.52; 
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4.4.5. Synthesis of Trinuclear Ru(II), Rh(III) and Ir(III) Pyridyl-ether Complexes 
4.4.5.1. General Synthetic Method for Trinuclear Complexes 
The ligand 2,4,6-Tris-[4-(pyridin-4-ylmethoxy)-phenyl]-[1,3,5]triazine (4.2) (2 molar 
equivalent) was dissolved in DCM (15 cm
3
) and the appropropriate ruthenium, rhodium or 
iridium dimer (3.1 molar equivalent) was added and the reaction solution was stirred for 16 
hours at room temperature. The reaction solvent was then reduced under reduced pressure to 
approximately a third of its original volume. The product was then precipitated from solution 


































2,4,6-Tris-[4-(pyridin-4-ylmethoxy)-phenyl]-[1,3,5]triazine (4.2) (0.0675 g, 0.107 mmol) was 
added to stirred solution of dichloro(p-cymene)ruthenium(II) dimer (0.102 g, 0.167 mmol) in 
DCM (15 cm
-3
). The reaction was allowed to stir at room temperature for 16 hours at which 
time the volume of the solvent was reduced to approximately 5 cm
-3
 and an excess of diethyl 
ether was added; precipitating the product (4.6). The product (4.6) was isolated as a yellow 
brown amorphous solid by filtration under reduced pressure, washed with diethyl ether and 
dried. Yield: 0.0767 g, 46 %. Mp: 207-211 °C, decomposition without melting.
1
H NMR (400 
MHz, CDCl3-d1): δ (ppm) = 9.02 (br s, 6H, Ha), 8.53 (br s, 6H, Hg), 7.36 (br s, 6H, Hb), 6.95 
(br s, 6H, Hf), 5.48 (br s, 6H, Ho), 5.27 (br s, 6H, Hn), 5.12 (br s, 6H, Hd), 3.01 (m, 3H, Hk), 
2.12 (s, 9H, Hp), 1.56 (br s, 18H, Hj).  IR (atr, cm
-1
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C=Ntriazine), 1149 (s, -C-O-CH2-). Elemental Analysis for  C69H72Cl6N6O3Ru3: 
found C 52.11; H, 5.03; N, 4.62 %; calculated for C69H72Cl6N6O3Ru3 ∙CH6O2: C, 51.98; H, 





































2,4,6-Tris-[4-(pyridin-4-ylmethoxy)-phenyl]-[1,3,5]triazine (4.2) (0.0614 g, 0.0974 mmol) 
was suspended in a stirred solution of dichloro(pentamethylcyclopentadienyl)rhodium(III) 
dimer (0.101 g, 0.162 mmol) in methanol (20 cm
-3
). The reaction mixture was stirred at 
reflux for 16 hours and then cooled to room temperature.  The product (4.3) was isolated as 
dark orange amorphous solid by filtration under reduced pressure, washed with methanol (10 
cm
-3
) and diethyl ether (10 cm
-3
) and dried. Yield: 0.108 g, 71 %. Mp: 267 °C, decomposition 
without melting.
1
H NMR (400 MHz, CDCl3-d1): δ (ppm) = 9.02 (d, 
3
J(Ha-Hb): 6.00 Hz, 6H, 
Ha), 8.66 (d, 
3
J(Hg-Hf): 8.79 Hz, 6H, Hg), 7.47 (d, 
3
J(Hb-Ha): 6.40 Hz, 6H, Hb), 7.06 (d, 
3
J(Hf-
Hg): 8.80 Hz, 6H, Hf), 5.23 (s, 6H, Hd), 1.56 (s, 45H, Hj). IR (atr, cm
-1
) υ =  1613 (w, 
C=Npyridyl),  1606 (w, C=Ntriazine), 1146 (s, -C-O-CH2-).  Elemental Analysis for  
C69H75Cl6N6O3Rh3: found C, 52.00; H, 4.72; N, 5.10 %; calculated for  

















































2,4,6-Tris-[4-(pyridin-4-ylmethoxy)-phenyl]-[1,3,5]triazine (4.2) (0.0496 g, 0.0786 mmol) 
was suspended in a stirred solution of dichloro(pentamethylcyclopentadienyl)iridium(III) 
dimer (0.103 g, 0.129 mmol) in methanol (20 cm
-3
). The reaction mixture was stirred at 
reflux for 16 hours and then cooled to room temperature.  The product (4.3) was isolated as 
yellow amorphous solid by filtration under reduced pressure, washed with methanol (10 cm
-3
) 
and diethyl ether (10 cm
-3
) and dried. Yield: 0.131 g, 91 %. Mp: 257 °C, decomposition 
without melting.
 1
H NMR (400 MHz, CDCl3-d1): δ (ppm) = 8.99 (d, 
3
J(Ha-Hb): 6.40 Hz, 6H, 
Ha), 8.65 (d, 
3
J(Hg-Hf): 8.80 Hz, 6H, Hg), 7.45 (d, 
3
J(Hb-Ha): 4.00 Hz, 6H, Hb), 7.04 (d, 
3
J(Hf-
Hg): 8.80 Hz, 6H, Hf), 5.24 (s, 6H, Hd) 1.56 (s, 45H, Hj). IR (atr, cm
-1
) υ =  1619 (w, 
C=Npyridyl),  1606 (w, C=Ntriazine), 1146 (s, -C-O-CH2-). Elemental Analysis for  
C69H75Cl6N6O3Ir3: found C, 45.10; H, 4.31; N, 4.81 %; calculated: C, 45.40; H, 4.14; N, 4.60. 
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4.4.6. X-Ray Structure Analysis 
Single-crystal X-ray diffraction data were collected on a Bruker KAPPA APEX II DUO 
diffractometer using graphite-monochromated Mo-K radiation ( = 0.71073 Å). Data 
collection was carried out at 173(2) K. Temperature was controlled by an Oxford Cryostream 
cooling system (Oxford Cryostat). Cell refinement and data reduction were performed using 
the program SAINT.
54
 The data were scaled and absorption correction performed using 
SADABS
2
. The structure was solved by direct methods using SHELXS-97
55
 and refined by 




 and using the graphics 
interface program X-Seed.
56,57
 The programs X-Seed and POV-Ray
58
 were both used to 
prepare molecular graphic images. There are three water and one methanol molecules in the 
asymmetric unit and all were refined with half site occupancy factors. One water oxygen 
atom was refined anisotropically and all other non-hydrogen atoms of the solvents were 
refined with isotropic displacement parameters. The carbon atoms from C30 to C39 on the 
main molecule were restrained geometrically to a reasonable shape and were refined 
isotropically. All other non-hydrogen atoms on the main molecule were refined 
anisotropically. All hydrogen atoms, except those of the solvent molecule and the hydroxyl 
hydrogen H2 on O2, were placed in idealised positions and refined with geometrical 
constraints. The hydrogen atom H2 was located in the difference electron density map and 
refined with distance of O2-H2 set to 0.97 Å. The structure was refined to R factor of 0.0563. 
The highest peak is 3.01e/Å
3
,  1.01 Å from IR1; the deepest hole is -1.95 e/Å
3
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5.1. Introduction 
The synthesis and biological study of molecules containing aromatic ester functionalities is 
not uncommon. In fact, the inclusion of this type of moiety when considering the design of 
potential new chemotherapeutics is important as they are highly lipophilic groups and thus, 
may enhance diffusion of the drug through cell membranes.
1,2
 There are numerous examples 
of aromatic esters with a variety of bioactivities in the literature. A series of lipophilic esters 
prepared from 4-acetyl-2-(2-hydroxyethyl)-5,6-bis(4-chlorophenyl)-2H-pyridazin-3-one (I, 
Figure 5.1.) have shown in vivo efficacy as antihypertensive agents.
3
 A library of aromatic 
esters derived from cinnamic acid (II) have demonstrated anti-inflammatory effects in vitro
4
 
and ester functionalized analogues of bezafibrate (III) have also been investigated as orally 
active hypolipidemic agents.
5
 Tyrosyl (2-(4-hydroxyphenyl)ethanol) is a known antioxidant 


































(IV) MS-275  
Figure 5.1. Examples of aromatic ester derivatives studied for different bioactivities. 
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As cancer chemotherapeutics, the pyridyl ester containing compound MS-275 (IV) 
is currently undergoing phase II clinical trials.
7
 Larger polyester scaffolds have also gained 
considerable attention for tumor targeting either as micelles or via conjugation of the 
potential drug molecule onto the polyester scaffold.
8-12
 Polyester dendrimers have been found 
to be less toxic and exhibit better biodegradability compared to polyamine and polyamide 
derivatives.
13
 Thus, the premise of these studies is that these macromolecular scaffolds act as 
drug delivery vehicles, allowing preferential uptake by tumors through endocytosis. Once in 
the tumor cell, the ester bonds are hydrolyzed by esterases and the active drug moieties are 
released.  
 
Mono- and polynuclear ruthenium-arene and pentamethylcyclopentadienyl rhodium and 
iridium pyridyl complexes have demonstrated promising pharmacological activities 
particularly as antiproliferative agents making them viable candidates for further study.
14-16
 
There have been several reports of the conjugation of the ruthenium arene moieties to mono- 
and di-aryl esters to give antitumoral agents with encouraging activities. An ethacrynic acid 
derivatized RAPTA complex (V, Figure 5.2) was found to inhibit glutathione-S-transferases 
with an activity that was better than the free acid while the RAPTA-C complex was 
completely inactive.
17-19
 Mono- and dipyridyl ester containing ruthenium arene complexes 
(VI and VII) have demonstrated similar in vitro activities against both the cisplatin sensitive 
(A2780) and resistant (A2780cisR) human ovarian tumor cell line.
20
 The pyridyl ester 
containing complex, 5-fluorouracil-1-methyl isonicotinate ruthenium arene (VIII), showed a 




   These examples demonstrate the viability of platinum group metal (PGM) functionalized 
pyridyl ester complexes as in vitro pharmacological agents. The pyridyl ester groups may 
increase the lipophilic nature of these complexes thereby allowing the active metal moieties 
to reach its target.  
In this chapter, the synthesis and characterization of two di- and tripyridyl aromatic ester 
compounds along with their new Ru(II), Rh(III) and Ir(III) functionalized organometallic 
complexes is described. The rationale for the use of these ligands is to increase the lipohilic 
nature of the complexes by having more than one ester functionality. Further to this, the 
preparation of these complexes aims to couple the established in vitro pharmacological 
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of the compounds synthesized have been evaluated in vitro as antitumor agents 
against the A2780 (cisplatin-sensitive) and A2780cisR (cisplatin-resistant) human ovarian 
carcinoma cell lines and as antiparasitic agents against the P. falciparum strains, NF54 
(chloroquine sensitive) and Dd2 (chloroquine resistant), and the T. vaginalis strain G3 and 






























V: ethacrynic acid derivatized RAPTA complex
VI: Mono pyridyl ester ruthenium arene complex











VIII: 5-fluorouracil-1-methyl isonicotinate ruthenium 
arene complex  
Figure 5.2. Examples of arene ruthenium ester complexes studied for activity as in vitro antitumor agents. 
 
5.2. Results and Discussion 
5.2.1. Synthesis and characterization of di- and tripyridyl ester ligands 
Before the di- and tripyridyl ester ligands 5.1 and 5.2 were successfully prepared, two known 
reaction methods were initially attempted to synthesize compound 5.2 (Routes (i) and (ii), 
Scheme 5.1.) in order to establish a route that could be used for the preparation of both 
ligands. The Steglich Esterification method was first employed. 4-Pyridine carbinol was 
reacted with 1,3,5-benzene-tricarboxylic acid using N,N'-dicyclohexylcarbodiimide (DCC) as 
a coupling reagent and 4-dimethylaminopyridine (DMAP) as a catalyst. However, proton 
NMR analysis of the crude solid isolated revealed it to be unreacted DCC. Repeating this 



































Scheme 5.1.  
 
 
This route may not have been successful due to the poor solubility of the triacid precursor in 
DCM. The acid, 1,3,5-benzene-tricarboxylic acid, displayed better solubility in the alcoholic 
solvents methanol and ethanol but alcoholic solvents are not ideal as they would also undergo 
esterification.  
 
The second route was then attempted, where a mixture of the tricarboxylic acid and a large 
excess of 4-pyridine carbinol along with a few drops of sulfuric acid was heated (without 
solvent) to a temperature slightly higher (65 °C) than the melting point of the alcohol for 16 
hours. As with the previous method, a white solid was isolated but analysis using proton 
NMR revealed the solid to be unreacted tricarboxylic acid. Ligands 5.1 and 5.2 were finally 
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Ligand 5.1 was prepared by reaction of isonicotinic acid with 1,4-
(bromomethyl)benzene in the presence of potassium carbonate in DMF (Eqn. 5.1, Scheme 
5.2). The same reaction method was used for the preparation of ligand 5.2 which was 
obtained by reaction of 4-(bromomethyl)benzene with 1,3,5-benzene-tricarboxylic acid. Both 
ligands were isolated in high yields as air and moisture stable white solids. Both of these 





Analysis of the 
1
H NMR spectra for 5.1 and 5.2 revealed that the pyridyl protons ortho and 
meta to nitrogen resonate between 8.60 - 8.90 and 7.35 – 7.50 ppm respectively as doublets 
due to through-bond coupling to each other. The coupling constants observed are typical of 
para-substituted 4-pyridyl rings. Compared to the tripyridyl ligand 5.2, the protons Ha of the 
pyridyl rings in 5.1 are slightly more deshielded. This can be attributed to the ester 
functionalities that are bonded in the para position of the pyridyl rings giving rise to a much 
higher electron withdrawing effect on the Ha protons compared to ligand 5.2 where a 
methylene CH2 spacer separates the ester functionalities from the pyridyl rings.  
 
In the case of both ligands, a singlet observed at 5.41 and 5.45 ppm for 5.1 and 5.2 
respectively confirmed esterification had occurred as these resonances correspond to the 
presence of the alkyl (-CH2) ester protons and agree with the resonances observed for other 
aromatic alkyl ester compounds.
21-23
  For ligand 5.1, the aromatic protons of the central 
benzene core is observed as a singlet at 7.49 ppm whereas for ligand 5.2, the three protons of 
the benzene ring are observed at 8.98 ppm due to the strongly electron withdrawing nature of 
the ester functionalities bonded to the ring in the 1, 3 and 5 positions.  
 




H} NMR spectrum of 5.2 where the ester 
functionalized carbons (Cf) of the phenyl ring resonate at 144.2 ppm. The most deshielded 




H} NMR spectra of 5.1 and 5.2 is seen at approximately 
164.5 ppm and is assigned to the carbonyl carbon of the ester substituents. The carbons, Ha 
and Hb, of the pyridyl rings resonate at approximately 150.0 and 122.0 ppm respectively. For 
5.1, the para-substituted carbon (Cc) of the pyridyl rings is observed further downfield at 
137.3 ppm compared to 5.2 (131.1 ppm) as a consequence of the deshielding effect of the 
ester functional groups. For 5.2, the ester functionalities are situated one carbon away from 
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Further spectroscopic analysis of ligands 5.1 and 5.2 using infrared (IR) spectroscopy reveals 
that the ester C=O bond vibration is observed in the expected region at approximately 1720 
cm
-1
. A single absorption band is observed at 1605 and 1611 cm
-1
 for 5.1 and 5.2 respectively 
due to the C=N stretching of the pyridyl rings. The O-CH2 bond vibration of the ester 
functionalities is assigned to a strong absorption band observed in the region of 1230 and 
1280 cm
-1
 for both ligands.    
 
5.2.2. Synthesis and Characterisation of PGM Complexes  
 
Ligands 5.1 and 5.2 were reacted with the precursors, dichloro(p-cymene)ruthenium(II) 
dimer, dichloro(pentamethylcyclopentadienyl)rhodium(III) dimer or dichloro(pentamethyl-
cyclopentadienyl)iridium(III) dimer to yield the corresponding di- or trinuclear complexes 
5.3 - 5.8 (Schemes 5.3 and 5.4) in moderate to high yields. All of the complexes were 
prepared using the same method. The appropriate ligand and dimer were stirred in DCM at 
room temperature for 16 hours and the resulting product was precipitated from the reaction 















































5.4: M = Rh, orange solid, 92 % yield

















Complexes 5.3 – 5.8 are new compounds and were fully characterized using several 
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Spectroscopic evidence confirming peripheral metalation of ligands 5.1 and 5.2 via 
the pyridyl nitrogens was garnered from the NMR and IR spectral analyses.  
 
The proton NMR spectra for complexes 5.3 – 5.8 all show a downfield shift of the protons 
ortho to nitrogen compared to their corresponding free ligands (5.1 and 5.2, Figures 5.3. and 
5.4.) which is typical for monodentate 4-pyridyl ligands coordinated to Ru(II), Rh(III) or 
Ir(III) metal centers.
14,16,24-31
 This deshielding of the protons Ha would be expected upon 
metal coordination to the nitrogen as it leads to less electron density in the ortho carbon-
hydrogen bond due to strong back-bonding between an empty π*-orbital of nitrogen and a 
filled d-ordital of the transition metal.  
 
Similar to the free ligands (5.1 and 5.2), in the dinuclear complexes (5.3 - 5.5) this 
deshielding of the doublet associated with the ortho protons (Ha) of the pyridyl ring is much 
more pronounced compared to the trinuclear complexes 5.6 – 5.8 due to the proximity of the 
ester groups to the pyridyl rings. For all of the complexes (5.3 - 5.8), the resonances assigned 
to the ester methylene protons display minimal change compared to the free ligands 








































































5.7: M = Rh, orange solid, 88 % yield
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For the di- and tri-ruthenium complexes, 5.3 and 5.6, the p-cymene ligand displays 
proton resonances characteristic of similar neutral piano-stool dichloro ruthenium 
complexes.
16,24,27,29-31
 The methyl protons of the isopropyl group (Hh) are observed at ca. 1.30 
ppm, resonating as a doublet due to coupling to the proton Hi and the proton Hi is observed as 
a multiplet between 2.90 and 3.00 ppm. The methyl protons Hn resonate as a singlet at 2.10 
ppm. The aromatic protons, Hk and Hm, of the p-cymene ligand resonate as two doublets 
between 5.00 and 5.50 ppm.  The methyl protons of the pentamethylcyclopentadienyl ligands 
of the rhodium (5.4 and 5.7) and iridium (5.5 and 5.8) complexes are seen as a singlet 
between 1.50 and 1.60 ppm in the proton NMR spectra for these complexes.  
 




H} NMR spectroscopy reveals a high frequency 
shift of the resonance assigned to Ca compared to the free ligand (5.1 and 5.2) (Table 5.1) 
confirming metal coordination to the pyridyl nitrogens. For complexes 5.3-5.5, a shift 
downfield of approximately 5.0 ppm is noted compared to 5.1. In comparison to the free 
ligand 5.2, a shift of approximately 5.0 ppm for Ca is observed for the triruthenium complex 
5.6 and around 3.0 ppm for the rhodium and iridium analogues (5.7 and 5.8).  
Similar to the proton NMR spectra for complexes 5.3-5.8, little to no effect is observed on the 
other carbon resonances assigned to the metal-coordinated ester ligands. The resonances 
assigned to the carbonyl carbon (Cd in 5.3-5.5 and Ce in 5.6-5.8) as well as the alkyl ester 
carbon (Ce in 5.3-5.5 and Cd in 5.6-5.8) occur at approximately the same shift compared to 
the free ligand. This serves as further evidence that coordination to the ester oxygens does not 
occur. 
For the rhodium (5.4 and 5.7) and iridium (5.5 and 5.8) complexes, the carbon resonance 
associated with the methyl substituents (Ch) of the pentametylcyclopentadienyl ligand are 
observed between 8.5 and 9.0 ppm. The aromatic carbons (Ci) of the ring are observed at 
approximately 95.0 ppm for the rhodium complexes and in the iridium complexes these 
carbons resonate further upfield at approximately 86.0 ppm. These shifts are similar to other 
piano-stool Cp* rhodium and iridium complexes.
32-35
 The p-cymene moieties of complexes 
5.3 and 5.6 show two singlets between 82.0 and 83.0 ppm due to the resonances of the 
unsubstituted aromatic carbons of the ring. The isopropyl substituted aromatic carbon (Cj) 
and the methyl substituted aromatic carbon (Cm) resonates at approximately 97.0 and 104.0 
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Figure 5.3. Proton NMR spectra for compounds 5.1, 5.3 and 5.4 run in CDCl3. 
 
 
Further analysis of the complexes 5.3 – 5.8 using infrared spectroscopy reveals no shift in the 
absorption band associated with the C=O bond vibration of the now metalated ligands,  
supportive of the evidence gleaned from the NMR analyses that metal coordination to the 
ester oxygen atoms does not occur. The C=N bond vibration of the pyridyl functionalities do 
exhibit an expected shift to higher frequency as a consequence of metal complexation to 
nitrogen. A high frequency increase of 15 – 20 cm
-1
 is noted and agrees with literature 
examples.
36-39
 For all of the complexes, a strong absorption band in the region of 1200 – 1300 
cm
-1
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H} NMR shift (ppm) 
Compound Ca Cc Cd Ce 
5.1 150.6 137.3 164.9 67.0 
5.3 155.9 138.5 163.6 67.5 
5.4 154.0 138.7 163.8 67.4 
5.5 154.4 138.7 163.4 67.5 
5.2 150.3 131.1 65.5 164.3 
5.6 155.1 130.8 64.7 163.8 
5.7 153.6 130.8 64.7 163.9 
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Mass spectral analysis of complexes 5.3 – 5.8 using ESI-MS reveals molecular ion 
fragments corresponding to the molecular weights of the proposed structures (Table 5.2). 
Complexes 5.4 and 5.7 exhibit base peaks corresponding to the sodium adduct and complexes 
5.3 and 5.8 form adducts with methonal upon either protonation or loss of chlorido ligands. 
Complexes 5.5 and 5.6 show m/z peaks corresponding to the loss of a chlorido ligand. Within 
these complexes, there are several potential sites of ionization, thus mass fragments 
corresponding to multiply charged species is possible.  
Table 5.2. Mass Spectral Data for Complexes 5.3 – 5.8 
Complex m/z Assignment (Intensity) 
5.3 312.01 ([M – 3Cl + 3CH3OH]
3+
 (100 %) 
5.4 989.02 ([M - H + Na]
+ 
(100 %) 
5.5 1100.21 ([M -Cl]
+ 
(100 %) 
5.6 1367.03 [M – Cl]
+
 (20%) 
5.7 1432.01 [M - H + Na]
+
  (100%) 




5.2.3. Electronic Spectral Analysis 
The electronic properties of compounds 5.1 – 5.8 were analyzed using UV-vis Spectroscopy. 
Figures 5.5. and 5.6. show the UV-vis spectra for the dipyridyl ester (5.1 and 5.3-5.5) and 
tripyridyl ester compounds (5.2 and 5.6-5.8) respectively. Table 5.3 lists the energy 
absorptions observed. All of the complexes were analysed at a concentration of 0.1 mM in 
chloroform and assignment of the absorption bands were made based on similar complexes 




Figure 5.5. UV-vis Spectra for compounds 5.1 and 5.3-5.5. The compounds were analysed at ambient 

















Figure 5.6. UV-vis Spectra for compounds 5.2 and 5.6-5.8. The compounds were analysed at ambient 
temperature using a 0.1 mM solution of each compound in chloroform in a 1 cm quartz cuvette. 
 
A hyperchromic shift in the intensity of the spectra for the complexes 5.3-5.8 is noted in 
comparison to their free ligands.  The ligands, 5.1 and 5.2, are white solids and thus show no 
absorption in the visible region of the spectrum. For all of the compounds, the absorption 
band observed between 200-300 nm is assigned to the intraligand n-π* and π-π* transitions of 
the aromatic and ester groups. These transitions exhibit a red shift upon complexation; the 
metal moieties effectively act as an auxochrome causing the intraligand transitions to shift to 
longer wavelength. In general, the absorption spectra for all of the compounds exhibit fairly 
broad bands, which is characterisitic of highly conjugated aromatic systems. Charge transfer 
bands observed between 300-350 and 400-450 nm are characteristic of the MLCT dπ-π* 
transitions between the metal and ligand.  
Table 5.3. Spectral Data for compounds 5.1 – 5.8 ascertained using UV-vis Spectrometry 
Compound λmax (nm)
a 
5.1 272 (n-π*/π-π*intraligand)   
5.3 280 (n-π*/π-π*intraligand) 337 (MLCT dπmetal–π*ligand) 400-450 (MLCT dπmetal–π*ligand) 
5.4 280 (n-π*/π-π*intraligand)  410 (MLCT dπmetal–π*ligand) 
5.5 290 (n-π*/π-π*intraligand) 324 (MLCT dπmetal–π*ligand) 400-450 (MLCT dπmetal–π*ligand) 
5.2 257 (n-π*/π-π*intraligand)   
5.6 260 (n-π*/π-π*intraligand) 299 (MLCT dπmetal–π*ligand) 405 (MLCT dπmetal–π*ligand d) 
5.7 250 (n-π*/π-π*intraligand) 335 (MLCT dπmetal–π*ligand) 402 (MLCT dπmetal–π*ligand) 
5.8 284 (n-π*/π-π*intraligand) 334 (MLCT dπmetal–π*ligand) 400-450 (MLCT dπmetal–π*ligand) 
a
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5.2.4. Single Crystal X-ray Diffraction (XRD) Analysis 
The molecular structures of complexes 5.4 and 5.5 were elucidated using single crystal XRD. 
Crystals were grown from a solution of chloroform and hexane.  Both complexes crystallize 
with two complex molecules and four chloroform molecules in the asymmetric unit with a 
monoclinic system and P21 space group. Figures 5.6 and 5.7 show the molecular structures of 
5.4 and 5.5 and Tables 5.4 – 5.6 list the crystal data and selected bond lengths and angles.  
 
 
Figure 5.6. Molecular structure of Complex 5.4 with hydrogen atoms omitted for clarity 
 
The determined molecular structures of complexes 5.4 and 5.5 validate the structures of 5.3 - 
5.8 evidenced by the spectroscopic and spectrometric characterizations discussed earlier. In 
the structures of both dinuclear complexes, each metal center adopts a typical ‘piano-stool’ 
conformation with the two chlorido and the pyridyl ring as the three legs and a pseudo-
tetrahedral coordination geometry. The pentamethylcyclopentadienyl ring is bound to the 
metal in the expected η
5
 manner. The pyridyl ester ligand is coordinated to each metal center 
in a monodentate fashion as suggested by the spectroscopic characterizations. Comparison of 
the Rh-C and Ir-C bond lengths between the metal and each bonded carbon of the 
pentamethylcyclopentadienyl ring reveal them to be similar indicating that the ring is 
symmetrically bound to rhodium (5.4) or iridium (5.5). The bond lengths observed in 5.4 and 
5.5 between the metal and the coordinated atoms are approximately 2.40 Å (M-Cl), 2.10 Å 
(M-C) and 2.10 Å (M-N). These values agree with those observed for similar complexes in 
the literature
16,24,28,34,35,38,39,41
 as well as the expected length calculated from the covalent radii 
of iridium or rhodium, chlorine (M-Cl: 2.40 (Ir); 2.41 (Rh) Å), carbon (M-C: 2.09 (Ir); 2.10 
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Table 5.4. Crystal Data for 5.4·2CHCl3 and 5.5·2CHCl3 
 Complex 5.4·2CHCl3 Complex 5.5·2CHCl3 
Formula C42H48Cl10N2O4Rh2 C42H48Cl10Ir2N2O4 
Formula weight 1205.14 1383.72 
Crystal system Monoclinic Monoclinic 
Space group P21 P21 
a (Å) 11.5800(6) 11.572(2) 
b (Å) 20.4163(11) 20.505(4) 
c (Å) 21.4575(11) 21.518(4) 
β (deg.) 102.7920(10) 103.65(3) 
V (Å
3
) 4947.1(4) 4961.9(17) 
Z 4 4 
Dc (g.cm
-3
) 1.618 1.852 
µ (mm
-1
) 1.249 5.938 
θ range for data collection (deg.) 1.80 to 27.56 1.84 to 27.46 
Limiting indices -15 < h < 7 0 < h < 14 
 -26 < k < 26 0 < k < 26 
 -23 < l < 27 -27 < l < 27 
no. of reflns meads 36455 11634 
no. of reflns used (Rint) 22713  10862  
no. of params 1001 1021 
R1 0.1052 0.0404 
wR2 0.2009 0.0942 
goodness of fit on F2 1.023 1.040 
 
In the coordinated pyridyl-ester ligand of both complexes 5.4 and 5.5, the C-N bond lengths 
in the pyridyl ring are found to be between 1.30 – 1.35 Å. The alkyl C-O bond lengths of the 
ester functionalities are between 1.30 and 1.36 Å and the C=O bond lengths are shorter (1.16 
– 1.20 Å), comparing favourably to the interatomic distances typical of pyridines and 
aromatic esters (C=N: 1.34 Å, C-O: 1.43 Å and C=O: 1.23 Å).
43
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M = Rh 
Complex 
5.5·2CHCl3 




M = Rh 
Complex 
5.5·2CHCl3 
M = Ir 
M1-N1 2.119(8) 2.095(8) M2-N2 2.116(8) 2.114(8) 
M1-C1 2.054(14) 2.160(9) M2-C31 2.137(9) 2.143(10) 
M1-C2 2.099(11) 2.161(9) M2-C32 2.143(8) 2.157(10) 
M1-C3 2.146(12) 2.162(9) M2-C33 2.169(9) 2.163(11) 
M1-C4 2.203(16) 2.132(11) M2-C34 2.154(9) 2.193(12) 
M1-C5 2.093(13) 2.130(10) M2-C35 2.139(8) 2.136(11) 
M1-Cl1 2.412(2) 2.401(3) M2-Cl3 2.399(2) 2.415(3) 
M1-Cl2 2.399(2) 2.415(3) M2-Cl4 2.416(2) 2.394(3) 
N1-C11 1.321(12) 1.361(13) N2-C28 1.323(12) 1.344(13) 
N1-C15 1.337(11) 1.342(14) N2-C29 1.362(12) 1.379(13) 
O1-C16 1.160(12) 1.198(14) O3-C25 1.291(12) 1.312(13) 
O2-C16 1.332(13) 1.364(14) O4-C25 1.218(12) 1.196(14) 
 




M = Rh 
Complex 
5.5·2CHCl3 




M = Rh 
Complex 
5.5·2CHCl3 
M = Ir 
C4-M1-Cl1 92.8(4) 136.9(4) C34- M2-Cl3 94.4(3) 93.2(3) 
C3-M1-Cl1 117.0(3) 101.8(4) C33- M2-Cl3 124.8(3) 109.6(3) 
C1- M1-Cl1 138.6(4) 121.5(3) C31- M2-Cl3 135.8(3) 152.3(4) 
C2- M1-Cl1 153.0(3) 94.7(3) C32- M2-Cl3 160.4(3) 148.2(3) 
C5- M1-Cl1 100.9(4) 158.8(3) C35- M2-Cl3 100.3(3) 112.5(4) 
N1- M1-Cl1 88.4(2) 87.2(3) N2- M2-Cl3 89.3(2) 86.0(2) 
C4- M1-Cl2 123.7(3) 135.8(4) C34- M2-Cl4 123.7(3) 137.9(4) 
C3- M1-Cl2 96.1(3) 161.0(3) C33- M2-Cl4 95.6(3) 103.0(3) 
C1- M1-Cl2 131.7(4) 96.7(3) C31- M2-Cl4 133.9(3) 120.7(4) 
C2- M1-Cl2 97.0(3) 125.1(3) C32- M2-Cl4 100.4(3) 94.2(3) 
C5- M1-Cl2 156.5(4) 101.2(3) C35- M2-Cl4 160.3(3) 159.3(4) 
N1- M1-Cl2 88.8(2) 87.0(2) N2- M2-Cl4 87.2(2) 86.7(2) 
Cl2- M1-Cl1 89.44(8) 87.31(10) Cl3- M2-Cl4 90.28(9) 86.94(10) 
C25-O3-C24-C21 -96.1(10) -92.9(12) C16-O2-C17-C18 -78.5(11) -84.3(12) 
 
With respect to the bond angles, the values observed between Cl-M-Cl and N-M-Cl are all 
close to 90 ° and the bond angles formed between the bonded carbons of the Cp* ligand, the 
metal and the chlorido ligand vary from 90 to 150 °. This trend has also been observed within 
the molecular structures of similar Cp*Ir(III) and Cp*Rh(III) pyridyl complexes.
16,24,28,38,39
 













 142 Synthesis and Study of Multinuclear PGM complexes as in vitro Pharmacological Agents 
central phenyl ring and each ester functionality is close to 90 ° indicating that the 
pyridyl rings orientate themselves almost perpendicular to the phenyl spacer thereby 
minimizing electrostatic interactions within the complex molecules. 
5.3. Summary 
Two di- and tri-pyridyl ester ligands (5.1 and 5.2) have been synthesised by alkylation of the 
carboxylic acid. These ligands were functionalized with either [(p-cymene)RuCl2], 
[(pentamethylcyclopentadienyl)RhCl2] or [(pentamethylcyclopentadienyl)IrCl2] moieties to 
give a series of new di- (5.3-5.5) and trinuclear (5.6-5.8) complexes. All of the compounds 
were isolated as air- and moisture-stable solids and were characterised using a variety of 
analytical and spectroscopic techniques. Proton NMR analyses of compounds 5.1-5.8 
revealed that the proximity of the ester functionalities to the pyridyl ring influences the 
deshielding effect on the protons ortho to nitrogen. Minimal change in the ester methylene 
proton resonances confirmed no metal coordination occurs to the oxygen atoms.  
 
The molecular structures of 5.4 and 5.5 confirms the monodentate coordination of the pyridyl 
ester ligands to each metal put forth by the spectroscopic and spectrometric characterisations 
of complexes 5.3 - 5.8. The elucidated molecular structures of the complexes 5.4 amd 5.5 
revealed a typical ‘piano-stool’ geometry around the metal and analysis of the dihedral angles 
formed between the central phenyl ring and the ester functionalities indicate that the pyridyl 
metal moieties position themselves almost perpendicular to the phenyl spacer thus 
minimizing electrostatic interactions. 
 
A study of their in vitro antiparasitic and antitumor activity has been undertaken and the 
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5.4. Experimental 
5.4.1. Chemicals and General Methods  
1,2,3,4,5-Pentamethylcyclopentadiene, α-phellandrene, 4-bromomethylpyridine hydro-
bromide, isonicotinic acid, 1,3,5-benzenetricarboxylic acid and 1,4-bis(bromomethyl)benzene 
were purchased from Sigma-Aldrich and used without further purification. Ruthenium 
trichloride trihydrate, rhodium trichloride trihydrate and iridium trichloride trihydrate were 
kindly donated by AngloAmerican Platinum Limited. All solvents used were analytical grade 
and dried over molecular sieves. All reactions were carried out in air unless otherwise stated. 





 and dichloro(pentamethylcyclopentadienyl)iridium(III) 
dimer
45
 were synthesised using literature methods.  
5.4.2. Spectroscopic and Analytical Methods 
Nuclear Magnetic Resonance (NMR) Spectra were recorded on a Varian Unity XR400 MHz 
(
1
H at 399.95 MHz, 
13
C at 100.58 MHz), Varian Mercury XR300 (
1
H at 300.08 MHz, 
13
C at 
75.46 MHz) or Bruker Biospin GmbH (
1
H at 400.22 MHz, 
13
C at 100.65 MHz) spectrometer 




C{1H} NMR shifts are reported using 
tetramethylsilane (TMS) as the internal standard and 
31
P{1H} NMR spectra were measured 
relative to H3PO4 as the external standard. NMR spectra were recorded in deuterated 
chloroform (CDCl3-D1) unless otherwise stated. Infrared (IR) absorptions were measured on 
Perkin-Elmer Spectrum 100 FT-IR Spectrometer using a Universal Diamond Attenuated 
Total Reflection (ATR) accessory. Microanalyses for C, H, and N were carried out using a 
Thermo Flash 1112 Series CHNS-O Analyser and melting points were determined using a 
Büchi Melting Point Apparatus B-540. Mass Spectrometry determinations were carried out 
on all new compounds using electrospray ionisation (ESI) on a Waters API Quattro Micro 
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5.4.3. Synthesis of Pyridyl-ester Ligands 















To a solution of 1,4-bis(bromomethyl)benzene (0.204 g, 0.772 mmol) in DMF (20 cm
3
), 
potassium carbonate (0.262 g, 1.89 mmol) and isonicotinic acid (0.197 g, 1.60 mmol) was 
added. The reaction mixture was stirred at 80 °C for 18 hours. Upo  cooling to room 
temperature, the reaction mixture was diluted with ethyl acetate (100 cm
3
) and washed with 
deionized water (2 x 50 cm
3
) and brine (1 x 30 cm
3
). The organic layer was then dried over 
magnesium sulfate, filtered and the solvent evaporated to yield the product (5.1) as an off-
white amorphous solid. Yield: 0.239 g, 89 %. Mp: 223-225 °C.
1
H NMR (400 MHz, CDCl3-
d1): δ (ppm) = 8.80 (d, 
3
J(Ha-Hb): 7.99 Hz, 4H, Ha), 7.89 (d, 
3
J(Hb-Ha): 8.00 Hz, 4H, Hb), 
7.49 (s, 4H, Hg), 5.41 (s, 4H, He).  
13
C NMR (400 MHz, CDCl3-d1): δ (ppm) = 164.9 (Cd), 
150.6 (Ca), 137.3 (Cc), 135.7 (Cf), 128.7 (Cg), 122.9 (Cb), 67.0 (Ce). IR (atr, cm
-1
) υ =  1719 
(s, C=O), 1597 (s, C=N), 1270(s, =C-O-CH2-). Elemental Analysis for  C20H16O4N2: found C, 
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To a solution of 1,3,5-benzenetricarboxylic acid (0.200 g, 0.952 mmol) in DMF (20 cm
3
), 
potassium carbonate (0.8161 g, 5.90 mmol) and 4-bromomethylpyridine hydrombromide 
(0.748 g, 2.96 mmol) was added. The reaction mixture was stirred at 80 °C for 18 hours. 
Upon cooling to room temperature, the reaction mixture was diluted with ethyl acetate (100 
cm
3
) and washed with deionized water (2 x 50 cm
3
) and brine (1 x 30 cm
3
). The organic layer 
was then dried over magnesium sulfate, filtered and the solvent evaporated to yield the 
product (5.2) as an off-white amorphous solid. Yield: 0.392 g, 85 %. Mp: 125-127 °C. 
1
H 
NMR (400 MHz, CDCl3-d1): δ (ppm) = 8.98 (s, 3H, Hg), 8.66 (d, 
3
J(Ha-Hb): 5.80 Hz, 6H, 
Ha), 7.36 (d, 
3
J(Hb-Ha): 6.13 Hz, 6H, Hb), 5.45 (s, 6H, Hd).  
13
C NMR (400 MHz, CDCl3-d1): 
δ (ppm) = 164.3 (Ce), 150.3 (Ca), 144.2 (Cf), 135.1 (Cg), 131.1 (Cc), 122.1 (Cb), 65.5 (Cd). IR 
(atr, cm
-1
) υ =  1726 (s, C=O), 1605 (s, C=N), 1237 (s, =C-O-CH2-). Elemental Analysis for  
C27H21O6N3: found C, 64.64; H, 5.00; N, 7.38 %; calculated for C27H21O6N3∙C2H4O: C, 
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5.4.4. Synthesis of Dinuclear Ru(II), Rh(III) and Ir(III) Pyridyl-ether Complexes 
5.4.4.1. General Synthetic Method for Dinuclear Complexes 
The ligand (5.1) (1 molar equivalent) was dissolved in DCM (15 cm
3
) and the appropriate 
ruthenium, rhodium or iridium dimer (1.1 molar equivalent) was added and the reaction 
solution was stirred for 16 hours at room temperature. The reaction solvent was then reduced 
to approximately a third of its original volume. The product was then precipitated from 
solution by addition of diethyl ether and isolated by vacuum filtration, washed with diethyl 
ether and dried.  
 




























Diisonicotinic Acid 1,4-Xylylene Diester (5.1) (0.0536 g, 0.154 mmol) was reacted with 
dichloro(p-cymene)ruthenium(II) dimer (0.101 g, 0.163 mmol). The product (4.3) was 
isolated as dark red amorphous solid. Yield: 0.148 g, 97 %. Mp: 226-228 °C, decomposition 
without melting).
1
H NMR (400 MHz, CDCl3-d1): δ (ppm) = 9.24 (d, 
3
J(Ha-Hb): 6.41 Hz, 4H, 
Ha), 7.85 (d, 
3
J(Hb-Ha): 6.59 Hz,4H, Hb), 7.46 (s, 4H, Hg), 5.46 (d, 
3
J(Hl-Hk): 5.68 Hz, 4H, 
Hl), 5.41 (s, 4H, He), 5.24 (d, 
3
J(Hk-Hl): 5.86 Hz, 4H, Hk), 3.00-2.96 (m, 2H, Hi), 2.10 (s, 6H, 
Hn), 1.32 (d, 
3
J(Hh-Hi): 6.96 Hz, 12H, Hh).  
13
C NMR (400 MHz, CDCl3-d1): δ (ppm) = 163.6 
(Cd), 155.9 (Ca), 138.5 (Cc), 135.5 (Cf), 128.8 (Cg), 123.5 (Cb), 103.8 (Cm), 97.4 (Cj), 83.1 
(Cl), 82.4 (Ck), 67.5 (Ce), 30.7 (Ci), 22.3 (Ch), 18.2 (Cn). IR (atr, cm
-1
) υ =  1719 (s, C=O), 
1611 (s, C=N), 1271 (s, =C-O-CH2-). Elemental Analysis for  C39H46Cl4N2O3Ru2: found C, 
48.34; H, 4.92; N, 1.89 %; calculated C39H46Cl4N2O3Ru2∙C4.5H11ClO: C, 50.01; H, 4.61; N, 
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Diisonicotinic Acid 1,4-Xylylene Diester (5.1) (0.0538 g, 0.154 mmol) was reacted with 
dichloro(pentamethylcyclopentadienyl)rhodium(III) dimer (0.0954 g, 0.154 mmol). The 
product (5.4) was isolated as a bright orange amorphous solid. Yield: 0.141 g, 92 %. Mp: 
169-171 °C, decomposition without melting. 
1
H NMR (400 MHz, CDCl3-d1): δ (ppm) = 9.16 
(br s, 4H, Ha), 7.92 (d, 
3
J(Hb-Ha): 6.59 Hz, 4H, Hb), 7.47(s, 4H, Hg), 5.42 (s, 4H, He), 1.59 (s, 
30H, Hh).  
13
C NMR (400 MHz, CDCl3-d1): δ (ppm) = 163.8 (Cd), 154.0 (Ca), 138.7 (Cc), 
135.6 (Cf), 128.77 (Cg), 124.1 (Cb), 94.2 (Ci), 67.4 (Ce), 8.9 (Ch).  IR (atr, cm
-1
) υ =  1739 (s, 
C=O), 1613 (s, C=N), 1278 (s, =C-O-CH2-).Elemental Analysis for  C40H46Cl4N2O4Rh2: 
found C, 44.62; H, 5.20; N, 1.36 %; calculated: C, 49.71; H, 4.79; N, 2.89. ESI-MS: m/z  
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Diisonicotinic Acid 1,4-Xylylene Diester (5.1) (0.0426 g, 0.122 mmol) was reacted with 
dichloro(pentamethylcyclopentadienyl)iridium (III) dimer (0.101 g, 0.127 mmol). The 
product (5.4) was isolated as a bright yellow amorphous solid. Yield: 0.136 g, 92 %. Mp: 295 
- 296 °C.
1
H NMR (400 MHz, CDCl3-d1): δ (ppm) = 9.17 (d, 
3
J(Ha-Hb): 6.78 Hz, 4H, Ha), 
7.90 (d, 
3
J(Hb-Ha): 7.99 Hz, 4H, Hb), 7.48 (s, 4H, Hg), 5.43 (s, 4H, He), 1.55(s, 30H, Hh).  
13
C 
NMR (400 MHz, CDCl3-d1): δ (ppm) = 163.4 (Cd), 154.4 (Ca), 138.7 (Cc), 135.6 (Cf), 128.8 
(Cg), 124.5 (Cb), 86.1 (Ci), 67.5 (Ce), 8.5 (Ch). IR (atr,cm
-1
) υ = 1739 (s, C=O), 1613 (s, C=N), 
1278 (s, =C-O-CH2-). Elemental Analysis for  C40H46Cl4N2O4Ir2: found C, 37.91; H, 4.16; N, 
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5.4.5. Synthesis of Trinuclear Ru(II), Rh(III) and Ir(III) Pyridyl-ether Complexes 
5.4.5.1. General Synthetic Method for Trinuclear Complexes 
The ligand (5.2) (2 molar equivalent) was dissolved in DCM (15 cm
3
) and the appropriate 
ruthenium, rhodium or iridium dimer (3.1 molar equivalent) was added and the reaction 
solution was stirred for 16 hours at room temperature. The reaction solvent was then reduced 
to approximately a third of its original volume. The product was then precipitated from 
solution by addition of diethyl ether and isolated by vacuum filtration, washed with diethyl 
ether and dried.  
 































Benzene-1,3,5-tricarboxylic acid tripyridin-4-ylmethyl ester (5.2) (0.0519 g, 0.107 mmol) 
was reacted with dichloro(p-cymene)ruthenium(II) dimer (0.106 g, 0.174 mmol). The product 
(5.6) was isolated as a yellow brown amorphous solid. Yield: 0.109 g, 70 %. Mp: 215-216 
°C.
 1
H NMR (400 MHz, CDCl3-d1): δ (ppm) = 9.03 (d, 
3
J(Ha-Hb): 6.41 Hz, 6H, Ha), 8.80 (s, 
3H, Hg), 7.35 (d, 
3
J(Hb-Ha): 6.41 Hz,6H, Hb), 5.47 (d, 
3
J(Hl-Hk): 5.86 Hz, 6H, Hl), 5.43 (s, 
6H, Hd), 5.27 (d, 
3
J(Hk-Hl): 6.04 Hz, 6H, Hk), 2.80-3.10 (m, 3H, Hi), 2.09 (s, 9H, Hn), 1.31 (d, 
3
J(Hh-Hi): 6.96 Hz, 18H, Hh).  
13
C NMR (400 MHz, CDCl3-d1): δ (ppm) = 163.8 (Ce), 155.1 
(Ca), 146.6 (Cg), 135.1 (Cf), 130.8 (Cc), 123.0 (Cb), 103.6 (Cm), 97.2 (Cj), 82.8 (Cl), 82.2 (Ck), 
64.7 (Cd), 30.7 (Cn), 22.3 (Ch), 18.2 (Ci). IR (atr, cm
-1
) υ =  1728 (s, C=O), 1617 (s, C=N), 
1232 (s, =C-O-CH2-). Elemental Analysis for  C57H63Cl6N3O6Ru3: found C, 48.30; H, 5.23; 
N, 2.28 %; calculated: C, 48.83; H, 4.53; N, 2.99. ESI-MS: m/z  1367.03 ([M – Cl]
+
 , 20%); 
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Benzene-1,3,5-tricarboxylic acid tripyridin-4-ylmethyl ester (5.2) (0.0513 g, 0.106 mmol) 
was dichloro(pentamethylcyclopentadienyl)rhodium(III) dimer (0.101 g, 0.163 mmol). The 
product (5.7) was isolated as dark orange amorphous solid. Yield: 0.132 g, 88 %. Mp: 209-
210 °C.
1
H NMR (400 MHz, CDCl3-d1): δ (ppm) = 9.00 (br s, 6H, Ha), 8.89 (s, 3H, Hg), 7.43 
(d, 
3
J(Hb-Ha): 6.59 Hz, 6H, Hb), 5.48 (s, 6H, Hd), 1.59 (s, 45H, Hh). 
13
C NMR (300 MHz, 
DMSO-d6): δ (ppm) = 163.9 (Ce), 153.6 (Ca), 146.9 (Cg), 135.2 (Cf), 130.8 (Cc), 123.6 (Cb), 
94.22 (Ci), 64.7 (Cd), 8.9 (Ch). IR (KBr, cm
-1
) υ =  1723 (s, C=O), 1616 (m, C=N), 1225 (s, -
C-O-CH2-).  Elemental Analysis for  C57H66Cl6N3O6Rh3: found C, 47.45; H, 5,80; N, 0.94 %; 
calculated: C, 48.53; H, 4.72; N, 2.99. ESI-MS: m/z  1432.01 ([M - H + Na]
+
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Benzene-1,3,5-tricarboxylic acid tripyridin-4-ylmethyl ester (5.2) (0.0397 g, 0.0821 mmol) 
was dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (0.100 g, 0.125 mmol). The 
product (4.3) was isolated as a bright yellow amorphous solid. Yield: 0.113 g, 82 %. Mp: 
227-230 °C, decomposition without melting.
1
H NMR (400 MHz, CDCl3-d1): δ (ppm) = 9.01 
(d, 6H,
 3
J(Ha-Hb): 6.78 Hz, Ha), 8.90, (s, 3H, Hg), 7.42 (d, 
3
J(Hb-Ha): 6.78 Hz, 6H, Hb), 5.43 
(s, 6H, Hd), 1.47 (s, 45H, Hh). 
13
C NMR (300 MHz, DMSO-d6): δ (ppm) = 163.9 (Ce), 153.6 
(Ca), 146.9 (Cg), 135.2 (Cf), 130.8 (Cc), 123.8 (Cb), 85.9 (Ci), 64.6 (Cd), 8.6 (Ch). IR (KBr, 
cm
-1
) υ =  1729 (s, C=O), 1612 (m, C=N), 1230 (s, -C-O-CH2-).  Elemental Analysis for  
C57H66Cl6N3O6Ir3: found C, 38.80; H, 4.28 ; N, 1.57 %; calculated: C, 40.78; H, 3.96; N, 
2.50. ESI-MS: m/z  363.05 ([M + 5H + 4CH3OH]
+
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5.4.5. X-Ray Structure Analysis 
Single-crystal X-ray diffraction data were collected on a Bruker KAPPA APEX II DUO 
diffractometer using graphite-monochromated Mo-K radiation ( = 0.71073 Å). Data 
collection was carried out at 173(2) K. Temperature was controlled by an Oxford Cryostream 
cooling system (Oxford Cryostat). Cell refinement and data reduction were performed using 
the program SAINT.
46
 The data were scaled and absorption correction performed using 
SADABS.
36
 The structure was solved by direct methods using SHELXS-97
47
 and refined by 




 and using the graphics 
interface program X-Seed.
48,49
 The programs X-Seed and POV-Ray
50
 were both used to 
prepare molecular graphic images. 
For complex 5.4, there are four chloroform molecules in the asymmetric unit. Two of them 
were modelled with the chlorine atoms disordered over two positions with each having site 
occupancy 0.50. All non-hydrogen atoms of the main molecule, except the carbon atoms 
C1A-C10A and C36B-C40B, were refined anisotropically. C1A-C10A and C36B-C40B were 
refined with isotropic temperature factors and were restrained to a reasonable geometry. All 
hydrogen atoms were placed in idealised positions and refined with geometrical constraints. 
The structure was refined to R factor of 0.072. The highest peak is 2.89 e/Å3, 0.92 Å from 
Rh2B and the deepest hole is -0.71 e/Å3, 0.57 Å from CL4X. The Flack x parameter was 
refined with BASF and TWIN commands to be 0.54936 with esd 0.03821. 
For complex 5.5, there are four chloroform molecules in the asymmetric unit. Two of them 
were modelled with the chlorine atoms disordered over two positions with each having site 
occupancy 0.50. All non-hydrogen atoms of the main molecule, except the carbon atoms 
C6A-C10A and C6B-C10B, were refined anisotropically. C6A-C10A and C6B-C10B were 
refined with isotropic temperature factors and were restrained to a reasonable geometry. All 
hydrogen atoms were placed in idealised positions and refined with geometrical constraints. 
The structure was refined to R factor of 0.0360. The highest peak is 3.12e/Å3, 0.86 Å from 
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The clinical success of cisplatin and its analogues for the treatment of different cancers has 
had a profound effect on establishing the use of metal complexes in medicine. Lately, 
increasing drug resistance and the emergence of unwanted side effects to currently available 
therapies have bred a need for novel pharmacological agents. Thus, the design and study of 
metal-chemotherapeutics complexes as potential pharmaceuticals may potentially identify 
new drug candidates. Apart from platinum, ruthenium(II), rhodium(III) and iridium(III), have 
been identified as biologically relevant metals and their complexes are gaining attention as 
alternatives to platinum-containing compounds. The design and study of these complexes as 
potential drug candidates has been the subject of numerous reviews.
1-13
 
Ruthenium is able to access a range of oxidation states [Ru(II), Ru(III) and Ru(IV)] under 
physiological conditions and its compounds may be less toxic than those of platinum.
14-18
 
This reduced toxicity is believed to be a consequence of ruthenium being able to mimic iron 
in the binding to biological molecules like albumin and transferrin.
14
 Cancer cells rapidly 
divide and so exhibit a greater demand for iron causing transferrin receptors to be over-




As detailed in Chapter 1 (section 1.2.1.2.), the discovery of the antimetastatic activity of 
NAMI-A (1.21, Figure 6.1)
19-21
 and the antineoplastic ability of KP-1019 (1.22)
22,23
 has 
effectively established the biological relevance of ruthenium. Both these compounds have 
recently completed Phase I clinical trials
24-28
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1.6: BBR3464  
Figure 6.1. Structures of the Ru(III) metallotherapeutics currently in Phase II evaluation
19-23,32,33
 and BBR3464. 
 





 while KP1019 is an antineoplastic agent that has demonstrated  
activity against a wide range of preclinical tumor models.
18,36,37
 KP1019 exerts its cytotoxic 
effect through induction of apoptosis via the intrinsic mitochondrial pathway. 
 
Since their discovery, the study of organoruthenium complexes for antiprolifeartive activities 
has rapidly gained momentum and most of the examples found in the literature are largely 
made up of Ru(II) arene complexes which were first developed by two distinct research 
groups, Dyson and co-workers
14,38,39
 and Sadler and co-workers.
27,40
 The basis for the design 
and study of these arene-ruthenium(II) complexes was the suggestion that the previously 
studied Ru(III) complexes 1.21 and 1.22 were precursors from which the active Ru(II) 
species was generated in vivo.
27,40
 The amphilic nature of the arene-ruthenium moiety is also 
believed to enhance the antiproliferative activities of the overall complex.
41
 
While there are fewer reports on the application of Rh(III) and Ir(III) organometallic 
complexes as biological agents, they are slowly garnering more attention. An account of the 
anti-tumor properties of RhCl3∙3H2O actually predates the discovery of cisplatin
42
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cytotoxic abilities of Rh(III) and Ir(III) were not seriously considered until 
recently.
1,43
 This lack of interest has been attributed to the kinetic inertness of these metal 
ions.
1,43-45
 However, it has been proposed that this lack of reactivity can be overcome using 
one of two rational approaches, (i) the use of one or more ligands that provide a strong trans 
effect to improve the rate of substitution and (ii) complexation of these metals to ligands that 
display independent cytotoxic activities and can thus interact with specific biological targets.
1
   
The antitumor efficacy of BBR3464  demonstrated the validity of the concept of 
multinuclearity for the development of potential metallo-chemotherapeutics.
46,47
 Since the 
development of BBR3464, the study of polynuclear complexes containing other PGM metals 
has emerged as an area of great potential.
3,48-50
 A series of tetranuclear iridium, rhodium and 
ruthenium porphyrin complexes (Figure 6.2)  have also been studied for activity as dual 



















































































1.63: R = H
1.64: R = Me
1.65: R = 1-Me-4-isopropyl
1.66: R = 1,2,3,4,5,6-hexamethyl
1.67: R = 1,4-di(OOCEt)
1.68: M = Rh
1.69: M = Ir 1.70  
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Against parasitic diseases, metal complexes are emerging as potential metallo-antiparasitics. 
Malaria is amongst the deadliest and most widespread parasitic diseases found today. 
Currently, the standard first line therapy for uncomplicated P. falciparum malaria infections 
is artemisinin-based combined therapy (ACT).
53,54
 Despite the effectiveness of ACT 
treatments, the emergence of resistance to these drugs is a very real possibility and is under 
intense monitoring.
54
 Recent reports of resistance and suspected resistance of P. falciparum 
to artemisinins highlight the importance of developing alternative drug candidates  since most 
of the currently developed drugs are mainly artemisinin derivatives and may eventually 
become susceptible to parasite resistance as well.
55-59
 
Published accounts of the study of PGM complexes as antiplasmodial agents are largely 
made up of chloroquine or other amino-quinoline metal-conjugates.
53,60,61
 Sánchez-Delgado 
et al reported that a [Ru(II)-chloroquine]2 dimer and mononuclear Rh(I) complex (Figure 6.3) 
proved active against P. falciparum strains in vitro.
62
 The dinuclear ruthenium complex 
(1.85) is 4.5 times more active than chloroquine diphosphate against two chloroquine 
resistant P. falciparum strains, FcB1 and FcB2. The rhodium complex (1.86) exhibited 



























Consequent to the initial chloroquine metal conjugate work pioneered by Sánchez-Delgado et 
al, came the discovery of the chloroquine analogue, Ferroquine (1.87).
64
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containing complex has shown impressive antiplasmodial activity and is even 
active in chloroquine resistant strains.
61,64-66
 It has completed Phase I clinical trials and is 
expected to complete Phase II clinical trials against uncomplicated malaria soon. Iridium-
chloroquine analogues (1.92 – 1.94) have also been studied for in vitro antiplasmodial 
activity on cultures of P. Berghei (Figure 6.4).
67
 These complexes were able to inhibit 































1.94: (CH3)2CO  




Ruthenium-arene chloroquine conjugates (Figure 6.5) have been extensively studied for their 
in vitro antiplasmodial against three chloroquine resistant (W2, Dd2 and K1) and four 
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 There are fewer examples of antiplasmodial PGM metal complexes that are non-
quinolone based. A series of cationic platinum complexes containing substituted bipyridyl 
and phenanthroline ligands were tested for antiplasmodial activity against the D10 
(chloroquine sensitive) and K1 (chloroquine resistant) strains.
69
 They inhibited parasite 
growth at concentrations in the nanomolar range. Several examples of mononuclear 
ruthenium and palladium thiosemicarbazone complexes (Figure 6.6) were reported to show 





 W2 (chloroquine resistant)
71
 and D10 (chloroquine sensitive)
71
 P. 
falciparum strains. Polynuclear cyclopalladated thiosemicarbazone derivatives have also been 
found to demonstrate mild inhibition of parasite growth on the 3D7 (chloroquine sensitive) 













1.102: R = CH3 


















1.104: R = CH3 









1.100: R = CH3 
















1.106: R = CH3 

















1.108: R = CH3 













1.98: Ar = phenyl, 5-chlorophenyl, naphthyl 
                 or ferrocenyl
         R = H or 1-ipropyl-3-methyl
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In this chapter, the in vitro pharmacological evaluation of the pyridyl ether (4.3 - 4.5 and 4.6-
4.8, Figure 6.7) and pyridyl ester (5.3 - 5.5 and 5.6 - 5.8, Figure 6.8) complexes and their free 
ligands (4.1, 4.2, 5.1 and 5.2) for antitumor and antiparasitic activity will be discussed. 
Selections of the compounds were screened for antiparasitic activity against a Chloroquine 
sensitive (CQS) Plasmodium falciparum strain and the Trichomonas vaginalis parasite strain 
G3.  Antitumor activity was investigated by in vitro assay against a cisplatin sensitive and a 























4.4: M = Rh




































Cl4.7: M = Rh
4.8: M = Ir  
Figure 6.7. Di- and trinuclear PGM pyridyl ether complexes (4.3-4.5 and 4.6-4.8) and their corresponding free 




















































5.4: M = Rh








































5.7: M = Rh
5.8: M = Ir
 
Figure 6.8. Di- and trinuclear PGM pyridyl ester complexes (5.3-5.5 and 5.6-5.8) and their corresponding free 
ligands (5.1 and 5.2). 
 
6.2. Turbidimetric Solubility Assay 
There are four cornerstones to early drug discovery; Absorption, Distribution, Metabolism 
and Excretion (ADME).  The first step in evaluation of potential drug candidates for in vitro 
activity is analysis of their solubility in aqueous medium. This is an important property 
because it has a bearing on a compound’s bioavailability since it impacts on absorption. 
Solubility also validates the in vitro assay data obtained. In general, based on their solubility 
range (Table 6.1.); compounds can be classed into three different categories. If a compound 
displays solubility greater than 100 μg/ml, then it should have good absorption. With respect 
to metal complexes, often polynuclear complexes display poor solubility in aqueous-based in 
vitro assays and are sometimes screened as suspensions in the assay thus casting doubt on the 
in vitro activities observed. One method used to validate aqueous solubility during early drug 
discovery is the Turbidimetric (kinetic) Solubility Assay.
74-77
 
 For compounds 4.1 – 4.8 and 5.1 – 5.8 and the dimers [(p-cymene)RuCl2]2, [Cp*RhCl2]2 and 
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PBS buffer to give a range of concentrations and allowed to equilibrate. A 
solubility range of the test compound was then determined from the concentration at which 
the compound began to precipitate from solution causing turbidity. This turbidity was 
detected by assessing the light scatter caused by the suspended particles using UV-vis 
spectroscopy. 
 
Table 6.1. The three solubility categories used to class compounds  
Solubility Range 
< 10 μg/ml Sparingly soluble 
10 – 60 μg/ml Partially soluble 
> 60 μg/ml Soluble 
 
Table 6.2 lists the solubility ranges of compounds 4.1-4.8 and 5.1-5.8 and the [(p-
cymene)RuCl2]2, [Cp*RhCl2]2, [Cp*IrCl2]2 dimers. In micromolar concentration, most of the 
compounds were soluble in the PBS buffer up to the maximum concentration tested. 
Converting this data to μg/ml shows that all of the compounds had solubility greater than > 
60 μg/ml. Reserpine and Hydrocortisone were used as controls for the solubility assays. 
Complex 4.6 showed the lowest solubility but it is still displayed good solubility in the 
buffer. All of the free ligands (4.1, 4.2, 5.1 and 5.2) as well as the trinuclear rhodium and 
iridium ester complexes 5.7 and 5.8 and the ruthenium, rhodium and iridium dimers display 
no turbidity up to the highest concentration tested.  
Overall, the data ascertained implies that the di- and tripyridyl ether and ester compounds are 
good candidates for in vitro biological testing. Precipitation of these compounds from the 
various in vitro assays would be unlikely and thus the activities observed for these 
compounds are a true reflection of their in vitro activity since all of the compounds should 
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Table 6.2. Turbidimetric Solubility Data for Compounds 4.1-4.8 and 5.1-5.8 
Compound 
Determined Turbidimetric Solubility  
(μM) 
Determined Turbidimetric Solubility  
(μg/ml) 
4.1 >200 > 64.27 
4.2 > 200 > 126.14 
4.3 160 - 200 149.35 - 186.70 
4.4 80 - 120 75.15 - 112.73 
4.5 160 - 200 178.89 - 223.61 
4.6 40 - 80 61.97 - 123.94 
4.7 80 - 120 124.62 - 186.94 
4.8 80 - 120 146.06 - 219.09 
5.1 > 200 > 69.67 
5.2 > 200 > 96.69 
5.3 160 - 200 153.72 - 192.15 
5.4 160 - 200 154.63 - 193.28 
5.5 80 - 120 91.05 - 137.41 
5.6 > 200 > 280.41 
5.7 > 200 > 282.12 
5.8 > 200 > 335.71 
[(p-cymene)RuCl2]2 > 200 > 122.48 
[Cp*RhCl2]2 > 200 > 103.62 
[Cp*IrCl2]2 > 200 > 159.34 
Reserpine 20 - 40 12.17 - 24.34 
Hydrocortisone > 200 > 72.49 
 
6.3. In Vitro Screening 
6.3.1. In vitro Antiparasitic Activity  
The pyridyl ether compound series (4.1-4.8) and pyridyl ester compound series (5.1-5.8) were 
evaluated for antiparasitic activity against the CQS NF54 P. falciparum strain and the T. 
vaginalis parasite strain G3. Trichomonas vaginalis is a flagellated facultative anaerobic 
protozoan, which causes the sexually transmitted infection trichomoniasis in humans and is 
reported to infect more than 170 million people worldwide, mainly in industrialized 
countries.
78
 Infection can have serious implications like premature birth and increased risk of 
acquiring HIV, cervical cancer and aggressive prostate cancer.
78-81
  Metronidazole is the 
current FDA-approved treatment
82
 but approximately 5% of all cases reported display 
resistance to this compound and this percentage is increasing.
83
 There is therefore a need to 
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6.3.1.1. In vitro P. falciparum Activity 
 
The in vitro antiplasmodial activity of all compounds was first ascertained against the 
chloroquine sensitive (CQS) NF54 P. falciparum strain. Compounds exhibiting the best 
activities were then screened for inhibitory effects on the chloroquine resistant (CQR) P. 
falciparum strain Dd2. The IC50 values determined with standard error of the mean (SEM) 
values are shown in Table 6.3. The compounds showing the best activities are highlighted in 
red. The ruthenium, rhodium and iridium dimers, [(p-cymene)RuCl2]2, [Cp*RhCl2]2, 
[Cp*IrCl2]2 and the organometallic chloroquine analogue, Ferroquine, were also screened for 
activity. Chloroquine diphosphate was screened as a control for the in vitro experiments. 
 
Table 6.3. In vitro IC50
a
 data for compounds 4.1 – 4.8 and 5.1 – 5.8 against the chloroquine sensitive P. 
falciparum strain NF54 







4.1 pyridyl ether none none 36.36 3.91 
4.2 pyridyl ether none none 0.39 0.06 
5.1 pyridyl ester none none 48.42 0.62 
5.2 pyridyl ester none none 22.18 3.46 
4.3 pyridyl ether (p-cymene)RuCl2 2 10.68 1.41 
4.4 pyridyl ether Cp*RhCl2 2 13.67 1.51 
4.5 pyridyl ether Cp*IrCl2 2 56.79 9.95 
5.3 pyridyl ester (p-cymene)RuCl2 2 7.04 0.72 
5.4 pyridyl ester Cp*RhCl2 2 25.16 2.23 
5.5 pyridyl ester Cp*IrCl2 2 42.63 1.01 
4.6 pyridyl ether (p-cymene)RuCl2 3 0.24 0.01 
4.7 pyridyl ether Cp*RhCl2 3 0.23 0.03 
4.8 pyridyl ether Cp*IrCl2 3 1.64 0.25 
5.6 pyridyl ester (p-cymene)RuCl2 3 5.87 0.58 
5.7 pyridyl ester Cp*RhCl2 3 10.84 2.55 
5.8 pyridyl ester Cp*IrCl2 3 10.27 2.04 
[(p-cymene)RuCl2]2 -  2 16.80 2.94 
[Cp*RhCl2]2 - - 2 20.90 0.87 
[Cp*IrCl2]2 - - 2 59.40 19.45 
Ferroquine - - 1 0.03 0.01 
Chloroquine diphosphate - - - 0.02 0.01 
a concentration inhibiting 50% of parasite growth 
b SEM: standard error of the mean 
 
With respect to the free ligands (4.1, 4.2, 5.1 and 5.2), the tripyridyl ether ligand (4.2) was the 














Chapter 6. In Vitro Pharmacological Evaluation of Ru(II), Rh(III) and Ir(III) Pyridyl Complexes 167 
ether ligand was more active (4.1, IC50 = 36.36 μM) and the tripyridyl ester ligand 
(5.2) shows better activity than both the dipyridyl ligands. The significantly greater activity 
observed for 4.2 compared to the other ligands may be attributed to the central triazine core. 
The incorporation of a triazine moiety into potential antimalarials has been previously 
reported.
84,85







 and K1 (CQR)
85
 P. falciparum strains similar to the IC50 value 
determined for 4.2. Substituted s-triazine compounds are believed to target dihydrofolate 
reductase (DHFR) in the P. falciparum parasite.
84,86
 DHFR is an enzyme that catalyzes the 
nicotinamide adenine dinucleotide phosphate (NADPH) dependent reduction of dihydrofolate 
to tetrahydrofolate. Further to this, functionalization of ligand 4.2 with ruthenium (4.6) and 
rhodium (4.7) led to an enhancement of the in vitro antiplasmodial activity [IC50 = 0.24 μM 
(4.6) and 0.23 μM (4.7)]. The iridium derivative 4.8 (IC50 = 1.64 μM) was less active but 
inspection of all compounds tested reveal that ligand 4.2 and its trinuclear organometallic 
complexes (4.6-4.8) displayed significantly greater activity.  
 
While the other compounds tested displayed only moderate activities, a trend in activities 
could be observed. For the pyridyl ether series (4.1-4.8), the presence of the Cp*IrCl2 
moieties (4.5 and 4.8) seems to have a detrimental effect on inhibitory activities. Both these 
complexes were less active than the corresponding free ligand; complex 4.5 is 0.64 times less 
active than 4.1 and complex 4.8 is 0.24 times less active than 4.2. This is not observed for the 
pyridyl ester series (5.1-5.8) where the iridium derivatives show enhanced activity compared 
to the corresponding free ligands. In fact, the tripyridyl ester complex 5.8 (IC50 = 10.27 μM) 
is twice as active compared to 5.2 (IC50 = 22.18 μM). This contrast in activity may be due to 
the differences in structural orientation within the complexes brought about by the ester 
functionality compared to the ether group. Based on the molecular structures determined for 
complexes 4.5, 5.4 and 5.5 (Chapter 4 and Chapter 5), the pyridyl and phenyl rings in the 
ligands of the pyridyl ether complexes (4.3-4.8) are almost co-planar while for the pyridyl 
ester complexes (5.3-5.8) the pyridyl and aromatic rings reside in different planes most likely 
to minimize steric and electronic effects between the pentamethylcyclopentadienyl-metal 
moieties.  
 
Consideration of the antiplasmodial data obtained for the dipyridyl ester complex series (5.3-
5.5) showed that these complexes were much more active than their corresponding free 
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activity as the metal moiety was varied. Complex 5.3 (IC50 = 7.04 μM) was the 
most active, followed by 5.4 (IC50 = 25.16 μM) and then 5.5 (IC50 = 42.63 μM) was the least 
active of the three complexes (5.3-5.5). For all of the dinuclear complexes (4.3-4.5 and 5.3-
5.5) it is clear that activity decreased with a change in metal moiety in the order of (p-
cymene)RuCl2 > Cp*RhCl2 > Cp*IrCl2. 
  
 For both the pyridyl ether and pyridyl ester series, functionalization of the free ligands (4.1, 
4.2, 5.1 and 5.2) with either the (p-cymene)RuCl2 (4.3, 4.6, 5.4 and 5.6) or Cp*RhCl2 (4.4, 
4.7, 5.4 and 5.7) moieties led to a strong increase in antiplasmodial activity suggesting that 
these metal moieties play a role in activity. Comparison of the activities of the dimers, [(p-
cymene)RuCl2]2, [Cp*RhCl2]2 and [Cp*IrCl2]2, to the corresponding ether (4.3-4.8) and ester 
(5.3-5.8) complexes reveals that the dimers are less active than the di- and trinuclear 
complexes with the exception of complex 5.4. However, this observation coupled with the 
fact that the complexes (4.3-4.8 and 5.3-5.8) are more active than the free ligands suggests 
that there is a cooperative effect between metal moiety and ligand on antiplasmodial activity. 
Both the ligands (4.1, 4.2, 5.1 and 5.2) and the dimers were only moderately active on their 
own but conjugation of the different metal moieties onto the corresponding ligand led to a 
beneficial increase in activity.  
 
Overall, from the in vitro data determined on the NF54 CQS strain several key trends for the 
design of better organometallic antimalarials can be discerned. The incorporation of a triazine 
moiety into the complex structure (4.6-4.8) has a profound effect on activity. The trinuclear 
complexes display better activities compared to the dinuclear derivatives when strictly 
compared within each compound series (pyridyl ether and pyridyl ester) thus proposing that 
an increase in metal moieties leads to an increase in activity in vitro. All of the complexes 
showed better activity than the corresponding free ligand. The pyridyl ether series (4.1-4.8) 
displayed better activity against the P. falciparum CQS strain NF54 compared to the pyridyl 
ester series (5.1-5.8). However, the tripyridyl ester complexes (5.6-5.8) were more active than 
the dipyridyl ether (4.3-4.5) complexes and the dipyridyl ester complexes showed the least 
promising activity. The order of activity of the complexes can be summarized as follows; 
tripyridyl ether complexes (4.6-4.8) > tripyridyl ester complexes (5.6-5.8) > dipyridyl ether 
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Since the triazine containing complexes 4.3 and 4.4 along with their free ligand 4.2 
showed enhanced activities compared to the other complexes screened against CQS NF54 
strain, they were screened for in vitro antiplasmodial activity against the chloroquine resistant 
(CQR) P. falciparum strain Dd2 (Table 6.4). All three compounds were less active against 
the Dd2 strain compared to the NF54 strain. The complexes 4.6 (IC50 = 0.64 μM) and 4.7 
(IC50 = 0.44 μM) were more active than the free ligand 4.2 (IC50 = 0.86 μM) indicating 
functionalization of 4.2 with the metal moieties enhances antiplasmodial activity. Complex 
4.7 was more active than complex 4.6. Against the NF54 strain, the ruthenium complexes 
were more active than the rhodium complexes when strictly compared within each class 
(ligand type and number of metal moieties) but against the Dd2 strain, it may be that the 
rhodium complexes might have better activity. Screening of all the other ruthenium (4.3, 5.3 
and 5.6) and rhodium (4.4, 5.4 and 5.7) against the Dd2 strain must be carried out to confirm 
if complexes of rhodium will be better than ruthenium derivatives against this chloroquine 
resistant strain. 
 
Their resistance index (RI) was determined based on the IC50 values observed for each P. 
falciparum strain.  The RI value is an important implement when analysing potential drug 
candidates. A low RI value may suggest that the compound is likely to exhibit activity against 
resistant parasite strains.
87,88
 A RI value of 1 or less is ideal. Chloroquine has a very high RI 
value (6.65) and compounds 4.2 and 4.7 have a much lower RI value (2.22 and 1.89 
respectively) suggesting that these compounds are likely to be active against chloroquine-
resistant strains of the parasite.  
 
Table 6.4. In vitro IC50 data for most active compounds against the NF54 (CQ sensitive) and Dd2 (CQ 










4.2 0.39 0.86 (0.07) 2.22 
4.6 0.24 0.64 (0.03)
 2.67 
4.7 0.23 0.44 (0.06) 1.89 
Chloroquine diphosphate 0.02 0.133 6.65 
a standard errors are given in parentheses 
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6.3.1.2. β-Hematin Inhibiton Assay 
 
The mechanism of hemozoin formation is currently a target for antiplasmodial drug 
discovery. In the life cycle of the Plasmodium falciparum parasite, degradation of the 
infected host’s hemoglobin to provide essential amino acids for parasite growth and nutrition 
is a vital step.
89
 The P. falciparum trophozoite ingests large quantities of the host’s 
hemoglobin (Figure 6.9).
61
 Within the acidic digestive food vacuole, the hemoglobin (Hb) is 
then degraded using several endopeptidases and the metalloprotease falcilysin to produce 
peptides which are further broken down to amino acids.
61
 A side product of this hemoglobin 
digestion is free heme which if toxic to the parasite. Free heme is reported to induce lipid 
peroxidation, oxygen-derived radical formation as well as protein and DNA oxidation.
90-93
 




Thus, to circumvent these effects, the parasite initiates a detoxification mechanism and 
removes the threat by conversion of the free heme into a crystalline solid known as hemozoin 
(also known as malaria pigment) which is nontoxic to the parasite.  Clinically used drugs, 
amodiaquine and chloroquine are believed to inhibit the formation of hemozoin.
95
  The ability 
of a potential drug to inhibit formation of hemozoin can be measured using the NP-40 
mediated β-hematin (synthetic hemozoin) inhibition assay. 
 
 
Figure 6.9. Graphical depiction of the hemoglobin degradation and heme detoxification process that occurs 















Chapter 6. In Vitro Pharmacological Evaluation of Ru(II), Rh(III) and Ir(III) Pyridyl Complexes 171 
There is evidence suggesting that neutral lipid particles act as the site of nucleation 
and crystal growth of hemozoin within the digestive food vacuole.
96
 NP-40 is a low cost, 
lipophilic detergent that can mediate the formation of synthetic hemozoin (β-hematin). The 
NP-40 mediated assay seeks to mimic the conditions of the acidic food vacuole in the parasite 
to give a better measure of hemozoin formation. Test compounds were screened at a range of 
concentrations between 0 – 500 μM in quadruplicate.  
 
The amount of hematin not converted to β-hematin was then assessed by addition of a 
pyridine solution which causes formation of a pyridine-ferrichrome complex which is 
detected by UV-vis spectroscopy.
97
 Figure 6.10A shows a prepared 96-well plate before 
incubation and Figure 6.10B shows the same plate after incubation and addition of the 
pyridine solution. The wells that have turned orange denote inhibition of β-hematin formation 
at that specific compound concentration. The absorbance data obtained is used to plot a 
sigmoidal dose-response curve from which the concentration for 50 % inhibition of β-






Figure 6.10. Images of (A) β-Hematin NP-40 Assay of compounds before incubation and (B) β-Hematin NP-40 
Assay of compounds after 16 h incubation at 37 °C followed by addition of pyridine solution. Note: Wells that 
have turned orange represent β-hematin inhibition at that particular compound concentration. 
 
From all of the compounds (4.1-4.8 and 5.1-5.8) screened for in vitro antiplasmodial activity 
against the NF54 CQS P. falciparum strain, the compounds showing cytotoxicities of 
approximately 10 μm or less (4.2, 4.3, 4.6-4.8, 5.3 and 5.6-5.8) were assayed for β-Hematin 
inhibition (Table 6.5). The dimers, [(p-cymene)RuCl2]2, [Cp*RhCl2]2 and [Cp*IrCl2]2, as well 
as the ligand 5.2 were also assayed for comparison. The tri-ruthenium pyridyl ester complex 
5.6 showed the best inhibitory effect (IC50 = 7.76 uM) which was comparable to amodiaquine 
(IC50 = 6.83 μM) and the tripyridyl ether triazine ligand 4.2 was the second most active 













 172 Synthesis and Study of Multinuclear PGM complexes as in vitro Pharmacological Agents 
complex, was the least active (IC50 = 64.64 μM). Neither ligand 5.1 or 5.2 were 
able to inhibit β-hematin formation, yet their corresponding complexes (5.3 and 5.6-5.8) 
showed inhibitory effects suggesting that the overall complex structure is needed to stop 
formation of synthetic hemozoin. The fact that the dimers did not show activity also 
highlights the importance of the interaction between the metal and ligand for complexes 5.3 
and 5.6-5.8.   
 
Table 6.5. IC50 Data for Compounds Screened for β-Hematin Inhibitory Activity Using NP-40 mediated β-
Hematin Assay
a 
Compound IC50 (μM) 95 % Confidence Interval 
4.2 9.93 9.61-10.25 
4.3 37.16 36.30-38.04 
4.6 20.72 19.46-22.07 
4.7 20.56 18.75-22.55 
4.8 64.64 61.70-67.72 
5.1 No inhibition - 
5.2 No inhibition - 
5.3 29.19 28.09-30.34 
5.6 7.76 7.19-8.37 
5.7 24.99 21.47-29.90 
5.8 12.48 11.76-13.24 
 [(p-cymene)RuCl2]2 No inhibition - 
[Cp*RhCl2]2 No inhibition - 
[Cp*IrCl2]2 No inhibition - 
Ferroquine 14.51 13.72-15.34 
Chloroquine 18.43 17.56-19.34 
Amodiaquine 6.83 6.57-7.10 
a Only compounds showing in vitro cytotoxic values of approximately 10 μM or less were screened. 
 
 
The tri-ruthenium and tri-rhodium pyridyl ether complexes (4.6 and 4.7) exhibited the best in 
vitro parasite growth inhibition against the NF54 strain. These complexes were found to have 
β-hematin inhibitory activities [IC50 = 20.72 μM (4.6) and 20.56 μM (4.7)] similar to 
chloroquine (IC50 = 18.43 μM). The tripyridyl ester rhodium complex (5.7) displayed 
moderate inhibition (IC50 = 24.99 μM) while the iridium derivative (5.8) was very active 
(IC50 = 12.48 μM). Overall, the best inhibitor of β-hematin formation were the triruthenium 
pyridyl ester complex (5.6), the ligand 4.2 and the complex 5.8; which were better at 
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All of the compounds screened using the NP-40 mediated assay are polyaromatic in 
nature making them capable of intermolecular π-π interactions. Thus, it is possible that these 
compounds can inhibit formation of hemozoin through π-π stacking with hematin. Most of 
the compounds screened using this assay were able to inhibit β-hematin formation in a lipidic 
atmosphere to some degree. Should these compounds be able to enter the acidic food vacuole 
of the parasite intact, then they may very likely inhibit parasite growth through inhibition of 
hemozoin.  
 
A direct correlation between the activities observed for the β-hematin inhibition assays and 
the activities obtained for the compounds in the parasite is not possible as the β-hematin 
inhibition assays are carried out in a parasite free medium. 
 
6.3.1.3. In vitro T. vaginalis Activity 
 
The effect on parasite viability of a selection of the pyridyl ether (4.2-4.8) and all the pyridyl 
ester (5.1-5.8) compound series were evaluated on the T. vaginalis strain G3 (Figures 6.11A 
and 6.11B). Cells were inoculated with 50 and 25 μM doses of compounds. All of the 
compounds were able to influence parasite viability in a dose dependent manner. For the 
pyridyl ether series (4.2-4.8) at 50 μM, the best percent inhibitions were observed for 
complexes 4.4 (92.4 %) and 4.8 (89.4 %). Moderate inhibitory effects were observed for 
complexes 4.5-4.7 (81.8, 65.2 and 83.3 % respectively). The tripyridyl ether ligand (4.2) 
demonstrated only 72.7 % inhibition while its rhodium and iridium complexes (4.7 and 4.8) 
displayed much better inhibitions; the ruthenium derivative (4.6) showed decreased inhibition 
(65.2 %) compared to 4.2. The dinuclear rhodium and iridium complexes (4.4 and 4.5) also 
displayed better % inhibitions (92.4 and 81.8 % respectively) than the ruthenium analogue 




























Figure 6.11. Graphical Representation of % inhibition data ascertained for compounds 4.2 – 4.8 (Chart A) and 
5.1 – 5.8 against T. vaginalis strain G3 
 
When comparing the dinuclear (4.3-4.5) and trinuclear (4.6-4.8) pyridyl ether complexes, it 
can be discerned that with respect to the type of metal moiety, the dinuclear complexes 
display similar inhibitory effects to their trinuclear analogues. This seems to imply that in the 
case of the pyridyl ether series, there is no increase in activity with an increase in the number 
of metal moieties. Furthermore, the incorporation of the triazine core does not appear to result 
in enhanced inhibitory effects as the dinuclear and trinuclear complexes show similar activity 
as evidenced by their percent inhibitions. At the lower concentration of 25 μM, a decrease in 
the percent inhibitions is observed for all of the compounds. Ligand 4.3 and complex 4.6 
display the highest decrease in activity (17.1 and 14.3 % respectively) while complex 4.7 
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similar inhibitions at 25 μM (72.3 and 78.7 %) and the same trend can be seen for 
the iridium complexes 4.5 and 4.8. Out of all the pyridyl ether complexes, the rhodium 
complexes (4.4 and 4.7) have shown the best in vitro activity against G3. 
 
In contrast, the pyridyl ester series (5.1-5.8) were not as active as the pyridyl ether series (4.2-
4.8). At 50 μM, the tripyridyl ester ligand (5.2) displayed better inhibitory activity (62.1 %) 
than the dipyridyl ester ligand 5.1 (42.4 %) but a decrease in compound concentration to 25 
μM resulted in ligand 5.2 displaying a much lower activity than 5.1 (38.8 vs 51.1 %). At both 
25 and 50 μM concentrations, the dinuclear ruthenium (5.3) and iridium (5.5) complexes 
exhibited better activities than the dinuclear rhodium complex 5.4. At 25 μM, complexes 5.3 
and 5.5 were not as active (24.5 and 19.1 % respectively) as their corresponding free ligand 
5.1 (51 %). The iridium derivative 5.5 had better activity than the free ligand at both 
concentrations (65.3 % at 25 μM and 74.2 % at 50 μM). The trinuclear complexes 5.7 and 5.8 
displayed better inhibitory activity compared to the free ligand 5.2 at both 25 and 50 μM 
concentrations. At 50 μM, the tri-ruthenium complex 5.6 showed similar inhibition (44.7 %) 
to ligand 5.2 (42.4 %) and is less active than 5.2 at 25 μM (51 % vs 34 %). Complex 5.8 
exhibited the best activity out of all the pyridyl ester complexes tested at both compound 
concentrations. At 25 μM, the iridium complexes, 5.5 and 5.8, exhibit similar inhibitory 
activities of 65.3 and 67.3 % respectively. Complexes 5.3 and 5.4 display the weakest activity 
out of the all the pyridyl ester compounds (5.1-5.8).  
 
Comparison of the pyridyl ether complexes (4.3-4.8) to the pyridyl ester complexes (5.3-5.8) 
reveals that the tripyridyl ether iridium complex 4.8 has similar activity to the tripyridyl ester 
iridium complex 5.8 at both compound concentrations. The dinuclear pyridyl ether 
complexes (4.3-4.5) showed superior activity than the dipyridyl ester complexes. At 25 μM, 
the pyridyl ether rhodium complexes 4.4 and 4.7 are more active than the pyridyl ester 
rhodium complexes 5.4 and 5.7. In contrast, the pyridyl ether ruthenium complexes 4.3 and 
4.6 were less active than the pyridyl ester ruthenium complexes 5.3 and 5.6.  
 
Overall, complex 5.8 displayed the best inhibitory effect out of all complexes tested but taken 
as a whole, the pyridyl ether series (4.2-4.8) are much better inhibitors of the T. vaginalis 
strain G3 with the tri-rhodium complex 4.7 showing the slightest decrease in activity with a 
decrease in compound concentration. None of the compounds (4.1-4.8 and 5.1-5.8) were not 
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displayed 100 percent inhibition at both concentrations. Nevertheless, these 
complexes represent a new chemotype for the inhibition of the T. vaginalis strain G3. 
Modification of the ligand structure and/or the metal moieties may increase the activity of 
these compounds. For example, pyridyl ether or pyridyl ester ligands that are able to chelate 
to the metal in a bidentante manner may lead to the formation of complexes that are more 
stable in the biological medium. Modification of the arene or cyclopentadienyl ligands to give 
added water solublility to the metal moieties could also enhance activity.  
 
6.3.2. In vitro Antitumor Activity  
The pyridyl ether series (4.1-4.8) and the pyridyl ester series (5.1-5.8) were evaluated for 
antiproliferative activity on the A2780 (cisplatin sensitive) and A2780cisR (cisplatin 
resistant) human ovarian carcinoma cell line. The toxicity of the pyridyl ester series on 
healthy cells was also assessed using the human embryonic kidney (HEK) cell line. Cells 
were incubated with each compound at different concentrations up to a maximum 
concentration of 200 μM.  The IC50 determinations are shown in Table 6.6 and a graphical 
respresentation of the most active compounds’ activities is depicted in figure 6.12.  
None of the compounds in the pyridyl ether series (4.1-4.8) demonstrated inhibitory activities 
on either the A2780 or A2780cisR cell lines up to the highest concentration tested (200 μM). 
In the pyridyl ester series (5.1-5.8), the dinuclear iridium complex 5.5 and the trinuclear 
complexes (5.6-5.8) were the only compounds to show antiproliferative activity implying that 
the role played by the number of aryl ester groups and the type of metal moiety in the 
complex influences inhibitory activity. Complexes 5.6 and 5.7 showed comparable activity to 
each other (IC50 = 53.0 and 52.4 μM respectively) in the A2780 cell line. The di- and 
trinuclear iridium complexes 5.5 (IC50 = 101.9 μM) and 5.8 (IC50 = 97.0 μM) also displayed 
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Table 6.6. IC50
a
 Determinations for Compound 4.1 – 4.8 and 5.1 – 5.8 against cisplatin sensitive 























none none > 200
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cisplatin - - 1 1.5 25 16.66 7 
a IC50: concentration inhibiting 50% of cell growth 
b  Error values are given in parentheses. 
c Resistance Index = IC50 A2780cisR/IC50 A2780 
dNo activity was observed up to the highest concentration of compound, 200 μM. 
 
All of the active complexes (5.5 – 5.8) were less toxic to healthy cells with the tri-iridium 
complex 5.8 showing the greatest difference in toxicities between the carcinoma cells (A2780 
and A2780cisR) and healthy cells (HEK). Complexes 5.5 – 5.8 were also less toxic than 
cisplatin toward the HEK cell line. This suggests that ruthenium, rhodium and iridium 
complexes of pyridyl ester complexes may likely show better uptake into cancer cells 
compared to healthy cells.  Complex 5.8 was more active against the A2780cisR cell line 
(IC50 = 45.5 μM) than the A2780 cell line. The ruthenium complex 5.6 was 1.6 times less 
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53.0 μM). None of the complexes were as active as cisplatin against either 
carcinoma cell line (IC50 = 1.5 (A2780) and 25 (A2780cisR) μM). Comparison of 5.6-5.8 to 
each other revealed that the ruthenium (5.6) and rhodium (5.7) complexes had better 
antiproliferative activity compared to the iridium complex 5.8. Complex 5.7 displayed the 
best activity against both cell lines compared to 5.6 and 5.8 and it is the least toxic to healthy 
cells.  
As mentioned earlier in (Section 6.3.1.1.), the resistance index (RI) for a compound is used as 
a tool to estimate whether a potential chemotherapeutic will develop or be susceptible to 
known resistance mechanisms.
98
 This index has been used to assess other metal complexes 
studied for antitumor activity.
98,99
 An RI index close to or less than one is ideal. Inspection of 
the resistance index for complexes 5.6-5.8 reveal that complexes of this type are less likely to 
be vulnerable to currently known resistance mechanisms compared to cisplatin. Complex 5.8 
showed superior activity against the A2780cisR cell line compared to A2780 giving rise to a 
much lower RI value of 0.46 compared to the other active pyridyl ester complexes (5.5-5.7).  
 
 
Figure 6.12. Graphical representation of the complexes showing activity against the A2780, A2780cisR 
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Within the pyridyl ester series (5.1-5.8) it has been demonstrated that the dinuclear 
complexes (5.3-5.5) are not as active as the trinuclear complexes, implying that increasing the 
size and the number of metal centers of the overall complex increases antitumor activity. This 
effect has also been observed for other multinuclear arene-ruthenium complexes.
48,100,101
 
Other di-, tri-, tetra- and hexanuclear ruthenium arene complexes have been studied for in 
vitro cytotoxic activity against the A2780 and A2780cisR cell lines.
48,99,100,102,103
 Most of 
these complexes demonstrated better activities than all of the complexes screened during this 
study (4.3-4.8 and 5.3-5.8). However, it is important to note that the complexes reported in 
the literature contain ligands that are not structurally similar to the pyridyl ether (4.1 and 4.2) 
and pyridyl ester (5.1 and 5.2) ligands used to prepare 4.3-4.8 and 5.3-5.8 and in some cases 
the coordination mode of the ligands to the metal are different to that of complexes 4.3-4.8 
and 5.3-5.8. In some of the reported complexes, the ligands chelate to the metal in a bidentate 
fashion.  
Further to this, all of the compounds (4.1-4.8 and 5.1-5.8) must be screened for anti-tumor 
activity on a panel of other tumor cell lines. It is possible that these compounds may 
selectively inhibit cell growth against other tumor cell lines.   Overall, in contrast to the 
antiparasitic studies, the tripyridyl ester complexes display better antiproliferative activities 
than the pyridyl ether series (4.1-4.8). It’s possible that the pyridyl ether series are selective to 
parasitic cells but screening against other tumor cell lines need to be carried out to ascertain if 
this is true. The activity of the pyridyl ester series (5.1-5.8) could be enhanced by 
modification of the ligand system and the metal moieties.  
6.4. Summary 
Two new series of di- and trinuclear ruthenium, rhodium and iridium complexes have been 
evaluated for in vitro biological activity. All of the complexes and their free ligands (4.1-4.8 
and 5.1-5.8) were found to exhibit moderate to high antiplasmodial activity against the NF54 
CQS P. falciparum strain. The trinuclear pyridyl ether complexes (4.6-4.8) and their free 
ligand demonstrated significantly higher activities than the other complexes tested and this 
was attributed to the incorporation of a central triazine moiety into their structures. The 
trinuclear complexes display better activities compared to the dinuclear derivatives when 
strictly compared within each compound series (pyridyl ether and pyridyl ester) thus 
proposing that an increase in metal moieties leads to an increase in activity in vitro. All of the 
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The most active compounds were assayed for inhibition of β-hematin formation and most of 
the compounds inhibited formation of synthetic hemozoin to some degree. This activity may 
be consequence of their polyaromatic structure. Should these compounds be able to enter the 
acidic food vacuole of the parasite intact, then they may very likely inhibit parasite growth 
through inhibition of hemozoin. 
 
Against the Trichomonas vaginalis strain G3, both the pyridyl ether and pyridyl ester 
compound series decreased parasite viability in a dose dependent manner. The complex 5.8 
displayed the best inhibitory effect out of all complexes tested but as a whole, the pyridyl 
ether series (4.2-4.8) were much better inhibitors of the T. vaginalis strain G3.  
 
Antitumoral studies against the A2780 and A2780cisR cell lines revealed that the trinuclear 
pyridyl ester complexes were the only active complexes. The tri-iridium complex (5.8) was 
found to be twice as active against the cisplatin resistant cell line (A2780cisR) compared to 
the A2780 cell line and also demonstrated the lowest toxicity against human embryonic 
kidney (HEK) cells. The rhodium complex 5.7 displayed the best inhibitory effect compared 
to its ruthenium (5.6) and iridium (5.8) derivatives. 
 
The activity of the pyridyl ether (4.1-4.8) and pyridyl ester (5.1-5.8) series could be improved 
through modification of the ligand structure and/or the metal moieties may increase the 
activity of these compounds. The design of pyridyl ether or pyridyl ester ligands that can to 
chelate to the metal in a polydentante manner may lead to the formation of complexes that are 
more stable and hence display better pharmacological activites. Modification of the arene or 
cyclopentadienyl ligands of the metal moieties to give added hydrophilicity could also 
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6.5. Experimental 
6.5.1. P. falciparum in vitro assay.  
The test samples were tested in triplicate on one occasion against chloroquine-sensitive 
(CQS) NF54 strain and chloroquine-resistant (CQR) Dd2 strain of Plasmodium falciparum. 
Continuous in vitro cultures of asexual erythrocyte stages of P. falciparum were maintained 
using a modified method.
104
 Quantitative assessment of antiplasmodial activity in vitro was 
determined via the parasite lactate dehydrogenase assay using a modified method.
105
 The test 
samples were prepared to a 20 mg/cm
3
 stock solution in 100% DMSO and sonicated to 
enhance solubility. Stock solutions were stored at -20ºC. Further dilutions were prepared on 
the day of the experiment. Chloroquine (CQ) was used as the reference drug in all 
experiments. A full dose-response was performed for all compounds to determine the 
concentration inhibiting 50% of parasite growth (IC50–value). Test samples were tested at a 
starting concentration of 100 μg/cm
3
, which was then serially diluted 2-fold in complete 
medium to give 10 concentrations; with the lowest concentration being 0.2 μg/cm
3
. The same 
dilution technique was used for all samples. CQ was tested at a starting concentration of 100 
ng/cm
3
 against the CQR strain and 1000 ng/cm
3
 against the CQS strain. The highest 
concentration of solvent to which the parasites were exposed to had no measurable effect on 
the parasite viability (data not shown). The IC50-values were obtained using a non-linear 
dose-response curve fitting analysis via Graph Pad Prism v.4.0 software. 
6.5.2. T. vaginalis in vitro susceptibility assay. 
Trichomonas vaginalis strain G3 was cultured anaerobically in 15 mL conical centrifuge 
tubes containing 10 mL of Diamond’s TYM media, pH 6.2.   Dimethyl sulfoxide was used to 
dissolve compounds and generate 100 mM stock concentrations of each compound.  Each 
compound was then tested at two concentrations, 25 uM and 50 uM, for in vitro inhibition of 
parasite growth. DMSO alone controls as well as tubes of untreated cells were carried along 
side-by-side. Test cultures were incubated for 24-hours at 37°C under anaerobic 
conditions.  Cell densities were determined using a hemacytometer.   Percentage inhibition 
was determined by comparing cell numbers in treatment tubes with the DMSO control 
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6.5.3. A2780 and A2780cisR cancer in vitro assay.  
The human A2780 and A2780cisR ovarian carcinoma cells were obtained from the European 
Collection of Cell Cultures (Salisbury,UK). Cells in the log phase of growth were seeded at a 
densitiy of 2000-2500 per well into 96-well culture treated plates in 0.1 mL of complete 
media in all wells except for one column reserved for the media only control. The cells were 
allowed to attach during an overnight incubation at 37°C, 5% CO2 prior to treating with test 
compounds. Test compounds were serially diluted in complete culture media and added to 
each well in a volume of 0.1 mL for a total final volume of 0.2 mL/well (max 0.1% DMSO 
final, where used). Cells were exposed to test compounds for 72 hours at 37°C, 5% CO2. 
Then, the culture supernatant was carefully removed from all wells of each plate and 0.02 mL 
of MTT reagent was added to each well. The plates were returned to the incubator for 2 h. 
Following the incubation period, DMSO (0.1 mL) was added to all wells to dissolve the 
formazan crystals. The plates were allowed to shake on a table shaker at room temperature 
for 15 min and the absorbance at 590 nm was measured using a SpectraMAX e5 plate reader 
(Molecular Devices). The percentage of surviving cells was calculated from the ratio of 
absorbance of treated to untreated cells. The IC50 values for the inhibition of cell growth were 
determined by fitting the plot of the log of the ratio between the percentages of surviving 
cells, divided by the amount of dead cells, against the log of drug concentration using a linear 
threshold function. 
6.5.4. Detergent mediated assay for β-hematin inhibitors.  
The β-hematin formation assay method described by Carter et al.
95
 was modified for manual 
liquid delivery. Stock solutions of the test compounds were prepared at 10 mM, 2 mM and 
0.4 mM by dissolving each sample in DMSO with sonication. Test compounds were 
delivered to a 96 well plate in triplicate from 0-500 μM (final concentration) with a total 
DMSO volume of 10 μL in each well. Deionized H2O (70 μL) and NP-40 (20 μL; 30.55 μM) 
were then added. A 25 mM hematin stock solution was prepared by sonicating hemin in 
DMSO, for complete dissolution, and then suspending 177.76 μL of this in a 2M acetate 
buffer (pH 4.8). The homogenous suspension (100 μL) was then added to the wells to give 
final buffer and hematin concentrations of 1 M and 100 μM respectively.  The plate was 
covered and incubated at 37°C for 16 hours in a water bath. Analysis of the assay was carried 
out using the pyridine-ferrichrome method developed by Ncokazi and Egan.
97
  A solution of 
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was prepared and 32 μL added to each well to give a final pyridine concentration of 
± 5% (v/v). Acetone (60 μL) was then added to assist with hematin dispersion. The UV-vis 
absorbance of the plate wells was read on a SpectraMax plate reader. Sigmoidal dose-
response curves were fitted to the absorbance data using GraphPad Prism v5.00. 
6.5.5. Turbidimetric Solubility Assay 
Preparation of 0.01M pH 7.4 Phosphate Buffered Saline (PBS) involved dissolving 1 intact 
PBS buffer tablet (EC Diagnostics AB, Sweden) in sufficient distilled water to make 1000 
mL of a solution comprising 0.14M NaCl, 0.003M KCl and 0.01M phosphate buffer. This 
solution was filtered through a 0.22 μm nylon filter to remove any particulate contaminants 
and the pH ascertained using a pH meter. The test compounds were prepared by making 10 
mM stock solutions in DMSO from which, dilutions of the compounds in both DMSO and 
0.01M pH 7.4 PBS were prepared in a 96-well plate, in triplicate. Wells in columns 1-6 
contained compounds in DMSO and columns 7-12 contained the compounds in PBS at 
similar nominal concentrations as those in DMSO. The final volume of solvent in each assay 
plate well was 200 μL, prepared by pipetting 4 μL each of solution from the pre-dilution plate 
to the corresponding well into both DMSO and PBS (both 196 μL). This ensured that the 
final concentration of DMSO in the PBS aqueous buffer did not exceed 2 % v/v. The 
different concentrations in DMSO were prepared to serve as controls to determine potential 
false turbidimetric absorbance readings arising from the compounds in solution absorbing 
incident radiation at the analysis wavelength. After making the assay plate preparation, the 
plate was covered and left to equilibrate for 2 hours at ambient temperature. After incubation, 
UV-vis absorbance readings from the plate were measured at 620 nm. Corrected absorbance 
readings at different concentrations of test compounds were calculated by subtracting 
absorbance of the blank (DMSO and 1 % DMSO in PBS) from each subsequent 
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7.1. Introduction 
Cross-coupling reactions are a set of transition metal catalyzed reactions that are an essential 
synthetic tool and palladium containing complexes are the most extensively employed 
catalyst systems for these reactions.  Some of the most well-known and widely used cross-
coupling reactions are the Heck, Stille, Suzuki-Miyaura and Buchwald-Hartwig cross-
couplings.
1,2









  Thus, the search for a metal 
complex which can catalyze these types of reactions efficiently while maintaining high 
chemo- and regio-selectivity and recyclability is an ongoing process. In cross-coupling 
reactions, palladium(II) complexes are generally used as catalyst precursors from which the 
active Pd(0) species is generated in situ. One disadvantage of the current catalyst systems 
used is that the metal complex sometimes undergoes decomposition during the reaction 
leading to poor recyclability of the metal complex as well as impurities in the products 
making the process a costly one.
10
   
Thiosemicarbazones are widely known for their metal chelating abilities to a large variety of 
metals.
11
 These compounds can be classified as hybrid ligands as they are capable of acting 
as bi- or multidentate ligands through several donor atoms.
12
 Studies into the biological 
applications of thiosemicarbazone metal complexes are prolific. Research into their role in 
catalysis however, is still a relatively new area of interest. One of the earliest reports of their 
catalytic abilities was published in 1998 by Pelagatti and co-workers; they found that 
tridentate [N,N,S] thiosemicarbazone palladium(II) complexes were able to catalyze 
chemoselective homogenous hydrogenation reactions.
13
 More recently, a cyclometallated 
ruthenium(II) thiosemicarbazone complex was used for the catalytic transfer hydrogenation 
of substituted ketones with high efficiency.
14
 Moderate activities were also observed for the 
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Tridentate pincer-type Pd(II) complexes are known to efficiently catalyze carbon-
carbon coupling reactions.
16-19
 Tridentate thiosemicarbazone Pd(II) complexes may exhibit 
similar behavior. The thiosemicarbazone ligand occupies three of the four coordination sites 
available on the metal and this may restrict how the olefinic or organo-halide substrates 
coordinate to the metal thus influencing the selectivity of the catalyst. These complexes are 
also known to exhibit high thermal stability, both in the solid state and in solution, making 
them good candidates for high temperature homogenous catalysis. Within our group, we have 
investigated the synthesis and application of tridentate [O,N,S] Pd(II) thiosemicarbazone 
complexes as anticancer and antimalarial agents.
20-22
 To demonstrate the versatility of these 
complexes (Figure 7.1), we have also studied their catalytic activity as catalyst precursors for 
the Mizoroki-Heck coupling reaction and have recently published some of our findings.
23
  
For these reasons, four Pd(II) analogues of the cycloplatinated complexes discussed in 
Chapter 2 were prepared in order to undertake a preliminary investigation as catalyst 
precursors for the Suzuki-Miyaura cross couplings of a variety of aryl halides and aryl 







1.99: R = H,  3-OMe, 3-tBu or  5-Cl 
Figure 7.1. Tridentate [O,N,S] Pd(II) thiosemicarbazone complexes that were investigated for activity as 





7.2. Results and discussion 
7.2.1.  Synthesis and Characterisation of Cyclopalladated complexes 
 
The thiosemicarbazone ligands, 3,4-dichloroacetophenone thiosemicarbazone (2.1) was 
treated with a suspension of potassium tetrachloropalladate in deoxygenated ethanol and 
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appropriate phosphane to give the corresponding mono- (7.2) and dinuclear (7.3 

















































P    P = bis(diphenylphoshino)ferrocene (7.2), 90 % yield
 
             trans-bis(diphenylphosphino)ethylene (7.3), 79 % 
             yield
7.2: L = PPh3, 75 % yield(ii)
(ii)













































Each complex was isolated as an air- and moisture-stable amorphous yellow solid with high 
thermal stability. The 
1
H NMR spectra for complex 7.1 showed only two singlets in the 
aromatic region and both integrated for one proton each, supporting palladation of the ortho-
carbon upon loss of the proton. The absence of a signal corresponding to the hydrazinic 
proton corroborates coordination of sulfur to palladium in the thiolato form and formation of 
a new imine bond upon deprotonation of the hydrazinic nitrogen.
24,25
 The amino (-NH2) 
protons of the coordinated ligand 2.1 in each of the phosphane containing complexes 7.2-7.4 
resonate as a singlet in each spectrum between 6.79 and 6.99 ppm. These resonances are 
slightly upfield compared to the tetranuclear precursor 7.1, where these protons are observed 
as singlets at 7.17 and 7.11 ppm respectively. This slight shielding may be due to increased 
electron density around the metal and hence greater electron distribution over the ligand due 
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The cyclopentadienyl (Cp) protons of the bis(diphenylphosphino)ferrocene (dppf) 
bridging ligand for compounds 7.3 as two broad singlets between 4.50 and 5.10 ppm, the 
downfield peak is assigned to the protons α to the carbon-phosphorus bond. For compound 
7.4, the alkene protons of the trans-bis(diphenylphosphino)ethylene (dppe) ligand are 




H} NMR spectra 
for the tetranuclear complex 7.1, coordination of the imine nitrogen to palladium is further 
supported by the assignment of the imine carbon (Cg) to a peak at 166.1 ppm, a downfield 
shift relative to the free ligand (2.1) where it resonates at 145.2 ppm. This is in accordance 
with resonances observed for similar complexes.
25,26
 An upfield shift of approximately 10 
ppm of the thiolato carbon (Ci) in the complex 7.1 is noted in comparison to the thione 
carbon of the free ligand (2.1) confirms coordination of sulfur in the thiolato form.
26
 The 
ortho-carbon shows a large shift from approximately 128.0 ppm in the free ligand to 165.0 
ppm. This extreme deshielding of the carbon nucleus is characteristic of palladation of the 
ortho-carbon and substantiates formation of the cyclopalladated complex 7.1.
26,27
 Compared 
to 7.1, similar resonances are observed for the imine carbon in complexes 7.2 – 7.4. A 
downfield shift is observed for the thiolato carbon (Ci) resonance from between 167.7 ppm 
for 7.1 to between 175.0 – 179.0 ppm for 7.2 – 7.4 is also noted.  
 




H} NMR spectra. The 
phosphorus nucleus of the mononuclear complex 7.2 resonates at 38 .75 ppm; the phosphorus 
nuclei of the dppf ligand of 7.3 occurs at a lower chemical shift of 29.19 ppm as a 
consequence of the electron-rich ferrocenyl moiety and the phosphorus singlet of the trans-
dppe ligand in complex 7.4 occurs at 34.18 ppm. All of these resonances are consistent with 





Only two absorption bands are observed in the N-H region of the infrared spectrum for all 
complexes (7.1 – 7.4), indicating that there are only two amine bonds in the complexes 
compared to that of the free ligands. The formation of the second imine bond is supported by 
the observation of two absorption bands between 1525 and 1620 cm
-1
. The lower frequency 
band is assigned to the palladium coordinated imine. A shift to lower frequency compared to 
the free ligand is attributed to the loss of double bond character upon coordination of the 
nitrogen to the metal. The higher absorption band is hence assigned to the stretching vibration 
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the thiolate form. ESI-mass spectrometry was used to further characterise the 
complexes (7.1 – 7.4) prepared. All of the compounds exhibit molecular ion peaks 
corresponding to each compound in its protonated form. 
 
7.2.2. Preliminary Catalytic Activity in the Suzuki-Miyaura Cross Coupling Reaction 
The four cyclopalladated thiosemicarbazone complexes (7.1-7.4) were evaluated for their 
ability to catalyze a series of Suzuki-Miyaura cross coupling reactions. The first step was to 
screen different catalytic conditions to optimize activity. Table 7.1 shows the data ascertained 
for these reactions. The palladium catalyst precursors (7.1-7.4) were first screened for the 
Suzuki-Miyaura cross coupling of 4-(methoxy)-iodobenzene and phenylboronic acid in 
dioxane using K3PO4 as the base (Entries 1-5, Table 7.1). The mononuclear complex 7.2 (1 
mol %) gave a 95 % yield of the coupled product when the reaction was carried out at 
100 °C.  However, a decrease in the reaction temperature to 60 °C yielded only 20 % of the 
coupled product (Entry 2). At 60 °C, the tetranuclear complex 7.1 and dinuclear complex 7.3 
also showed low activity while the bis(diphenylphosphino)ferrocene bridged complex 7.4 
(0.5 mol %) showed a much more promising activity of 60 %. Thus, this complex was chosen 
for further screening of catalytic conditions. 
With the aryl halide substrate changed to 4-(methoxy)-bromobenzene and using 0.5 mol % of 
7.4 at 100 °C, it was found that the best yields were obtained when the cross coupling 
reactions were carried out in DMF or dioxane (Entries 6-10). Further catalytic reactions in 
DMF using different bases at 100 °C (Entries 11-15) showed a significant decrease in activity 
particularly when cesium carbonate or triethylamine are used as the base for the cross 
coupling reactions. Varying the temperature (Entries 16-18) and carrying out the reactions 
under argon (Entries 17 and 18) showed that better yields were obtained as the temperature 
was increased with a 94 % yield obtained at 130 °C. Screening these different conditions 
showed that complex 7.4 exhibited the best activity when a 0.5 mol % complex loading was 
used in DMF with K3PO4 as base at 130 °C under argon. Under the same conditions, 
Pd(OAc)2 using PPh3 as co-ligand afforded only 78 % of the coupled product (entry 19).  
Using these optimal conditions, the complex 7.4 was then applied to the Suzuki-Miyaura 
cross-coupling of bromobenzene with different arylboronic acid substrates. Figure 7.2 shows 
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Table 7.1. Screening various catalytic conditions.
 [a]
 




X = I, Br
MeO
 





1 I 7.2 (1) K3PO4 Dioxane 100 95 
2 I 7.2 (1) K3PO4 Dioxane 60 20 
3 I 7.1 (0.5) K3PO4 Dioxane 60 19 
4 I 7.3 (0.25) K3PO4 Dioxane 60 10 
5 I 7.4 (0.5) K3PO4 Dioxane 60 60 
6 Br 7.4 (0.5) K3PO4 Dioxane 100 44 
7 Br 7.4 (0.5) K3PO4 DMF 100 43 
8 Br 7.4 (0.5) K3PO4 DMSO 100 10 
9 Br 7.4 (0.5) K3PO4 Toluene 100 34 
10 Br 7.4 (0.5) K3PO4 NMP 100 30 
11 Br 7.4 (0.5) K2CO3 DMF 100 25 
12 Br 7.4 (0.5) Cs2CO3 DMF 100 5 
13 Br 7.4 (0.5) 
t
BuOK DMF 100 20 
14 Br 7.4 (0.5) Et3N DMF 100 5 
15 Br 7.4 (0.5) Na2CO3 DMF 100 22 
16 Br 7.4 (0.5) K3PO4 DMF 120 58 
17
c Br 7.4 (0.5) K3PO4 DMF 120 67 
18
c Br 7.4 (0.5) K3PO4 DMF 130 94 
19
c,d
 Br Pd cat. (0.5) K3PO4 DMF 130 78 
a Reaction conditions: Aryl halide (0.3 mmol), phenylboronic acid (0.4 mmol), Pd-complex (0.25-1 mol%), base (2 equiv), solvent (2 mL), 
60-130 oC, 24 h, air. b Isolated yield (based on aryl halide). c The reaction was performed under argon atmosphere. d Pd(OAc)2/PPh3 (1:2). 
 
A product yield of 95 % was observed when the substrate 4-methoxy-phenylboronic acid was 
used (Entry 2, Figure 7.2) and 88 % yield was obtained when the 3-methoxy derivative was 
used (Entry 3). Allowing the reaction to proceed for 48 hours resulted in the product yield 
increasing to 90 % (Entry 4). Only a 31 % yield was obtained for the reaction using 2-
methoxy-phenylboronic acid as substrate (Entry 5), this low yield could be due to steric 
hindrance from the methoxy substituent. The catalytic reactions using the phenylboronic acid 
(entry 1) and 4-methyl-phenylboronic acid (entry 6) substrates both resulted in a 93 % yield 
of coupled product. The complex 7.4 was also able to efficiently catalyze the coupling of the 
chlorido substituted phenylboronic acid with bromobenzene (Entry 7) but a slight decrease in 
activity was observed when the halide substituent is changed to fluorine (Entry 8). High 
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Br + B(OH)2
R 7.4 (0.5 mol%)
K3PO4, DMF




Figure 7.2. Suzuki-Miyaura coupling of bromobenzene and aryl boronic acids using 7.4. The catalytic 
conditions: Bromobenzene (0.3 mmol), arylboronic acid (0.4 mmol), 7.4 (0.5 mol%), K3PO4 (2 equiv), DMF (2 
mL), 130 
o
C, 24-48 h, Ar. 
b
 Isolated yield based on bromobenzene (average of two runs). 
 
The Suzuki-Miyaura coupling reactions between phenylboronic acid and different aryl 
halides using 7.4 as pre-catalyst also displayed promising results (Figure 7.3). Yields of 99 % 
were obtained when the substrates 3-bromoacetophenone, 3-bromopyridine or 3-methoxy-
bromobenzene were used (Entries 2, 4 and 10, Figure 7.3). The coupling reactions using aryl 
bromide substrates containing a chlorido or fluorido substituent also demonstrated high 
product yields (Entries 1 and 8). In contrast to the arylboronic acid derivative (Entry 5, Figure 
7.2), a moderately good yield of 70 % was observed for the substrate 2-methoxy-
bromobenzene (Entry 11, Figure 7.3).  
When the reaction was allowed to proceed for 48 hours, a yield of 77 % was obtained for the 
less reactive 4-nitro-chlorobenzene (Entry 13). Much lower activity is observed for the 
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14 and 15, complex 7.4 efficiently catalyzed the coupling of phenylboronic acid and 
different aryl halides irrespective of the type of substituent (electron withdrawing or electron 
donating) with yields between 70 – 99 % being attained. This moderate to excellent activity 
was also upheld when the substituents were varied on the phenylboronic acid (Figure 7.3). 
This preliminary study has demonstrated the versatility of this complex as it is able to 
produce a wide variety of coupled products and its effectiveness does not seem to be 
dependent on the type of aryl substrate used.  
 
B(OH)2+X
R 7.4 (0.5 mol%)
K3PO4, DMF
130 oC, 24-48 h, Ar
R
X = Br, Cl  
 
Figure 7.3. Suzuki-Miyaura coupling reactions between phenylboronic acid and various aryl halides. The 
catalytic conditions: aryl halide (0.3 mmol), phenylboronic acid (0.4 mmol), 7.4 (0.5 mol%), K3PO4 (2 equiv), 
DMF (2 mL), 130 
o
C, 24-48 h, Ar. Isolated yield based on aryl halide (average of two runs). 
 
7.3. Summary 
Four cyclopalladated complexes (7.1-7.4) of ligand 2.1 were prepared by reaction with 
potassium tetrachloropalladate and subsequent cleavage of the Pd-S bridging bonds with 













 198 Synthesis and Study of Multinuclear PGM complexes as in vitro Pharmacological Agents 
that the ligand 2.1 acts as a tridentate dinegative [C,N,S] donor to palladium in the 
same manner as found in complexes 2.2-2.7 (Chapter 2).  
A preliminary screening of complexes 7.1-7.4 for activity as catalyst precursors for the 
Suzuki-Miyaura cross coupling reaction revealed complex 7.4 to be a robust catalyst. It was 
able to efficiently catalyze the coupling of various aryl halides and aryl boronic acids, 
irrespective of the type of electron-withdrawing or electron-donating substituent on the 
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7.4. Experimental 
7.4.1. Chemicals and General Methods 
All complexation reactions were performed under a nitrogen or argon atmosphere using a 
dual vacuum/nitrogen line and standard Schlenk-line techniques unless otherwise stated. All 
reaction solvents were dried by refluxing under an inert atmosphere over the appropriate 
drying agent and all samples were dried under vacuum. Reagents and solvents were 
purchased from commercial suppliers and used without further purification. PdCl2 was kindly 
donated by Johnson-Mathey Inc. The thiosemicarbazone ligand 2.1 
33
 and K2[PdCl4] 
34
 were 
synthesized according to previously published methods. 
 
7.4.2. Spectroscopic and Analytical Methods 
Nuclear Magnetic Resonance (NMR) Spectra were recorded on a Varian Unity XR400 MHz 
(
1
H at 399.95 MHz, 
13
C at 100.58 MHz), Varian Mercury XR300 (
1
H at 300.08 MHz, 
13
C at 
75.46 MHz) or Bruker Biospin GmbH (
1
H at 400.22 MHz, 
13
C at 100.65 MHz) spectrometer 




C{1H} NMR shifts are reported using 
tetramethylsilane (TMS) as the internal standard and 
31
P{1H} NMR spectra were measured 
relative to H3PO4 as the external standard. NMR spectra were recorded in deuterated 
chloroform (CDCl3-D1) unless otherwise stated. Infrared (IR) absorptions were measured on 
Perkin-Elmer Spectrum 100 FT-IR Spectrometer using a Universal Diamond Attenuated 
Total Reflection (ATR) accessory. Microanalyses for C, H, and N were carried out using a 
Thermo Flash 1112 Series CHNS-O Analyser and melting points were determined using a 
Büchi Melting Point Apparatus B-540. Mass Spectrometry determinations were carried out 
on all new compounds using electrospray ionisation (ESI) on a Waters API Quattro Micro 
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Potassium tetrachloropalladate (0.402 g, 1.230 mmol) was dissolved in deionised water (5 
cm
3
). Ethanol (40 cm
3
) was added and 3,4-dichloro-acetophenone thiosemicarbazone (2.1) 
(0.355 g, 1.356 mmol) was added to the resulting yellow suspension.  The reaction mixture 
was stirred at room temperature for 48 hours. The product (7.1) was collected as a yellow 
solid via filtration, washed with ethanol (3 x 10 cm
3
) and dried under vacuum. Yield: 0.326 g, 
73 %. M.p.: decomposition without melting 307-309 ºC. 
1
H NMR (399.95 MHz, DMSO): δ 
(ppm) = 7.36 (s, 1H, Hb), 7.17 (s, 2H, NH2), 6.71 (s, 1H, He), 1.99 (s, 3H, Hh). 
13
C NMR 
(75.46 MHz, DMSO):  δ (ppm) = 167.7 (Ci), 166.1 (Cg), 165.1 (Ca), 150.7 (Cf), 133.9 (Cc), 
129.9 (Cd), 126.8 (Ce), 126.6 (Cb), 14.3 (Ch). IR (KBr, cm
-1
) υ = 3442 (m, N-H), 3369 (m, N-
H), 1597 (s, C=N), 1560 (m, C=N), 1524 (s, C=C aromatics). Elemental Analysis for 
C36H28Cl8N12Pd4S4: found C 29.14, H  2.43, N 10.87, S 8.56 %; calculated C 29.44, H 1.93, 
N 11.46, S 8.76 %. ESI-MS: m/z 1468 ([M + 2H]
+
, 20%), 368 ([M/4 + H]
+
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Compound 7.1 (0.100g, 0.069 mmol) was suspended in dry acetone (15 cm
3
). 
Triphenylphosphine (0.073 g, 0.275 mmol) was added and the reaction was stirred under 
argon gas for 4 hours. The product (7.2) was collected as a bright yellow solid by filtration, 
washed with acetone (2 x 5 cm
3
) and dried under vacuum. Yield: 0.129 g, 75 %. M.p.: 
decomposition without melting 290-291 ºC. 
1
H NMR (300.08 MHz, DMSO): δ (ppm) = 7.42-
7.64 (m, 15H, PPh3), 7.20 (s, 1H, Hb), 6.79 (s, 2H, NH2), 6.10 (s,1H, He), 2.76 (s, 3H, Hh). 
13
C NMR (75.46 MHz, DMSO):  δ (ppm) = 176.6 (Ci), 163.6 (Cg), 152.7 (Ca), 136.1 (Cg), 
133.8 (Cd), 133.7 (Cc), 128.5-131.1 (PPh3), 126.2 (Ce), 126.1 (Ch), 13.0 (Ch). 
31
P NMR 
(121.47 MHz, DMSO):  δ (ppm) = 38.75 (PPh3). IR (KBr, cm
-1
) υ =  3474 (m, N-H), 3332 (s, 
N-H), 1601 (s, C=N), 1579 (m, C=N), 1496 (s, C=C aromatics). Elemental Analysis for 
C27H22Cl2N3PPdS: found C  51.36, H 3.49, N 6.29, S 4.84 %; calculated C 51.57, H 3.53, N 
6.68, S 5.10 %. ESI-MS: m/z  630 ([M + H]
+
, 100%).  
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Bis(diphenylphosphinoethylene)  (0.0592g, 0.149 mmol) was reacted with compound 7.1 
(0.105 g, 0.0719 mmol). The product (7.3) was isolated as a yellow solid. Yield: 0.134 g, 79 
%.  M.p.: 211-213 ºC (decomp.). 
1
H NMR (399.95 MHz, DMSO): δ (ppm) = 7.52-7.57 (m, 
20H, PPh2), 7.28-7.33 (m, 2H, Hα), 7.21 (s, 2H, Hb), 6.95 (s, 4H, NH2), 6.23 (s, 2H, He), 2.28 
(s, 6H, Hh). 
13
C NMR (100.57 MHz, DMSO): δ (ppm) = 176.6 (Ci), 164.0 (Cg), 163.3 (Ca), 
152.6 (Cf), 135.7 (Cd), 133.1-133.2 (PPh2), 131.4 (Cα), 131.1 (Cc), 128.9-129.0 (PPh2), 126.6 
(Ce), 125.3 (Cb), 13.1 (Ch). 
31
P NMR (161.90 MHz, DMSO): δ (ppm) = 34.18 (PPh2). IR 
(KBr, cm
-1
) υ = 3455 (m, N-H), 3317 (s, N-H), 1623 (m, C=N), 1605 (s, C=N), 1483 (s, C=C 
aromatics). Elemental Analysis for C44H36Cl4N6P2Pd2S2: found C 46.84, H 3.25, N 7.29, S 
5.74 %; calculated C 46.79, H 3.21, N 7.44, S 5.68 %. ESI-MS: m/z  1130.88 ([M + H]
+
, 50 
%), 565.95 ([M/2 + 2H]
2+
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Bis(diphenylphosphinoferrocene) (0.0786 g, 0.142 mmol) was reacted with compound 7.1 
(0.105 g, 0.0717 mmol). The product (7.4) was isolated as a yellow solid. Yield: 0.127 g, 90 
%. M.p.: decomposition without melting 204-206 ºC. 
1
H NMR (399.95 MHz, DMSO): δ 
(ppm) = 7.40-7.58 (m, 20H, PPh2), 7.25 (s, 2H, Hb), 6.96 (s, 4H, NH2), 6.08 (s, 2H, He), 5.07 
(br s, 4H, Cp-Hα), 4.27 (br s, 4H, Cp-Hβ), 2.31 (s, 6H, Hh). 
13
C NMR (100.57 MHz, DMSO): 
δ (ppm) = 178.6 (Ci), 163.8 (Cg), 152.7 (Ca), 136.14 (Cf), 133.0-133.2 (PPh2), 131.1 (Cd), 
129.4 (Cc), 128.4-128.5 (PPh2), 126.4 (Ce), 126.3 (Cb), 75.4-74.2 (Cα and Cβ), 13.3 (Ch). 
31
P 
NMR (161.90 MHz, DMSO): δ (ppm) = 29.19 (PPh3). IR (KBr, cm
-1
) υ = 3479 (m, N-H), 
3383 (m, N-H), 1595 (s, C=N), 1574 (s, C=N), 1491 (s, C=C aromatics). Elemental Analysis 
for C52H42Cl4FeN6P2Pd2S2: found C 48.96, H 3.52, N 6.22, S 4.10 %; calculated C 48.53, H 
3.28, N 6.53, S 4.98 %. ESI-MS: m/z  1288.87 ([M + H]
+
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7.4.7. General Procedure for Suzuki-Miyaura Reactions 
A Schlenk tube was charged with aryl boronic acid (0.4 mmol), K3PO4 (0.6 mmol) and the 
complex IV (0.5 mol%). The tube was connected to a vacuum line under argon and purged 
three times. N,N-dimethylformamide (2 mL) and aryl halide (0.3 mmol) were added. The 
reaction mixture was stirred at 130 °C between 24–48 h. At the end of the reaction, the 
reaction mixture was cooled to room temperature, diluted with diethyl ether and washed with 
water. The combined organic phase was dried over anhydrous Na2SO4. After removal of the 
solvent, the residue was subjected to column chromatography on silica gel using ethyl acetate 
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New mono- and polynuclear complexes containing platinum, ruthenium, rhodium or iridium 
have been synthesized and fully characterized using several analytical and spectroscopic 
techniques. The complexes prepared consist of three different classes that are based on the 
type of ligand system used for their preparation. 
Six new cycloplatinated thiosemicarbazone complexes (2.2-2.7) were prepared via C-H 
activation of the aromatic ring using the ligand 3,4-dichloroacetophenonethiosemicarbazone 
(2.1). Characterisation of complexes 2.2-2.7 using standard spectroscopic techniques revealed 
that the thiosemicarbazone ligand (2.1) acts as a tridentate dinegative donor to platinum. This 
was confirmed from the molecular structures of 2.2-2.4 which were determined using single 
crystal X-ray diffraction and show that the ligand coordinates to platinum in the expected 
tridentate manner via the ortho-carbon, imine nitrogen and thiolato sulfur. Reactivity studies 
of the mononuclear complex 2.4 with mono-, bis- and tris-(iodomethyl)benzene revealed that 
this complex was able to undergo oxidative addition reactions. This is noteworthy, as Pt(IV) 
complexes are believed to have pharmacological properties
1,2
 thus the preparation of Pt(IV) 
cycloplatinated thiosemicarbazone complexes could be relevant to the search for alternative 
platinum therapies for cancer. 
 
Two new pyridyl ether ligands (4.1 and 4.2) were synthesised using the Williamson Ether 
reaction. Both ligands were peripherally metallated with ruthenium, rhodium and iridium 
precursors to give the corresponding di- (4.3-4.5) and trinuclear (4.6-4.8) complexes. All of 
the compounds were isolated as air and moisture stable solids and were characterised using a 
variety of analytical and spectroscopic techniques. The molecular structure of 4.5 confirmed 
the monodentate coordination of the pyridyl ether ligands to each metal put forth by the 
spectroscopic and spectrometric characterisations of complexes 4.3 - 4.8. 
 
CHAPTER 8 
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Two di- and tri-pyridyl ester ligands (5.1 and 5.2) have been synthesised by 
alkylation of the carboxylic acid. These ligands were functionalized with either [(p-
cymene)RuCl2], [(pentamethylcyclopentadienyl)RhCl2] or [(pentamethylcyclopenta-
dienyl)IrCl2] moieties to give a series of new di- (5.3-5.5) and trinuclear (5.6-5.8) complexes. 
Spectroscopic characterisation revealed that, similar to the pyridyl ether ligands (4.1 and 4.2), 
the pyridyl ester ligands (5.1 and 5.2) act as monodentate donors to the metal via the pyridyl 
nitrogen. Proton NMR analyses of compounds 5.1-5.8 revealed that the proximity of the ester 
functionalities to the pyridyl ring influences the deshielding effect on the protons ortho to 
nitrogen. Minimal change in the ester methylene proton resonances confirmed no metal 
coordination occurs to the oxygen atoms of the ester functionality.  
 
The molecular structures of 5.4 and 5.5 confirm the monodentate coordination of the pyridyl 
ester ligands to each metal put forth by the spectroscopic and spectrometric characterisations 
of complexes 5.3 - 5.8. The elucidated molecular structures of the complexes 5.4 and 5.5 
revealed a typical ‘piano-stool’ geometry around the metal and analysis of the dihedral angles 
formed between the central phenyl ring and the ester functionalities indicate that the pyridyl 
metal moieties position themselves almost perpendicular to the phenyl spacer thus 
minimizing electrostatic interactions. 
 
8.1.2. In vitro Pharmacological Studies 
The thiosemicarbazone complex 2.1 and its mono-, di- and tetranuclear  complexes 2.2-2.6 
were screened for antiparasitic activity against Plasmodium falciparum and Trichomonas 
vaginalis strains and for antitumor activity against cisplatin-sensitive and cisplatin-resistant 
human ovarian carcinoma cell lines. They were found to exhibit moderate to low parasite 
growth inhibition and antiproliferative activities. The in vitro activities obtained for 2.1-2.8 
against the A2780 and A2780cisR cell lines revealed that cyclometalation of ligand 2.1 led to 
a decrease in in vitro activity. This is in contrast to previous reports where cycloplatination 
had a beneficial effect on activity. 
The lipophilic nature of the phosphane in each complex may influence the antiproliferative 
activities of 2.3-2.6. Complex 2.4 demonstrated the best IC50 out of all compounds tested 
against both cell lines and this activity may be due to the high hydrophilic nature of PTA 
which provides the right counter balance to the high lipophilicity of the platinum-
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through structural modification of the phosphanes to increase the hydrophilicity of 
the cycloplatinated complexes or by replacement of the phosphane with another type of 
ancillary ligand such as a monodentate nitrogen ligand. 
Against the D10 and Dd2 P. falciparum strains, complexes 2.2-2.4 were much more active 
than their free ligand 2.1 and the inactivity of complexes 2.5 and 2.6 may be attributed to the 
presence of the diphosphane ligand. The highly lipophilic nature of complex 2.2 may result in 
the complex being unable to enter the acidic food vacuole of the parasite efficiently thus 
accounting for moderate antiplasmodial activity. Complex 2.3 displayed the best inhibitory 
activity against both strains yet was much less active against the A2780 and A2780cisR cell 
lines suggesting that complex 2.3 may be selective for P. falciparum over tumor cell lines. 
All of the compounds (2.1 – 2.6) with the exception of 2.4 displayed moderate to low effects 
on parasite viability in the T. vaginalis strain T1. 
Evaluation of ligand 2.1 and complex 2.3 for their ability to inhibit β-hematin formation, it 
was found that these compounds do not target this process at the concentrations used in the 
assay. Preliminary stability studies of compounds 2.1 – 2.6 experiments with different short 
peptides and the amino acid methionine using 
1
H NMR imply that these compounds may be 
stable in the blood and cytoplasm and they may reach their antitumoral target intact.  
 
In vitro pharmacological evaluation of the two new series of di- and trinuclear ruthenium, 
rhodium and iridium complexes disclosed that all of the complexes and their free ligands 
(4.1-4.8 and 5.1-5.8) exhibited moderate to high antiplasmodial activity against the NF54 
CQS P. falciparum strain. The trinuclear pyridyl ether complexes (4.6-4.8) and their free 
ligand demonstrated significantly higher activities than the other complexes tested and this 
was attributed to the incorporation of a central triazine moiety into their structures. The 
trinuclear complexes (4.6-4.8 and 5.6-5.8) display better activities compared to the dinuclear 
derivatives when strictly compared within each compound series (pyridyl ether and pyridyl 
ester) thus proposing that an increase in metal moieties leads to an increase in activity in 
vitro. All of the complexes showed better activity than the corresponding free ligand. 
 
The most active compounds were assayed for inhibition of β-hematin formation and most of 
the compounds inhibited formation of synthetic hemozoin to some degree. This activity may 
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acidic food vacuole of the parasite intact, then they may very likely inhibit parasite 
growth through inhibition of hemozoin. 
 
Against the Trichomonas vaginalis strain G3, both the pyridyl ether and pyridyl ester 
compound series decreased parasite viability in a dose dependent manner. The complex 5.8 
displayed the best inhibitory effect out of all complexes tested but as a whole, the pyridyl 
ether series (4.2-4.8) were much better inhibitors of the T. vaginalis strain G3.  
 
Antitumoral studies against the A2780 and A2780cisR cell lines revealed that the trinuclear 
pyridyl ester complexes were the only active complexes. The tri-iridium complex (5.8) was 
found to be twice as active against the cisplatin resistant cell line (A2780cisR) compared to 
the A2780 cell line and also demonstrated the lowest toxicity against human embryonic 
kidney (HEK) cells. The rhodium complex 5.7 displayed the best inhibitory effect compared 
to its ruthenium (5.6) and iridium (5.8) derivatives. 
 
The activity of the pyridyl ether (4.1-4.8) and pyridyl ester (5.1-5.8) series could be improved 
through modification of the ligand structure and/or the metal moieties may increase the 
activity of these compounds. The design of pyridyl ether or pyridyl ester ligands that can to 
chelate to the metal in a polydentante manner may lead to the formation of complexes that are 
more stable and hence display better pharmacological activites. Modification of the arene or 
cyclopentadienyl ligands of the metal moieties to give added hydrophilicity could also 
enhance activity.  
 
8.1.3. Catalytic Evaluation 
An initial screening of the four cyclopalladated complexes (7.1-7.4) that were prepared 
revealed these compounds to have moderate catalytic activity for the Suzuki-Miyaura cross 
coupling reaction with the exception of 7.4. This dinuclear complex, which contains the 
bis(diphenylphoshinoferrocene) spacer was a robust catalyst. It was able to efficiently 
catalyze the coupling of various aryl halides and aryl boronic acids, irrespective of the type of 
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8.2. Future Outlook 
The moderate activities observed for the thiosemicarbazones (2.1-2.7) could be improved 
through structural modification of the phosphanes to increase the hydrophilicity of the 
cycloplatinated complexes or by replacement of the phosphane with another type of ancillary 
ligand such as a monodentate nitrogen ligand. 
 
Further oxidative addition reactivity studies of 2.4 with other bromo-methyl substrates could 
prove useful as it offers another way of introducing hydrophilic groups to platinum 
thiosemicarbazone complexes and the increase in coordination number may further stabilize 
platinum. Pt(IV) complexes have been studied for pharmacological activity and are thought 
to act as pro-drugs, from which the active Pt(II) species is generated within the cancer cell.
2
 It 
would be interesting to find out if Pt(IV) thiosemicarbazone complexes have improved 
antiproliferative and antiparasitic activities compared to Pt(II) derivatives.  
 
The tri-pyridyl ether ligand 4.2 and its corresponding trinuclear ruthenium, rhodium and 
iridium complexes (4.6-4.8) displayed antiplasmodial activities in the nanomolar range. This 
was attributed to the incorporation of a central triazine moiety into their structures and should 
be kept in mind when designing future polynuclear complexes of this type for antiparasitic 
study.  
 
The overall pharmacological activity of the pyridyl ether (4.1-4.8) and pyridyl ester (5.1-5.8) 
series could be improved through modification of the ligand structure and/or the metal 
moieties may increase the activity of these compounds. The design of pyridyl ether or pyridyl 
ester ligands that can to chelate to the metal in a polydentante manner may lead to the 
formation of complexes that are more stable and hence display better pharmacological 
activities. Modification of the arene or cyclopentadienyl ligands of the metal moieties to give 
added hydrophilicity could also enhance activity.  
 
With respect to the catalytic activity of complex 7.4, further studies of its ability to catalyze 
other coupling reactions should be undertaken. For example, tridentate mononuclear Pd(II) 
thiosemicarbazone complexes have shown high activity for the Heck coupling reaction.
3
 
Other mononuclear Pd(II) thiosemicarbazone complexes have displayed moderate to good 
activities for the Buchwald-Hartwig amination reaction.
4,5
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determine if complex 7.4 would be able to catalyze other coupling reactions with 
similar high activities as it achieved for the Suzuki-Miyaura cross-coupling reactions. 
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